{"meta":{"query_hash":"af7a8fbc2407","filters":{"venue":"Expert Opinion on Investigational Drugs"},"cohort_total":130,"direct_labels_cover":0,"predictions_cover":130,"exported":130,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/af7a8fbc2407","api":"https://metacan.xera.ac/api/v1/cohort?venue=Expert+Opinion+on+Investigational+Drugs"},"results":[{"id":"W1574978600","doi":"10.1517/13543784.2015.1057675","title":"Evidence to support peripheral and central IL-6 signaling targets to treat depression","year":2015,"lang":"en","type":"letter","venue":"Expert Opinion on Investigational Drugs","topic":"Tryptophan and brain disorders","field":"Neuroscience","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; St. Michael's Hospital","funders":"Canadian Institutes of Health Research","keywords":"Depression (economics); Medicine; Peripheral; Investigational Drugs; Psychology; Bioinformatics; Psychiatry; Biology; Internal medicine; Clinical trial","score_opus":0.08810745822753124,"score_gpt":0.3210609034709742,"score_spread":0.23295344524344297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1574978600","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021776982,0.011471221,0.00011701419,0.8811646,0.10587952,0.000010459452,0.00006676347,0.000026974652,0.0010455982],"genre_scores_gemma":[0.003144171,0.011686347,0.00021626477,0.70556927,0.2751,0.000030887328,0.000048278715,0.000021041706,0.004183745],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997908,0.0005739732,0.00040754044,0.00026435129,0.000640976,0.0002052477],"domain_scores_gemma":[0.98931366,0.0054365895,0.00084407406,0.00019626685,0.0034281653,0.0007812948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035049738,0.00070438883,0.0017285008,0.0007065641,0.0015525654,0.0023392977,0.0022737395,0.024320805,0.005246182],"category_scores_gemma":[0.026963355,0.0005300935,0.0012173535,0.0006194143,0.0016478789,0.0026622545,0.0010418424,0.028551186,0.006507974],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000780081,0.000024260782,0.00014184164,0.00019812869,0.000025141167,0.0010973171,0.000041476993,0.00004228852,0.0001878894,0.0010091683,0.98306525,0.01408924],"study_design_scores_gemma":[0.0002345337,0.00013398599,0.00078688294,0.00072221004,0.0000982651,0.0023594918,0.0001176923,0.00032014793,0.00047244033,0.004257788,0.99044144,0.000055008564],"about_ca_topic_score_codex":0.0017128428,"about_ca_topic_score_gemma":0.0032022565,"teacher_disagreement_score":0.024320805,"about_ca_system_score_codex":0.0027261893,"about_ca_system_score_gemma":0.0026541285,"threshold_uncertainty_score":0.01977992},"labels":[],"label_agreement":null},{"id":"W1622189727","doi":"10.1517/13543784.2015.1052403","title":"Development of experimental and early investigational drugs for the treatment of Ebola virus infections","year":2015,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Viral Infections and Outbreaks Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Public Health Agency of Canada","funders":"","keywords":"Investigational Drugs; Ebola virus; Medicine; Ebola vaccine; Virology; Ebolavirus; Intensive care medicine; Drug development; Biology; Virus; Pharmacology; Drug; Clinical trial; Internal medicine","score_opus":0.1577441369498381,"score_gpt":0.43332750397849157,"score_spread":0.2755833670286535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1622189727","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001884758,0.99742943,0.00016361153,0.00038399518,0.00024816958,0.000016849412,0.000050694205,0.000009806922,0.0015088745],"genre_scores_gemma":[0.0013300541,0.9972607,0.0002876212,0.00034729557,0.00012459207,0.000017744866,0.00005687434,0.0000019165604,0.0005732446],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997514,0.00005625172,0.000038359463,0.00003818478,0.000092058894,0.000023826726],"domain_scores_gemma":[0.99955446,0.00021924578,0.00007498369,0.000012377756,0.00011372554,0.000025245132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006437592,0.0006133093,0.0010643059,0.0018026112,0.00018564817,0.00075701444,0.00081316236,0.0011415634,0.005568375],"category_scores_gemma":[0.0010526573,0.00022268204,0.0007656239,0.0009877316,0.0003172023,0.0010124414,0.0004731216,0.0015493311,0.002212566],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010496813,0.00009218864,0.000162071,0.03517014,0.000179509,0.00023712486,0.000066193046,0.0003074124,0.0027323451,0.0042750565,0.03704216,0.91963077],"study_design_scores_gemma":[0.00004708238,0.00015682635,0.0005505955,0.0070859124,0.00020845402,0.0009146794,0.000040451683,0.00009766065,0.00093406485,0.0013876283,0.98855793,0.00001873349],"about_ca_topic_score_codex":0.0006140434,"about_ca_topic_score_gemma":0.0012533123,"teacher_disagreement_score":0.005568375,"about_ca_system_score_codex":0.00042918063,"about_ca_system_score_gemma":0.0007525062,"threshold_uncertainty_score":0.01862812},"labels":[],"label_agreement":null},{"id":"W1814864706","doi":"10.1517/13543784.2011.562190","title":"Investigational factor Xa inhibitors for thrombosis and acute coronary syndromes","year":2011,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Rivaroxaban; Apixaban; Medicine; Edoxaban; Dosing; Clinical trial; Intensive care medicine; Anticoagulant; Fondaparinux; Dabigatran; Pharmacodynamics; Atrial fibrillation; Discovery and development of direct thrombin inhibitors; Thrombosis; Pharmacokinetics; Pharmacology; Warfarin; Internal medicine; Venous thromboembolism; Thrombin","score_opus":0.2905933212457546,"score_gpt":0.4304623271137995,"score_spread":0.1398690058680449,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1814864706","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007980466,0.99600226,0.00012049144,0.0005825452,0.0004773288,0.000013112211,0.000032868287,0.000007654137,0.0026839685],"genre_scores_gemma":[0.0007407129,0.9962276,0.00021965645,0.0005169277,0.00055181666,0.00001535992,0.0000617962,0.0000018199758,0.0016643718],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99964523,0.00006921196,0.000046362115,0.00004352133,0.00016773824,0.000027915772],"domain_scores_gemma":[0.99948585,0.00017246981,0.00015415983,0.000012978089,0.00014578215,0.000028603317],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006805926,0.00082036585,0.0012522086,0.002233882,0.00018202524,0.0006615575,0.00062837516,0.0010334969,0.009214483],"category_scores_gemma":[0.00089159596,0.00019243656,0.00061518006,0.0027877304,0.00035237812,0.001016951,0.00044884603,0.0012037107,0.0057681086],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000085503765,0.000052520933,0.00015191943,0.021685937,0.000103934944,0.00022968288,0.000046952748,0.00012854525,0.00081743364,0.0020885859,0.071709745,0.90289927],"study_design_scores_gemma":[0.000052327203,0.0000705827,0.0010331112,0.007275233,0.0001373106,0.0016807917,0.000029601517,0.000046844867,0.0002528536,0.0009781776,0.9884316,0.000011677435],"about_ca_topic_score_codex":0.0007994808,"about_ca_topic_score_gemma":0.0014179656,"teacher_disagreement_score":0.009214483,"about_ca_system_score_codex":0.00040900486,"about_ca_system_score_gemma":0.0011713437,"threshold_uncertainty_score":0.030825555},"labels":[],"label_agreement":null},{"id":"W1897302030","doi":"10.1517/13543784.2015.1051220","title":"Targeting of cancer stem cells by inhibitors of DNA and histone methylation","year":2015,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"China Scholarship Council","keywords":"Histone; DNA methylation; Epigenetics; Cancer; Biology; Cancer research; Cancer epigenetics; Cancer stem cell; Stem cell; DNA; Genetics; Histone methyltransferase; Computational biology; Gene; Gene expression","score_opus":0.04232140536129853,"score_gpt":0.3578750581984829,"score_spread":0.3155536528371844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1897302030","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022629237,0.90573305,0.0073956586,0.024849314,0.0068735066,0.00022180205,0.001108089,0.0003748699,0.030814461],"genre_scores_gemma":[0.14457084,0.7900041,0.0047434377,0.013472977,0.0060092304,0.00023539455,0.001967325,0.000060401013,0.03893625],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99987996,0.00001999786,0.0000073223223,0.000023107881,0.00005077084,0.0000189178],"domain_scores_gemma":[0.9998846,0.000020105117,0.000030769057,0.0000034529367,0.000042752963,0.000018284632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024493053,0.00034812404,0.0003456367,0.00023178231,0.000105959814,0.00044029433,0.0003463426,0.0008447905,0.0064187115],"category_scores_gemma":[0.0002728262,0.00008197856,0.00034380815,0.00015977032,0.00017555564,0.00036088994,0.00024853868,0.00085129787,0.0024277407],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069248583,0.000149113,0.00090202695,0.008871167,0.00017898047,0.0004583866,0.000073132884,0.00093153404,0.111822486,0.008094386,0.1346852,0.7331411],"study_design_scores_gemma":[0.00022611521,0.00086587283,0.0019487891,0.0006983402,0.00013981783,0.0011513843,0.000049663347,0.0007410053,0.04179693,0.0024203404,0.949938,0.000023757031],"about_ca_topic_score_codex":0.0003531451,"about_ca_topic_score_gemma":0.0009010432,"teacher_disagreement_score":0.0064187115,"about_ca_system_score_codex":0.00043971007,"about_ca_system_score_gemma":0.0003138569,"threshold_uncertainty_score":0.021472692},"labels":[],"label_agreement":null},{"id":"W1965251241","doi":"10.1517/13543780902905848","title":"New treatments for idiopathic thrombocytopenic purpura: rethinking old hypotheses","year":2009,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Platelet Disorders and Treatments","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Canadian Institutes of Health Research; Amgen","keywords":"Thrombocytopenic purpura; Medicine; Immunology; Platelet","score_opus":0.1256630411908193,"score_gpt":0.3862692893222556,"score_spread":0.2606062481314363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965251241","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005320364,0.99781775,0.0000615826,0.0014549165,0.00028500013,0.0000029343853,0.000004527785,0.0000026495252,0.00031734415],"genre_scores_gemma":[0.00042637315,0.99801135,0.00016812497,0.00080954976,0.00039709464,0.000006363798,0.0000071243157,8.468984e-7,0.00017313146],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99925345,0.0002561076,0.000118084004,0.000076878896,0.00025890543,0.00003659509],"domain_scores_gemma":[0.9982167,0.0011474416,0.00017710886,0.000048609025,0.00034731603,0.000062776744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003069351,0.0009374419,0.002281395,0.0021791107,0.00033333089,0.0012178933,0.0015441747,0.0021307738,0.0032993946],"category_scores_gemma":[0.0024438703,0.0003228813,0.0007566928,0.0019807497,0.0012528648,0.0032681434,0.0006456345,0.0031081839,0.0016801088],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012767052,0.00008042332,0.00015151348,0.027780255,0.00021315618,0.0005613017,0.00014973471,0.0003378362,0.0007706886,0.0082040075,0.04634816,0.9152753],"study_design_scores_gemma":[0.000154321,0.0002076222,0.00086714927,0.018996436,0.00030761337,0.0027846252,0.0003152676,0.00019510552,0.00030865334,0.01021093,0.9656123,0.000040023642],"about_ca_topic_score_codex":0.00095306936,"about_ca_topic_score_gemma":0.002392993,"teacher_disagreement_score":0.0032993946,"about_ca_system_score_codex":0.0011245126,"about_ca_system_score_gemma":0.0015218164,"threshold_uncertainty_score":0.01623249},"labels":[],"label_agreement":null},{"id":"W1970919362","doi":"10.1517/13543784.11.8.1061","title":"Cytokine modulation in sepsis and septic shock","year":2002,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Macrophage Migration Inhibitory Factor","field":"Immunology and Microbiology","cited_by":113,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Sepsis; Medicine; Septic shock; Cytokine; Proinflammatory cytokine; Tumor necrosis factor alpha; Immunology; Inflammation","score_opus":0.05579661714413267,"score_gpt":0.3200596065372179,"score_spread":0.26426298939308523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970919362","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00032517497,0.99802494,0.00010158433,0.00020847667,0.00032661116,0.0000048545235,0.0000065137438,0.000004100276,0.0009977259],"genre_scores_gemma":[0.0022162513,0.99545175,0.00022520217,0.00031775562,0.0003454699,0.000010728385,0.000019409596,0.0000011930582,0.0014122579],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999864,0.000032186257,0.000017797074,0.000019772726,0.000052664906,0.00001364294],"domain_scores_gemma":[0.9999027,0.000030537092,0.000017366887,0.0000033521699,0.000033593496,0.000012363403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028970945,0.00066855,0.0010250185,0.0009358302,0.0002451083,0.00063650566,0.00048600102,0.0009389624,0.0022459326],"category_scores_gemma":[0.00029318436,0.00014085892,0.00024411967,0.0010973712,0.00030826696,0.0006778328,0.00034075242,0.0009338818,0.0019393077],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018617489,0.000120353456,0.00025677655,0.01008849,0.000053214244,0.0006135203,0.0000718564,0.00024681177,0.009077157,0.002220862,0.020493472,0.9565713],"study_design_scores_gemma":[0.000059518265,0.00038911068,0.002161954,0.0021231852,0.00009175435,0.0042174594,0.000100180376,0.00012901069,0.0030459086,0.0025124555,0.9851481,0.000021372067],"about_ca_topic_score_codex":0.000492907,"about_ca_topic_score_gemma":0.0010598141,"teacher_disagreement_score":0.0022459326,"about_ca_system_score_codex":0.00038284718,"about_ca_system_score_gemma":0.00056617457,"threshold_uncertainty_score":0.007513404},"labels":[],"label_agreement":null},{"id":"W1972990589","doi":"10.1517/13543784.16.9.1315","title":"Discontinued drugs in 2006: cardiovascular drugs translational medicine perspective","year":2007,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Health and Medical Research Impacts","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Translational medicine; Perspective (graphical); Medicine; Intensive care medicine; Translational research; Pipeline (software); Pharmacology; Computer science; Pathology; Artificial intelligence","score_opus":0.21975101929612723,"score_gpt":0.48077113902438307,"score_spread":0.26102011972825584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972990589","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012220528,0.9871443,0.00019488348,0.007505658,0.0020566299,0.0000059611257,0.000037851045,0.0000109449975,0.0029215442],"genre_scores_gemma":[0.00086454785,0.99109906,0.00024765646,0.0043413634,0.0020125213,0.0000075875155,0.00004749045,0.0000026522346,0.0013770956],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992353,0.00021261789,0.00011003238,0.0000988141,0.0002786413,0.000064626176],"domain_scores_gemma":[0.9977919,0.0010022401,0.0003602031,0.000045935743,0.00065432844,0.00014544904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024277512,0.00096719275,0.0019890168,0.0024908823,0.00038099178,0.0018579882,0.0010275665,0.0034682539,0.0065716323],"category_scores_gemma":[0.0026336785,0.00031959763,0.0009269446,0.0030574126,0.0006232731,0.0041018864,0.0008634408,0.003960114,0.0033006023],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012763753,0.00008074641,0.0002685148,0.012102194,0.00010939982,0.0005267557,0.000106837346,0.0003176598,0.0009255159,0.015893454,0.17847973,0.7910615],"study_design_scores_gemma":[0.000022505228,0.00011690272,0.00058327406,0.0030782453,0.000060045884,0.0011652322,0.00010005076,0.000063991334,0.00020929272,0.00239861,0.992188,0.000014016043],"about_ca_topic_score_codex":0.0017692458,"about_ca_topic_score_gemma":0.0049451645,"teacher_disagreement_score":0.0065716323,"about_ca_system_score_codex":0.0017325858,"about_ca_system_score_gemma":0.003133084,"threshold_uncertainty_score":0.02198428},"labels":[],"label_agreement":null},{"id":"W1974617095","doi":"10.1517/13543784.2012.668882","title":"ENMD-2076 for hematological malignancies","year":2012,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Hematology; Multiple myeloma; Oncology; Internal medicine; Myeloid leukemia; Cancer research; Leukemia; Aurora inhibitor; Expert opinion; Clinical trial; Lymphoma; Kinase; Cancer; Intensive care medicine; Biology; Cell cycle","score_opus":0.07468509289997952,"score_gpt":0.3500534612008316,"score_spread":0.2753683683008521,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974617095","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011163348,0.9979316,0.00007721903,0.00032594305,0.0002501651,0.0000072638413,0.000027327547,0.000007949024,0.0012608476],"genre_scores_gemma":[0.0007444749,0.99711776,0.00016309702,0.00038489592,0.00021977116,0.00000926153,0.000068592024,0.0000018794991,0.0012903013],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998611,0.000021393365,0.000019804735,0.000025781512,0.000058425023,0.000013472927],"domain_scores_gemma":[0.9998431,0.00005852156,0.000031375013,0.0000041146227,0.00004564332,0.000017279288],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038091515,0.0006414766,0.0010002542,0.0016755364,0.00019832862,0.0006042062,0.0007846988,0.0008616495,0.0058255796],"category_scores_gemma":[0.0004785344,0.00016781763,0.00053326524,0.001394348,0.00024786423,0.0008355273,0.0004513455,0.0015232583,0.0031322932],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009206661,0.00004386486,0.00008262594,0.014784717,0.00007600818,0.00018871989,0.000025568388,0.00017776794,0.0012000069,0.0011299655,0.046753045,0.93544567],"study_design_scores_gemma":[0.000041138454,0.00008745089,0.0005741997,0.00414527,0.00013659369,0.0017753043,0.000023965249,0.000063733925,0.00046600308,0.0006772072,0.9919973,0.000011665624],"about_ca_topic_score_codex":0.0008263844,"about_ca_topic_score_gemma":0.0019538382,"teacher_disagreement_score":0.0058255796,"about_ca_system_score_codex":0.000549097,"about_ca_system_score_gemma":0.0007561651,"threshold_uncertainty_score":0.019488513},"labels":[],"label_agreement":null},{"id":"W1988024888","doi":"10.1517/13543784.2013.822485","title":"Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia","year":2013,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Canadian Institutes of Health Research","keywords":"PCSK9; Ezetimibe; Alirocumab; Proprotein convertase; Evolocumab; Pharmacology; Tolerability; Kexin; Niacin; Medicine; Statin; Familial hypercholesterolemia; Dyslipidemia; Adverse effect; Internal medicine; Cholesterol; Endocrinology; Apolipoprotein B; Lipoprotein; LDL receptor; Disease; Apolipoprotein A1","score_opus":0.09729688680475103,"score_gpt":0.4063385413648205,"score_spread":0.3090416545600695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988024888","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017484467,0.99582857,0.00022310656,0.0006099275,0.00031887178,0.000023504586,0.000057513713,0.000017431581,0.0027462316],"genre_scores_gemma":[0.00087005115,0.9962999,0.0003122567,0.00055007805,0.00026495752,0.000020531746,0.000099077755,0.0000029191672,0.0015802413],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997925,0.00003520291,0.000024905936,0.000029604185,0.000095311814,0.000022488452],"domain_scores_gemma":[0.9997539,0.00007165703,0.000067681176,0.0000061736496,0.000076778146,0.000023853452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049165013,0.00072734203,0.0011813714,0.0011529437,0.0001728375,0.00072877615,0.0008052514,0.00093841914,0.008550635],"category_scores_gemma":[0.00055217254,0.00017770157,0.0006839015,0.0013758057,0.0002455567,0.00073866436,0.0004461722,0.0013607427,0.005135356],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009306829,0.00006285777,0.00007278401,0.014106462,0.00009323397,0.00009502045,0.000019625491,0.00012069699,0.0013207131,0.00092895277,0.040495824,0.9425908],"study_design_scores_gemma":[0.00009397381,0.0001536856,0.0007105026,0.00669535,0.00025741375,0.0011321733,0.000031114567,0.00008741672,0.00055453175,0.0010101822,0.9892587,0.000014927666],"about_ca_topic_score_codex":0.0005079214,"about_ca_topic_score_gemma":0.0013371373,"teacher_disagreement_score":0.008550635,"about_ca_system_score_codex":0.0004138598,"about_ca_system_score_gemma":0.00079516374,"threshold_uncertainty_score":0.028604746},"labels":[],"label_agreement":null},{"id":"W1988565068","doi":"10.1517/13543784.10.11.1937","title":"An update on the status of endothelin receptor antagonists for hypertension","year":2001,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Nitric Oxide and Endothelin Effects","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Endothelin receptor; Context (archaeology); Endothelin receptor antagonist; Clinical trial; Damages; Pulmonary hypertension; Intensive care medicine; Blood pressure; Drug; Pharmacology; Receptor; Internal medicine; Cardiology; Biology","score_opus":0.09096548893189195,"score_gpt":0.37419146824180255,"score_spread":0.2832259793099106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988565068","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018511344,0.98949826,0.00022871586,0.0027214324,0.0039314968,0.000016309326,0.000059273116,0.000021030233,0.0033383684],"genre_scores_gemma":[0.0007922747,0.98875016,0.0006219988,0.002786841,0.0036803023,0.000026249936,0.00010562947,0.000004122743,0.003232282],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995559,0.00010502241,0.0000890814,0.00004559093,0.00017189387,0.000032357893],"domain_scores_gemma":[0.99869627,0.000644478,0.00013590026,0.000026212592,0.00036931556,0.00012782778],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013597471,0.0010871341,0.0018701729,0.002578259,0.00039368853,0.0014015516,0.0014587952,0.002413789,0.011381823],"category_scores_gemma":[0.0020806498,0.00031623032,0.00076974614,0.002337331,0.00031168136,0.0022727642,0.0005206406,0.0019208384,0.006901128],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001473439,0.00012867567,0.00019594499,0.011999899,0.0001045334,0.00090780144,0.00008134023,0.00022493523,0.0013369471,0.0015635033,0.23413838,0.74917066],"study_design_scores_gemma":[0.000042922064,0.000116789255,0.00054158794,0.0025634177,0.00011619489,0.001589308,0.00004067183,0.00006454164,0.00014014618,0.00063554314,0.9941361,0.00001280272],"about_ca_topic_score_codex":0.0010829216,"about_ca_topic_score_gemma":0.0037903748,"teacher_disagreement_score":0.011381823,"about_ca_system_score_codex":0.00073641766,"about_ca_system_score_gemma":0.0013492453,"threshold_uncertainty_score":0.038076043},"labels":[],"label_agreement":null},{"id":"W1993494094","doi":"10.1517/13543784.16.10.1627","title":"Omega-3 fatty acid eicosapentaenoic acid. A new treatment for psychiatric and neurodegenerative diseases: a review of clinical investigations","year":2007,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Fatty Acid Research and Health","field":"Nursing","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"The Scarborough Hospital; University of Toronto; University of Prince Edward Island","funders":"","keywords":"Eicosapentaenoic acid; Clinical trial; Schizophrenia (object-oriented programming); Disease; Medicine; Depression (economics); Neuroprotection; Omega 3 fatty acid; Psychiatry; Placebo; Polyunsaturated fatty acid; Internal medicine; Docosahexaenoic acid; Fatty acid; Biology; Alternative medicine; Pathology; Biochemistry","score_opus":0.2169775897946894,"score_gpt":0.49454567394869875,"score_spread":0.27756808415400935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1993494094","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004754432,0.9993705,0.000029687768,0.00018415466,0.00008190484,0.000004257561,0.000010443991,0.0000018789748,0.00026953398],"genre_scores_gemma":[0.00025329756,0.99929285,0.00010742194,0.00012574201,0.000058129903,0.000005620648,0.0000115757075,4.642947e-7,0.00014492139],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996871,0.00005952996,0.000066731904,0.000047790483,0.00012258903,0.000016261227],"domain_scores_gemma":[0.9992687,0.00037226407,0.0001279002,0.0000142490235,0.00017724953,0.000039620085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009788782,0.00082736416,0.0025200022,0.0030319602,0.00029274085,0.00086228974,0.0008991645,0.0010644703,0.00483783],"category_scores_gemma":[0.0012726876,0.00030554435,0.00077633216,0.0036100976,0.00037647903,0.0011281085,0.000479329,0.0010705251,0.0020214259],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011570239,0.00007171303,0.00021502044,0.056143362,0.00022579274,0.00025227826,0.000054617925,0.00014318804,0.0010366284,0.0008753649,0.025119498,0.9157467],"study_design_scores_gemma":[0.0001431209,0.0002859222,0.0026785838,0.039910704,0.001033871,0.0027781252,0.00027088387,0.00011503575,0.0006247604,0.0020217786,0.950098,0.000039186605],"about_ca_topic_score_codex":0.0015639806,"about_ca_topic_score_gemma":0.003969754,"teacher_disagreement_score":0.00483783,"about_ca_system_score_codex":0.0006086741,"about_ca_system_score_gemma":0.0016022116,"threshold_uncertainty_score":0.01618421},"labels":[],"label_agreement":null},{"id":"W2000128451","doi":"10.1517/13543784.2014.907272","title":"Recent and current Phase II clinical trials in endometrial cancer: review of the state of art","year":2014,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical trial; Tolerability; Endometrial cancer; Context (archaeology); Disease; Drug development; Quality of life (healthcare); MEDLINE; Intensive care medicine; Cancer; Alternative medicine; Oncology; Bioinformatics; Internal medicine; Pharmacology; Drug; Pathology","score_opus":0.29065493866975994,"score_gpt":0.5403879654482976,"score_spread":0.24973302677853765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000128451","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007175409,0.9991166,0.000058714806,0.00026917833,0.000110529574,0.000021803186,0.000035436395,0.0000040703208,0.0003119059],"genre_scores_gemma":[0.0005804038,0.99866545,0.00016666952,0.00031903054,0.00008656494,0.000028571256,0.000036864243,0.0000015972068,0.00011492396],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990602,0.00025812248,0.0002692856,0.00010877394,0.0002501019,0.00005345849],"domain_scores_gemma":[0.9953784,0.002890267,0.00079212344,0.00007190516,0.00073723693,0.0001300668],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031806356,0.0009318952,0.0031684977,0.0025971925,0.00032629762,0.0015157798,0.0018516983,0.0017022331,0.005902423],"category_scores_gemma":[0.0061610597,0.0004606968,0.0020259088,0.004028743,0.00052251486,0.0015858066,0.0007281396,0.0016141289,0.0012488283],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031483427,0.000066697525,0.00019740165,0.2155592,0.00059310725,0.00013480097,0.000099527846,0.00025810918,0.0007342748,0.0010531034,0.023500275,0.7574887],"study_design_scores_gemma":[0.00028902793,0.00056222815,0.0019478155,0.19830564,0.0047976887,0.001311759,0.00021068862,0.00019801539,0.0006681771,0.0017727647,0.78988284,0.00005329283],"about_ca_topic_score_codex":0.001281687,"about_ca_topic_score_gemma":0.0031216312,"teacher_disagreement_score":0.005902423,"about_ca_system_score_codex":0.0009409663,"about_ca_system_score_gemma":0.0031467958,"threshold_uncertainty_score":0.019745529},"labels":[],"label_agreement":null},{"id":"W2000370942","doi":"10.1517/13543784.9.9.2051","title":"Animal models in xenotransplantation","year":2000,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Xenotransplantation and immune response","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"Medical Research Council; Physicians' Services Incorporated Foundation","keywords":"Xenotransplantation; Biology; Animal model; Computational biology; Transplantation; Medicine; Internal medicine; Endocrinology","score_opus":0.09810914091250716,"score_gpt":0.38366950857728577,"score_spread":0.2855603676647786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000370942","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006233629,0.76066154,0.16790837,0.004914734,0.0056095356,0.0009035822,0.0013709008,0.0009826651,0.051415056],"genre_scores_gemma":[0.034755856,0.7902015,0.14327914,0.0048182164,0.0034177594,0.0019990797,0.0037394308,0.0003655663,0.017423477],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968592,0.0013092079,0.00036264802,0.00030025924,0.0010036925,0.00016501798],"domain_scores_gemma":[0.99869555,0.0005967326,0.00018830014,0.00023609884,0.0001670732,0.000116282594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003541149,0.001307083,0.0019633968,0.002593465,0.00060345227,0.0023340818,0.0019084703,0.0028953282,0.0060755266],"category_scores_gemma":[0.0018348922,0.0005729301,0.0012862674,0.0024986512,0.0020073634,0.0022630426,0.0023248773,0.0056824195,0.0042598164],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007009198,0.00077702553,0.0022725747,0.01742644,0.00036753475,0.0027580045,0.00073575304,0.0036598514,0.13756515,0.17437166,0.0857846,0.57358056],"study_design_scores_gemma":[0.000042110532,0.0007982267,0.0013229472,0.0024189227,0.00013348716,0.005202744,0.00012591944,0.0008549128,0.017133825,0.02285081,0.9490444,0.000071687165],"about_ca_topic_score_codex":0.0005935342,"about_ca_topic_score_gemma":0.0005813581,"teacher_disagreement_score":0.0060755266,"about_ca_system_score_codex":0.0008487425,"about_ca_system_score_gemma":0.0011304413,"threshold_uncertainty_score":0.020324647},"labels":[],"label_agreement":null},{"id":"W2002307343","doi":"10.1517/13543784.2011.549125","title":"AMG 386: profile of a novel angiopoietin antagonist in patients with ovarian cancer","year":2011,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; Amgen (Canada)","funders":"","keywords":"Angiopoietin 2; Ovarian cancer; Medicine; Angiogenesis; Malignancy; Cancer; Oncology; Antagonist; Internal medicine; Disease; Tumor progression; Overall survival; Cancer research; Receptor; VEGF receptors; Vascular endothelial growth factor","score_opus":0.0426732515451642,"score_gpt":0.31938400671454525,"score_spread":0.27671075516938104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002307343","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22308134,0.7505119,0.0014095318,0.004514213,0.000523811,0.0002495646,0.0014265925,0.00009793392,0.018185116],"genre_scores_gemma":[0.70094675,0.2798055,0.003116535,0.005023862,0.0008484905,0.00027981208,0.0027745923,0.000031323765,0.0071732756],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999081,0.000027819024,0.000009532707,0.000013926217,0.000027800193,0.000012906783],"domain_scores_gemma":[0.9998642,0.000041839794,0.000041357354,0.0000025736697,0.00002527341,0.0000247386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028349928,0.00015943765,0.00038347417,0.00015809305,0.00007668117,0.00029887972,0.0001346725,0.00026545417,0.0025237962],"category_scores_gemma":[0.0005654775,0.000041565017,0.00023740929,0.00021243557,0.000058376656,0.00018621457,0.00010907515,0.0005049136,0.00047418033],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061831884,0.00027816428,0.011003143,0.0035714395,0.00046120622,0.00068466656,0.00011684729,0.0010703586,0.033102866,0.0009409265,0.019471446,0.9231157],"study_design_scores_gemma":[0.0065203966,0.041521344,0.10942013,0.003253761,0.0026540712,0.013302287,0.00033374896,0.0035050164,0.02481655,0.0034552244,0.79111326,0.00010426553],"about_ca_topic_score_codex":0.00019458572,"about_ca_topic_score_gemma":0.00070241,"teacher_disagreement_score":0.0025237962,"about_ca_system_score_codex":0.00021629913,"about_ca_system_score_gemma":0.00024054789,"threshold_uncertainty_score":0.008442998},"labels":[],"label_agreement":null},{"id":"W2003487329","doi":"10.1517/13543784.16.4.519","title":"Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent","year":2007,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Cardiac electrophysiology and arrhythmias","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; Cardiome Pharma Corp.","keywords":"Medicine; Atrial fibrillation; Cardiology; Sinus rhythm; Internal medicine; Exacerbation; Ranolazine; Anti-Arrhythmia Agents","score_opus":0.08118196522207384,"score_gpt":0.38167944945452537,"score_spread":0.30049748423245154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003487329","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016744022,0.9932969,0.0006169452,0.00036897583,0.00036087033,0.000020318894,0.00003479488,0.00003088588,0.0035957848],"genre_scores_gemma":[0.0058824383,0.9891746,0.0010664266,0.00048094353,0.0003635811,0.000026557942,0.00010565506,0.0000043587847,0.0028954432],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998969,0.000014717031,0.00001498859,0.00001979985,0.000042000196,0.000011653116],"domain_scores_gemma":[0.9999354,0.00002362521,0.00001575182,0.0000019801812,0.000014069503,0.000009260416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026109722,0.0007038524,0.0008932125,0.0012200675,0.00019851082,0.0005044061,0.00050967507,0.00084831193,0.002133841],"category_scores_gemma":[0.00022754593,0.00014438991,0.0003227696,0.0007477133,0.00021785556,0.00063681725,0.00024756877,0.00082865695,0.0019718073],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013064953,0.000109081426,0.00014823166,0.0062493593,0.000055663844,0.0010714624,0.000045825134,0.00027227466,0.012910008,0.001156034,0.01279172,0.96505976],"study_design_scores_gemma":[0.00012536708,0.0005544976,0.0015432457,0.0010065093,0.00012278432,0.009970963,0.000050461127,0.00021069088,0.0054641087,0.0007252805,0.98019356,0.000032565273],"about_ca_topic_score_codex":0.00041662692,"about_ca_topic_score_gemma":0.0009910276,"teacher_disagreement_score":0.002133841,"about_ca_system_score_codex":0.0002735821,"about_ca_system_score_gemma":0.0003360544,"threshold_uncertainty_score":0.007138431},"labels":[],"label_agreement":null},{"id":"W2004668464","doi":"10.1517/13543784.16.8.1183","title":"Looking for novel ways to treat the hallmarks of Alzheimer's disease","year":2007,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Alzheimer's disease research and treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Association of Nurses in Oncology","funders":"","keywords":"Disease; Medicine; Population ageing; Intensive care medicine; Population; Public health; Pathology","score_opus":0.1889479930650907,"score_gpt":0.4335896363934577,"score_spread":0.24464164332836702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004668464","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016263597,0.99519277,0.00035301707,0.0011686145,0.0006350724,0.000014158108,0.000018823914,0.00001593774,0.0024389897],"genre_scores_gemma":[0.0005213687,0.99658966,0.00061307085,0.0006693038,0.0003116685,0.00001526586,0.00003348506,0.0000019479457,0.0012443429],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999728,0.000059578004,0.00003243005,0.000041492196,0.000111723464,0.000026821177],"domain_scores_gemma":[0.999705,0.00011695315,0.000046174,0.000010475293,0.00009161165,0.000029714449],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007200221,0.0010705125,0.00230986,0.0018456894,0.0003757748,0.0010115803,0.0011426411,0.00211503,0.007980282],"category_scores_gemma":[0.0007062006,0.00023981188,0.000622744,0.0017110833,0.0005615922,0.001820787,0.0005301696,0.0022885054,0.006295841],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000789888,0.00014837459,0.00012057443,0.015007357,0.00010424245,0.00047322662,0.000066762834,0.00027844205,0.0038736733,0.0034383151,0.04529835,0.93111163],"study_design_scores_gemma":[0.00006859821,0.00020061519,0.00073401304,0.004464086,0.00014234961,0.0025707115,0.000113189,0.00009737422,0.0008809597,0.0032044093,0.98749894,0.000024697807],"about_ca_topic_score_codex":0.00077316933,"about_ca_topic_score_gemma":0.002065642,"teacher_disagreement_score":0.007980282,"about_ca_system_score_codex":0.0005491894,"about_ca_system_score_gemma":0.0010975135,"threshold_uncertainty_score":0.026696742},"labels":[],"label_agreement":null},{"id":"W2005370593","doi":"10.1517/13543784.2012.646081","title":"Apaziquone as an intravesical therapeutic agent for urothelial non-muscle-invasive bladder cancer","year":2011,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Victoria Hospital; London Health Sciences Centre; Western University","funders":"","keywords":"Urothelial carcinoma; Bladder cancer; Mitomycin C; Medicine; Urothelial cancer; Urology; Cancer; Cancer research; Urothelium; Cytotoxic T cell; Urinary bladder; Oncology; Internal medicine; Biology; Surgery; In vitro","score_opus":0.11641905106193319,"score_gpt":0.4085934940975326,"score_spread":0.2921744430355994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005370593","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018900166,0.99838257,0.0000871392,0.00017282972,0.00013613774,0.000007409374,0.000016857377,0.0000048227325,0.0010032275],"genre_scores_gemma":[0.0011758918,0.9974917,0.00016012025,0.00018464949,0.00009225684,0.000007711027,0.0000273682,0.0000010718753,0.00085915904],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998821,0.000024179035,0.000017665701,0.000020195734,0.00004570063,0.000010164469],"domain_scores_gemma":[0.99987876,0.00004659295,0.0000312426,0.0000030373265,0.000031798612,0.000008570666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033893695,0.00056424725,0.0009557847,0.0014226604,0.00018124605,0.00047317543,0.0005297054,0.0007384096,0.004988211],"category_scores_gemma":[0.00031527394,0.00014998464,0.000381146,0.0014964318,0.0002493276,0.0006734581,0.00026810964,0.00085419056,0.0019022514],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012556024,0.00008674351,0.00013781786,0.031770166,0.000108416454,0.0003714452,0.00005887394,0.0003646711,0.005320174,0.00220772,0.028976245,0.93047214],"study_design_scores_gemma":[0.000049733688,0.00022952605,0.001060434,0.0058307187,0.00018490822,0.0030767573,0.000060820676,0.00011354467,0.0017598567,0.0008739683,0.9867409,0.000018839857],"about_ca_topic_score_codex":0.0011339244,"about_ca_topic_score_gemma":0.0027755022,"teacher_disagreement_score":0.004988211,"about_ca_system_score_codex":0.0004222011,"about_ca_system_score_gemma":0.0007198684,"threshold_uncertainty_score":0.016687274},"labels":[],"label_agreement":null},{"id":"W2008784330","doi":"10.1517/13543780902752463","title":"Targeting apoptosis: preclinical and early clinical experience with mapatumumab, an agonist monoclonal antibody targeting TRAIL-R1","year":2009,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Monoclonal antibody; Apoptosis; Medicine; Cancer; Radiation therapy; Chemotherapy; Cancer research; Cancer cell; Immunology; Pharmacology; Oncology; Antibody; Internal medicine; Biology","score_opus":0.06154890020905902,"score_gpt":0.39466437696634865,"score_spread":0.33311547675728964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008784330","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017321515,0.9923375,0.000715507,0.0007367483,0.00029515795,0.00003095753,0.000055222623,0.000022995506,0.004073822],"genre_scores_gemma":[0.007376315,0.9866014,0.0010202479,0.00087562,0.00025284055,0.000037934384,0.00013469918,0.0000082151355,0.00369271],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997863,0.000046678837,0.000020583797,0.000038817874,0.00008391604,0.000023733146],"domain_scores_gemma":[0.99979204,0.00006714231,0.00003112685,0.000008339305,0.000071414834,0.000030032597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010649653,0.0010091474,0.0012847399,0.00082509906,0.00020634534,0.00090815214,0.00080235687,0.0010398929,0.0027914841],"category_scores_gemma":[0.00056272437,0.00019807425,0.00039136197,0.0008467166,0.0003555203,0.0010456637,0.00044175208,0.0013531458,0.0025340528],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035805683,0.0002036443,0.00015538592,0.0037273564,0.000059112874,0.00038293985,0.000058153917,0.00044035228,0.0077153402,0.0017321078,0.018700333,0.9664673],"study_design_scores_gemma":[0.00034925106,0.001592451,0.0012409687,0.0014759457,0.00017224059,0.0032690277,0.00006193221,0.0003358356,0.008079278,0.0017206796,0.98166245,0.000040066716],"about_ca_topic_score_codex":0.0005581391,"about_ca_topic_score_gemma":0.001450983,"teacher_disagreement_score":0.0027914841,"about_ca_system_score_codex":0.00077798293,"about_ca_system_score_gemma":0.000569021,"threshold_uncertainty_score":0.009338498},"labels":[],"label_agreement":null},{"id":"W2009085459","doi":"10.1517/13543780903336050","title":"Antivascular agents for non-small-cell lung cancer: current status and future directions","year":2009,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Bevacizumab; Medicine; Oncology; Targeted therapy; Lung cancer; Clinical trial; Internal medicine; Vascular endothelial growth factor; Chemotherapy; Monoclonal antibody; Cancer; Intensive care medicine; VEGF receptors; Immunology; Antibody","score_opus":0.03724310527637133,"score_gpt":0.35748955878031713,"score_spread":0.3202464535039458,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009085459","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000982317,0.9987099,0.000094767,0.00045434918,0.00019731917,0.0000047121907,0.000008020829,0.000006329864,0.0004264082],"genre_scores_gemma":[0.00042798102,0.9986224,0.00017532901,0.00022139878,0.00021396093,0.0000060209227,0.000015463092,9.659622e-7,0.0003163875],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99980515,0.000039229955,0.000027804968,0.000028737511,0.000078710116,0.000020519645],"domain_scores_gemma":[0.99953747,0.00021706444,0.00006451332,0.000009977739,0.00012277237,0.000048309394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009918191,0.00075437117,0.0015573055,0.0011945342,0.0002494396,0.0009240937,0.0010074726,0.0013222044,0.0037583443],"category_scores_gemma":[0.0007347937,0.00022436204,0.0005257758,0.0014312597,0.00047318154,0.0016276188,0.00045142896,0.0017966331,0.0022853143],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014578867,0.00010772873,0.00013965924,0.010485184,0.00006462858,0.00021306118,0.000030282199,0.00031261714,0.0017956811,0.0016112062,0.032189094,0.95290506],"study_design_scores_gemma":[0.000116779855,0.00031874466,0.000901981,0.0040819678,0.00019028595,0.0019548042,0.00007618486,0.00023677925,0.0007424661,0.00228253,0.9890726,0.0000248878],"about_ca_topic_score_codex":0.0007965481,"about_ca_topic_score_gemma":0.0019316329,"teacher_disagreement_score":0.0037583443,"about_ca_system_score_codex":0.00062085467,"about_ca_system_score_gemma":0.001149594,"threshold_uncertainty_score":0.012572885},"labels":[],"label_agreement":null},{"id":"W2011994674","doi":"10.1517/13543780903184591","title":"Discontinued psychiatric drugs in 2008","year":2009,"lang":"en","type":"article","venue":"Expert Opinion on Investigational Drugs","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Mental illness; Psychiatry; Mood disorders; Medicine; Disease; Mood; Psychology; Mental health; Anxiety","score_opus":0.025545702541629953,"score_gpt":0.32921201957993546,"score_spread":0.3036663170383055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011994674","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0404962,0.262075,0.0029522758,0.077236496,0.022324855,0.0005935728,0.019006122,0.00087224843,0.5744433],"genre_scores_gemma":[0.189456,0.1387875,0.005402436,0.08476544,0.006418042,0.0005087946,0.015380394,0.00020916763,0.5590722],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994205,0.00010606326,0.00007336237,0.000083112696,0.00023778657,0.00007914688],"domain_scores_gemma":[0.99925977,0.0001327722,0.00010869092,0.000053154505,0.00029333035,0.00015241539],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006677254,0.000392345,0.00052324426,0.00067146175,0.00070603774,0.001165283,0.00052450335,0.0015173663,0.038884405],"category_scores_gemma":[0.002317017,0.00014541527,0.00041623888,0.0007097925,0.00030918614,0.0006461549,0.00071961014,0.0019375557,0.01616786],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005815352,0.00020083599,0.003305126,0.00087402825,0.00006600969,0.0009298305,0.00012256386,0.00005048605,0.0014528858,0.0081881955,0.31865215,0.66557634],"study_design_scores_gemma":[0.00005028714,0.0001252359,0.005003676,0.00020670942,0.00002480805,0.001216182,0.000040865456,0.00003616438,0.00045780066,0.0004513158,0.99238,0.000007017106],"about_ca_topic_score_codex":0.0041495883,"about_ca_topic_score_gemma":0.012975277,"teacher_disagreement_score":0.038884405,"about_ca_system_score_codex":0.0018255634,"about_ca_system_score_gemma":0.0018452036,"threshold_uncertainty_score":0.1300813},"labels":[],"label_agreement":null},{"id":"W2013917368","doi":"10.1517/13543784.13.2.139","title":"Current and investigational treatment of psoriatic arthritis","year":2004,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital","funders":"","keywords":"Medicine; Psoriatic arthritis; Leflunomide; Psoriasis; Rheumatoid arthritis; Disease; Arthritis; Clinical trial; Antirheumatic drugs; Internal medicine; Oncology; Antirheumatic Agents; Immunology","score_opus":0.07521642956042679,"score_gpt":0.3736866971312487,"score_spread":0.2984702675708219,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013917368","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000115009374,0.99810946,0.000050189712,0.00016038238,0.00014555876,0.0000054871566,0.000013279559,0.0000042453084,0.0013963889],"genre_scores_gemma":[0.0007847468,0.997759,0.00012852116,0.00023711566,0.00016892726,0.000008634038,0.000025946754,8.827496e-7,0.0008862106],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995639,0.000088308654,0.000059288588,0.00006746398,0.00019243332,0.00002861199],"domain_scores_gemma":[0.9996524,0.00012821448,0.000087264416,0.00001608347,0.0000804686,0.000035602046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007590772,0.000719413,0.0013751443,0.0017170568,0.00028818054,0.0008316071,0.0008778998,0.0010989074,0.009055256],"category_scores_gemma":[0.00079644145,0.00020933549,0.00050427706,0.0020216145,0.0003873622,0.00091360084,0.0004570928,0.0011365202,0.004341007],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000101014324,0.0000819596,0.00011192523,0.012692179,0.000057104346,0.00020620447,0.00003292071,0.000076786404,0.0012154137,0.0007702113,0.019252704,0.9654017],"study_design_scores_gemma":[0.000105444815,0.0002664531,0.0014947598,0.0056033456,0.0001689222,0.0025418526,0.00007662331,0.00005223517,0.0007464337,0.0009235267,0.9880058,0.000014510234],"about_ca_topic_score_codex":0.0009202685,"about_ca_topic_score_gemma":0.0021119367,"teacher_disagreement_score":0.009055256,"about_ca_system_score_codex":0.00052924815,"about_ca_system_score_gemma":0.0009361084,"threshold_uncertainty_score":0.030292869},"labels":[],"label_agreement":null},{"id":"W2015553616","doi":"10.1517/13543784.11.7.937","title":"Novel therapies in the treatment of spondyloarthritis","year":2002,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Ankylosing spondylitis; Psoriatic arthritis; Observational study; Adalimumab; Clinical trial; Inflammatory arthritis; Intensive care medicine; Placebo; Tumor necrosis factor alpha; Arthritis; Internal medicine; Alternative medicine; Pathology","score_opus":0.11037823578546131,"score_gpt":0.3657993861203648,"score_spread":0.2554211503349035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015553616","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012848552,0.9984112,0.000070906724,0.00019929113,0.00011740754,0.000010086969,0.000011403315,0.0000041569083,0.0010470453],"genre_scores_gemma":[0.0007466827,0.9979717,0.00026987406,0.00021722993,0.00013097425,0.000012896206,0.000022006312,7.831293e-7,0.00062785967],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99959093,0.00011086525,0.000055665852,0.00004646933,0.00016659789,0.000029562503],"domain_scores_gemma":[0.9996587,0.00015744995,0.000073509844,0.000011448725,0.00007354659,0.00002539352],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010549658,0.0008531066,0.0020502224,0.002290902,0.00029209294,0.0008709017,0.000880511,0.001375777,0.007929973],"category_scores_gemma":[0.0007591719,0.00024083637,0.00059611857,0.0022892905,0.0004857794,0.0010796542,0.0004974111,0.0012814598,0.0035473935],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018504277,0.0001608233,0.00013001767,0.025064094,0.00014245819,0.00040404726,0.000060991126,0.00023605047,0.0023254873,0.0017488698,0.01734934,0.95219266],"study_design_scores_gemma":[0.00022467834,0.0004643912,0.0015659855,0.0089116655,0.0003037568,0.0026526006,0.0001214796,0.000094164905,0.0009879372,0.002265764,0.9823844,0.00002329427],"about_ca_topic_score_codex":0.0008928916,"about_ca_topic_score_gemma":0.0025853626,"teacher_disagreement_score":0.007929973,"about_ca_system_score_codex":0.0005852197,"about_ca_system_score_gemma":0.0010308636,"threshold_uncertainty_score":0.026528418},"labels":[],"label_agreement":null},{"id":"W2017150135","doi":"10.1517/13543784.14.8.1019","title":"Angiotensin-(1-7) and its receptor as a potential targets for new cardiovascular drugs","year":2005,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Renin-Angiotensin System Studies","field":"Medicine","cited_by":132,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Clinical Research Institute","funders":"","keywords":"Angiotensin II receptor type 1; Renin–angiotensin system; Angiotensin II; Receptor; Angiotensin receptor; Angiotensin-converting enzyme; Pharmacology; Internal medicine; Biology; Chemistry; Endocrinology; Medicine; Blood pressure","score_opus":0.06479758894437689,"score_gpt":0.35178939358215555,"score_spread":0.2869918046377787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017150135","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019173825,0.99745435,0.00010037387,0.0005618618,0.00023561771,0.000006169161,0.000011114715,0.0000044432386,0.0014342343],"genre_scores_gemma":[0.0010462615,0.99656385,0.00028182394,0.00044448389,0.00034904212,0.000009583854,0.000022950031,9.3007213e-7,0.0012810375],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99978703,0.00006306473,0.000024803825,0.000023422886,0.000083150626,0.000018548246],"domain_scores_gemma":[0.9997665,0.0001028368,0.000037283797,0.0000065877184,0.00006457729,0.000022202572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071969006,0.00056960026,0.0015385199,0.0012592888,0.00021364358,0.00071257673,0.0007341481,0.0011673627,0.005888123],"category_scores_gemma":[0.00048190434,0.00019535777,0.00035885838,0.0011283751,0.00029955577,0.0012309027,0.00031804413,0.0011049828,0.0036093588],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024976538,0.00017258603,0.0002456852,0.015162782,0.000121802674,0.001035619,0.00006723479,0.00029604614,0.004786624,0.0042225416,0.03988977,0.93374944],"study_design_scores_gemma":[0.00011400712,0.00029939984,0.0012250516,0.002897755,0.00017981498,0.0030572945,0.00011601747,0.00012273979,0.0010305536,0.0025302079,0.98840696,0.000020143729],"about_ca_topic_score_codex":0.0007359662,"about_ca_topic_score_gemma":0.0023381705,"teacher_disagreement_score":0.005888123,"about_ca_system_score_codex":0.00054786005,"about_ca_system_score_gemma":0.0010564356,"threshold_uncertainty_score":0.019697785},"labels":[],"label_agreement":null},{"id":"W2020509695","doi":"10.1517/13543784.16.3.397","title":"3<sup>rd</sup>PacRim Breast and Prostate Cancer Meeting","year":2007,"lang":"en","type":"article","venue":"Expert Opinion on Investigational Drugs","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Androgen receptor; Breast cancer; Context (archaeology); Estrogen; Medicine; Estrogen receptor; Cancer; Prostate; Oncology; Internal medicine; Gynecology; Cancer research; Biology","score_opus":0.03216663827553005,"score_gpt":0.34997464406226947,"score_spread":0.3178080057867394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020509695","genre_codex":"other","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016831032,0.032597836,0.0010394213,0.26746243,0.33145142,0.0004569957,0.0024229048,0.0003961518,0.36248976],"genre_scores_gemma":[0.012214081,0.01514751,0.0011797106,0.11247681,0.09174948,0.00038993746,0.001765596,0.00027387793,0.764803],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998841,0.00021679346,0.000065525324,0.00012699277,0.0005438297,0.00020596731],"domain_scores_gemma":[0.9973642,0.0003174959,0.00014147027,0.00007089488,0.0012813988,0.0008244592],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018128952,0.00075538654,0.0006628402,0.00077564665,0.0016267557,0.003283604,0.001542545,0.005298363,0.1330727],"category_scores_gemma":[0.0036650316,0.00030677055,0.0010249575,0.00054062135,0.000566762,0.00094137783,0.0012280231,0.0062746634,0.078038596],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006666894,0.000009754854,0.00009929777,0.00009055775,0.0000055613345,0.00017403418,0.000011194954,0.000019819783,0.00016177462,0.0002826751,0.98551744,0.013561304],"study_design_scores_gemma":[0.000015956786,0.00002376176,0.0008093886,0.000101782396,0.0000047329304,0.00015251279,0.000043746848,0.000043109296,0.0001157927,0.00015240752,0.9985299,0.0000067245414],"about_ca_topic_score_codex":0.0062130345,"about_ca_topic_score_gemma":0.024665646,"teacher_disagreement_score":0.1330727,"about_ca_system_score_codex":0.0028754945,"about_ca_system_score_gemma":0.0029506008,"threshold_uncertainty_score":0.44517255},"labels":[],"label_agreement":null},{"id":"W2021916888","doi":"10.1517/13543784.12.7.1067","title":"Potential new drugs for therapy of chronic obstructive pulmonary disease","year":2003,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Bern; University of Saskatchewan; Eli Lilly and Company","keywords":"Medicine; Inflammation; Chemokine; COPD; Immunology; Pulmonary disease; Monocyte; Lung; Disease; Internal medicine","score_opus":0.05510405966884598,"score_gpt":0.3654987197261629,"score_spread":0.3103946600573169,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021916888","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00030470834,0.99292773,0.0003717528,0.0006386888,0.0005564509,0.000031934367,0.000039677365,0.000022882547,0.0051061595],"genre_scores_gemma":[0.0012760693,0.99307597,0.0008203563,0.00060496264,0.0003862434,0.00003726407,0.00009291118,0.0000035339222,0.0037027244],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99972445,0.000049121852,0.000025947733,0.000040691302,0.00013303627,0.000026760476],"domain_scores_gemma":[0.99980396,0.000059836955,0.000032755914,0.0000104411,0.000062122876,0.00003085614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005787125,0.0011425834,0.0017746936,0.0025452964,0.00040437703,0.0009339895,0.0010061375,0.001549351,0.011592618],"category_scores_gemma":[0.00048413672,0.00023800056,0.0006778076,0.0016642397,0.0004934185,0.0014767782,0.0006285009,0.002016696,0.007648718],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001224651,0.00023775079,0.00012771208,0.009503758,0.00009184949,0.00053646887,0.00006482647,0.00030952177,0.0058727586,0.0038279279,0.04712573,0.93217933],"study_design_scores_gemma":[0.000088215005,0.0001791731,0.00049908546,0.0017230441,0.00007890901,0.001563781,0.000042183412,0.000104480154,0.0007969057,0.001568216,0.99333996,0.000016033388],"about_ca_topic_score_codex":0.0008692979,"about_ca_topic_score_gemma":0.0025569508,"teacher_disagreement_score":0.011592618,"about_ca_system_score_codex":0.00065702747,"about_ca_system_score_gemma":0.00089338014,"threshold_uncertainty_score":0.038781226},"labels":[],"label_agreement":null},{"id":"W2024461486","doi":"10.1517/13543784.2011.566862","title":"Aromatase inhibition: a potential target for the management of recurrent or metastatic endometrial cancer by letrozole: more questions than answers?","year":2011,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Letrozole; Medicine; Aromatase; Metastatic breast cancer; Tamoxifen; Endometrial cancer; Hormonal therapy; Oncology; Internal medicine; Clinical trial; Breast cancer; Aromatase inhibitor; Anastrozole; Disease; Cancer","score_opus":0.047020588754872035,"score_gpt":0.35858271814898407,"score_spread":0.31156212939411204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024461486","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000114285875,0.9977209,0.00009170595,0.0012294203,0.00033449286,0.000003352491,0.000013292277,0.0000055535725,0.00048703572],"genre_scores_gemma":[0.00077681773,0.9974763,0.0001896697,0.00068817777,0.0003100414,0.00000557776,0.000024613799,0.0000012064892,0.00052750355],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998592,0.00003494778,0.00001800667,0.000021285668,0.00005180541,0.0000147171095],"domain_scores_gemma":[0.9997645,0.00011212227,0.000039791474,0.0000055261194,0.000059094426,0.000018940907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005800074,0.00057264016,0.0012832847,0.0008176375,0.00021074236,0.0007454583,0.00074348215,0.0014160292,0.0025203787],"category_scores_gemma":[0.00067463174,0.00016741168,0.00042886066,0.0009389593,0.00039576925,0.0011452395,0.0002966625,0.001905507,0.0018463385],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016664817,0.000056449815,0.00017749167,0.011701973,0.0001077695,0.000477326,0.000045488832,0.00029893636,0.0027613512,0.0026333411,0.056770816,0.9248024],"study_design_scores_gemma":[0.000091322974,0.00023153229,0.0010499528,0.005262446,0.00022079589,0.0032862322,0.00011668607,0.00018507149,0.0009800866,0.002849777,0.9856983,0.000027825916],"about_ca_topic_score_codex":0.0007054876,"about_ca_topic_score_gemma":0.0021970053,"teacher_disagreement_score":0.0025203787,"about_ca_system_score_codex":0.0005433814,"about_ca_system_score_gemma":0.0007869885,"threshold_uncertainty_score":0.008431494},"labels":[],"label_agreement":null},{"id":"W2033435813","doi":"10.1517/13543784.12.11.1855","title":"Experimental and clinical studies show that the probucol derivative AGI-1067 prevents vascular growth","year":2003,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Probucol; Restenosis; Medicine; Internal medicine; Endocrinology; Lipoprotein; Cholesterol; Stent","score_opus":0.16570150015299992,"score_gpt":0.43428749972595293,"score_spread":0.26858599957295304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033435813","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6301601,0.316332,0.011031738,0.004146818,0.000609775,0.00040831446,0.0013978264,0.00079895003,0.035114486],"genre_scores_gemma":[0.9233044,0.06424631,0.003200103,0.0015716174,0.0004829415,0.00016717795,0.0014365013,0.000048732538,0.0055422406],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99975866,0.00005938101,0.000017833187,0.00003857516,0.00009438571,0.000031130265],"domain_scores_gemma":[0.99930704,0.00026238745,0.00018862667,0.000053030944,0.00009781036,0.000091206675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005976013,0.0005827625,0.0005439006,0.00043887526,0.00019825924,0.00035647632,0.00020690603,0.00047171902,0.0038488663],"category_scores_gemma":[0.0007991353,0.00008460861,0.0002943251,0.00033670542,0.0005462101,0.00029556686,0.00021261918,0.0010848608,0.0009396045],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007820341,0.004254835,0.018141385,0.0031718886,0.0004571927,0.0014889357,0.000113114584,0.0008032764,0.17216413,0.002729208,0.008562483,0.7802932],"study_design_scores_gemma":[0.006190958,0.11308979,0.26429746,0.0013569517,0.0019235327,0.024679506,0.00042157705,0.0035852815,0.24760665,0.005969608,0.3306656,0.00021307633],"about_ca_topic_score_codex":0.00036715792,"about_ca_topic_score_gemma":0.0006065984,"teacher_disagreement_score":0.0038488663,"about_ca_system_score_codex":0.00022620885,"about_ca_system_score_gemma":0.0003595114,"threshold_uncertainty_score":0.012875795},"labels":[],"label_agreement":null},{"id":"W2034340607","doi":"10.1517/13543784.2010.532123","title":"Na <sup>+</sup> /H <sup>+</sup> exchanger-1: a link with atherogenesis?","year":2010,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Ion Transport and Channel Regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Biogen Idec","keywords":"Dyslipidemia; Inflammation; Medicine; Intracellular; Diabetes mellitus; Vascular smooth muscle; Sodium–hydrogen antiporter; Internal medicine; Endocrinology; Chemistry; Pharmacology; Bioinformatics; Cell biology; Sodium; Biochemistry; Smooth muscle; Biology","score_opus":0.03270307871499557,"score_gpt":0.29272651002668293,"score_spread":0.26002343131168737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034340607","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012075182,0.99551183,0.00016556209,0.0017966147,0.0011453353,0.0000046091427,0.000022898315,0.000008264143,0.0012240887],"genre_scores_gemma":[0.0005330183,0.99605656,0.00023485688,0.00078367867,0.0006810556,0.000006697095,0.000036291407,0.0000018584998,0.0016660335],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99990344,0.000015190137,0.000012193193,0.000019095338,0.000038267328,0.000011857526],"domain_scores_gemma":[0.99981874,0.000051343293,0.000025891271,0.000005720212,0.00007303104,0.00002525253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039739488,0.00073634647,0.0013676306,0.00079810066,0.00025316965,0.0008730154,0.0008173963,0.0014895493,0.005925056],"category_scores_gemma":[0.0004668683,0.00018223259,0.00034673343,0.0011234767,0.00040707842,0.0020243707,0.0004470746,0.0017818926,0.00553189],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016113029,0.00006667257,0.00016278494,0.014417581,0.000087027445,0.00034378504,0.00006043065,0.00024205918,0.0039848383,0.004136519,0.12065404,0.8556832],"study_design_scores_gemma":[0.000030072086,0.00007876358,0.00071607396,0.0026204411,0.00008041194,0.0014272366,0.00009302577,0.0000836644,0.00058394193,0.0029805189,0.991288,0.000017940447],"about_ca_topic_score_codex":0.00070198637,"about_ca_topic_score_gemma":0.0014668432,"teacher_disagreement_score":0.005925056,"about_ca_system_score_codex":0.0006122882,"about_ca_system_score_gemma":0.001111188,"threshold_uncertainty_score":0.019821286},"labels":[],"label_agreement":null},{"id":"W2035153450","doi":"10.1517/13543784.15.4.335","title":"Optimal antimicrobial therapy: the balance of potency and exposure","year":2006,"lang":"en","type":"editorial","venue":"Expert Opinion on Investigational Drugs","topic":"Urinary Tract Infections Management","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; Royal University Hospital","funders":"","keywords":"Antimicrobial; Medicine; Intensive care medicine; Pharmacotherapy; Antibiotics; Clinical trial; Drug; Antimicrobial drug; Internal medicine; Pharmacology; Biology; Microbiology","score_opus":0.01338367502739927,"score_gpt":0.2792595564198222,"score_spread":0.2658758813924229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035153450","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000071056005,0.061286356,0.00040383593,0.071123086,0.865012,0.000021111155,0.000034701807,0.00006457383,0.0019832756],"genre_scores_gemma":[0.00097005087,0.06311037,0.00051798846,0.040899605,0.88845915,0.00002570374,0.000034561093,0.000028897506,0.005953792],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99681985,0.0007880884,0.0006054739,0.0003365298,0.0013003169,0.00014968403],"domain_scores_gemma":[0.9880178,0.0059639323,0.00066325784,0.00027702795,0.0041364036,0.00094171666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005176107,0.0031522796,0.0047714505,0.0014311771,0.0015129765,0.0049578515,0.0035348665,0.012902642,0.004962443],"category_scores_gemma":[0.017046748,0.0008884438,0.0014261147,0.001325865,0.003401345,0.0049847574,0.0009632261,0.023050502,0.0062994673],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000040757925,0.000015837606,0.000029551153,0.0006210658,0.000025299158,0.00016209854,0.000019408417,0.000042481563,0.000101912054,0.00066650595,0.9745315,0.023743639],"study_design_scores_gemma":[0.000054894845,0.000050832074,0.000221268,0.0006742967,0.000052423955,0.0006455619,0.00004989879,0.00013280012,0.00015170519,0.0016301018,0.996318,0.000018204682],"about_ca_topic_score_codex":0.0008703637,"about_ca_topic_score_gemma":0.0022508116,"teacher_disagreement_score":0.012902642,"about_ca_system_score_codex":0.0024162119,"about_ca_system_score_gemma":0.0017376364,"threshold_uncertainty_score":0.027374208},"labels":[],"label_agreement":null},{"id":"W2037261747","doi":"10.1517/13543780903143753","title":"Rosiglitazone maleate + metformin hydrochloride extend: review of an emerging compound","year":2009,"lang":"en","type":"article","venue":"Expert Opinion on Investigational Drugs","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Credit Valley Hospital; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Rosiglitazone; Metformin Hydrochloride; Metformin; Medicine; Glycemic; Type 2 diabetes; Pill; Pharmacology; Diabetes mellitus; Endocrinology","score_opus":0.03459180608237115,"score_gpt":0.337369398605298,"score_spread":0.30277759252292685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037261747","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016628626,0.9981323,0.00013995098,0.00084524363,0.000225145,0.000006101357,0.000008818029,0.0000041134313,0.0004721515],"genre_scores_gemma":[0.0011417327,0.99653876,0.00045284702,0.0009029761,0.0005155359,0.0000098593355,0.000021088785,0.000002420133,0.00041488657],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99939287,0.00013063906,0.000118338365,0.00010297253,0.00022799768,0.000027149668],"domain_scores_gemma":[0.9984487,0.00082457444,0.00023606257,0.000026797688,0.00038379256,0.000080132464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017875179,0.00072768587,0.0018918144,0.0023065852,0.0002859429,0.0010824492,0.0010979165,0.0016909392,0.0022691425],"category_scores_gemma":[0.0016470555,0.00038655428,0.00075472955,0.002246436,0.000521678,0.0023378723,0.00047463842,0.0020430798,0.0014752678],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023888919,0.00010566486,0.00021868144,0.014667318,0.0000987239,0.0008127435,0.000057154226,0.00028874291,0.0009829574,0.0021128734,0.03372272,0.94669354],"study_design_scores_gemma":[0.00013386205,0.0004619362,0.0012660788,0.007326395,0.00034508615,0.0038542068,0.00011964236,0.00030957907,0.00065377646,0.0016603312,0.9838381,0.00003104034],"about_ca_topic_score_codex":0.0010683398,"about_ca_topic_score_gemma":0.0031993736,"teacher_disagreement_score":0.0023065852,"about_ca_system_score_codex":0.0006358824,"about_ca_system_score_gemma":0.0009264952,"threshold_uncertainty_score":0.009453416},"labels":[],"label_agreement":null},{"id":"W2039029105","doi":"10.1517/13543784.13.3.245","title":"The therapeutic potential of angiotensin II receptor blockers in the treatment of heart failure","year":2004,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Heart Failure Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences","funders":"","keywords":"Angiotensin II; Heart failure; Medicine; Renin–angiotensin system; Aldosterone; Clinical trial; Internal medicine; Angiotensin Receptor Blockers; Cardiology; Angiotensin-converting enzyme; Angiotensin II receptor type 1; Pharmacology; Angiotensin receptor; Endocrinology; Receptor; Blood pressure","score_opus":0.043718400046902015,"score_gpt":0.33794365659088843,"score_spread":0.2942252565439864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039029105","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009019803,0.9988366,0.00005064758,0.00033427152,0.00010698693,0.0000046936493,0.000007086611,0.0000028382349,0.0005667654],"genre_scores_gemma":[0.0006290597,0.9985316,0.0001399812,0.00028370658,0.0001352894,0.000006713608,0.0000112655025,6.5070856e-7,0.00026178831],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995671,0.00014478335,0.000060533202,0.000045057794,0.00016012596,0.000022338987],"domain_scores_gemma":[0.99948275,0.00029707406,0.000092394184,0.000010797335,0.00008922699,0.000027789589],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011750036,0.0007054547,0.0023844095,0.0020579756,0.00021877521,0.0008373369,0.0009149937,0.001401543,0.0048528514],"category_scores_gemma":[0.0010120161,0.00021236915,0.00075109914,0.0022230854,0.00038163245,0.00095773366,0.00038875855,0.0012960938,0.0021282842],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001703333,0.000090503636,0.00015004318,0.02385451,0.00022329671,0.00027867965,0.000046208203,0.00022276348,0.0010484552,0.0014806628,0.016769718,0.9556648],"study_design_scores_gemma":[0.0003097001,0.0004810293,0.0030192614,0.01590115,0.00074551185,0.0028204122,0.00016059661,0.00019169676,0.0006409753,0.0031098,0.97258085,0.000039107275],"about_ca_topic_score_codex":0.0010348922,"about_ca_topic_score_gemma":0.0030053556,"teacher_disagreement_score":0.0048528514,"about_ca_system_score_codex":0.0005713225,"about_ca_system_score_gemma":0.00090420427,"threshold_uncertainty_score":0.016234457},"labels":[],"label_agreement":null},{"id":"W2043656098","doi":"10.1517/13543784.12.7.1143","title":"Clinically tested drugs for Alzheimer’s disease","year":2003,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Alzheimer's disease research and treatments","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Neuroinflammation; Disease; Medicine; Oxidative stress; Acetylcholinesterase; Clinical trial; Forebrain; Drug; Cholinergic neuron; Cholinergic; Pathological; Neuroscience; Pharmacology; Internal medicine; Psychology; Central nervous system; Biology","score_opus":0.1734363243478155,"score_gpt":0.45406705170395134,"score_spread":0.2806307273561358,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043656098","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00028305865,0.9907691,0.0003683172,0.00063866563,0.0006423291,0.000048778955,0.00007055893,0.000028816195,0.007150387],"genre_scores_gemma":[0.0018102562,0.9906303,0.0008443362,0.0008823169,0.00034466267,0.000054809992,0.00013057276,0.000004798886,0.005297935],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99969673,0.000048690148,0.000032116215,0.000052530806,0.00014106843,0.000028929948],"domain_scores_gemma":[0.99971503,0.000080485006,0.000059252496,0.000016733653,0.00009505328,0.00003336849],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007488221,0.0014580332,0.0020644767,0.0027282382,0.0004610454,0.0010725964,0.00150173,0.002047433,0.016367558],"category_scores_gemma":[0.00060820574,0.0003356972,0.00076274626,0.0020597451,0.0005916088,0.0015199814,0.0007024181,0.0019628298,0.010916039],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013660113,0.00019539667,0.00008532285,0.0131182745,0.00008074923,0.00052679173,0.000062614556,0.00024276701,0.0059347665,0.004396731,0.05218637,0.9230336],"study_design_scores_gemma":[0.000078652,0.0001885956,0.0002965616,0.0018876555,0.00006833685,0.0011210353,0.000032054355,0.000055633445,0.0010861878,0.0014863469,0.9936841,0.000014749918],"about_ca_topic_score_codex":0.0010069122,"about_ca_topic_score_gemma":0.0028298402,"teacher_disagreement_score":0.016367558,"about_ca_system_score_codex":0.000774864,"about_ca_system_score_gemma":0.001126831,"threshold_uncertainty_score":0.054754913},"labels":[],"label_agreement":null},{"id":"W2045036128","doi":"10.1517/13543784.2014.974803","title":"Ticagrelor for the treatment of peripheral arterial disease","year":2014,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Antiplatelet Therapy and Cardiovascular Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Ticagrelor; Medicine; Clopidogrel; Intensive care medicine; Expert opinion; Clinical trial; Disease; Adverse effect; Arterial disease; Cardiology; Pharmacology; Internal medicine; Myocardial infarction; Vascular disease","score_opus":0.0663237658817336,"score_gpt":0.3664681768823458,"score_spread":0.3001444110006122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045036128","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000079138976,0.99781895,0.00007681701,0.0003704427,0.00027537261,0.000007534039,0.000016800977,0.0000055111905,0.0013494231],"genre_scores_gemma":[0.00096482603,0.99740916,0.00017642872,0.00038505302,0.00030652882,0.000007904325,0.000039183633,0.0000013523942,0.0007096569],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99965715,0.00007286377,0.00005066556,0.000051455183,0.00014253754,0.000025326777],"domain_scores_gemma":[0.9996282,0.00016321582,0.000096525735,0.00000839771,0.00007980643,0.000023759101],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056894426,0.0006382503,0.0012279577,0.0023484933,0.0002180376,0.000784614,0.0006074399,0.0009857734,0.006286869],"category_scores_gemma":[0.00087231066,0.00015892675,0.0007007449,0.0021153863,0.00032154444,0.000728821,0.0005023786,0.0016414627,0.0030533515],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000086156215,0.000047214075,0.000106163716,0.028382715,0.00018684912,0.00018615351,0.000046078334,0.00017533494,0.0011905886,0.0021728554,0.037979655,0.9294403],"study_design_scores_gemma":[0.00007561601,0.00011545315,0.0009929319,0.014655109,0.0003757705,0.0023456437,0.000051432686,0.00011830685,0.0005081615,0.0018529635,0.9788866,0.000021907308],"about_ca_topic_score_codex":0.0009851548,"about_ca_topic_score_gemma":0.0016424794,"teacher_disagreement_score":0.006286869,"about_ca_system_score_codex":0.00044326324,"about_ca_system_score_gemma":0.00093349785,"threshold_uncertainty_score":0.021031618},"labels":[],"label_agreement":null},{"id":"W2047633734","doi":"10.1517/13543784.17.7.1029","title":"Heparin as an anticancer therapeutic","year":2008,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Proteoglycans and glycosaminoglycans research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Health Sciences","funders":"","keywords":"Heparin; Pharmacology; Intensive care medicine; Medicine; Anticancer drug; Drug; Internal medicine","score_opus":0.07779585488762812,"score_gpt":0.4086712590680824,"score_spread":0.33087540418045425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047633734","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020201408,0.99699044,0.00013633636,0.00061007915,0.0002855936,0.000004970709,0.000008947576,0.0000055820447,0.0017559525],"genre_scores_gemma":[0.0019111289,0.9957378,0.00024050876,0.00045334583,0.0003900711,0.000009952482,0.000022036853,0.0000012602341,0.0012338787],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998355,0.00003909583,0.000020326488,0.000030770596,0.00006050645,0.000013729373],"domain_scores_gemma":[0.9998487,0.000070753915,0.00002117193,0.000005780543,0.00003971369,0.000013841381],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004352659,0.00056959427,0.00089940184,0.0015449903,0.00021667975,0.0006862774,0.00050403125,0.0012389289,0.003225779],"category_scores_gemma":[0.00042322278,0.00017112453,0.00028478797,0.0012748234,0.00042849962,0.0008781592,0.00038627876,0.0014493625,0.0018263089],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009383978,0.00008178133,0.00018322718,0.007516703,0.000060138955,0.00044663931,0.00005544362,0.00031781863,0.0042923666,0.00725414,0.03458285,0.9451151],"study_design_scores_gemma":[0.00003131441,0.00012290443,0.0005018457,0.0015264701,0.00006318485,0.002280986,0.000032011183,0.00014280445,0.0017598147,0.001865055,0.99166095,0.000012635983],"about_ca_topic_score_codex":0.0007929164,"about_ca_topic_score_gemma":0.0012336816,"teacher_disagreement_score":0.003225779,"about_ca_system_score_codex":0.0006584329,"about_ca_system_score_gemma":0.00062576344,"threshold_uncertainty_score":0.010791302},"labels":[],"label_agreement":null},{"id":"W2047925472","doi":"10.1517/13543780903282759","title":"Darinaparsin: a novel organic arsenical with promising anticancer activity","year":2009,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Arsenic trioxide; Acute promyelocytic leukemia; In vivo; Cancer research; Arsenic; Pharmacology; Broad spectrum; Leukemia; In vitro; Chemistry; Medicine; Biology; Biochemistry; Immunology; Retinoic acid; Combinatorial chemistry","score_opus":0.044893318701998634,"score_gpt":0.3385623228525425,"score_spread":0.29366900415054387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047925472","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022059116,0.9900581,0.0011141441,0.0007254483,0.00028969723,0.000029195306,0.000057254383,0.000040547122,0.0054797432],"genre_scores_gemma":[0.00693644,0.9865357,0.0015075407,0.00040811053,0.00015973655,0.000021173453,0.00012204042,0.0000049463997,0.0043042954],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99991536,0.000011809682,0.000008753791,0.000019928659,0.00003429769,0.000009879656],"domain_scores_gemma":[0.99994874,0.000012851997,0.000012108929,0.0000020021707,0.00001593975,0.000008234406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026299976,0.0005273776,0.00075894664,0.00089586654,0.0001774515,0.0005091162,0.00044919658,0.00073813024,0.0028455956],"category_scores_gemma":[0.00013307772,0.00015258125,0.00026636102,0.0008061227,0.0002323791,0.0006078604,0.0002923183,0.0007853287,0.0027853795],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016900724,0.00012956011,0.00019976501,0.008474732,0.0000696015,0.00081490166,0.00006678571,0.0005844167,0.056983314,0.003943513,0.015663998,0.9129005],"study_design_scores_gemma":[0.00006991775,0.00035055992,0.00053000683,0.0005133542,0.00007192573,0.0024943687,0.000049758295,0.00017359371,0.013035058,0.0012715973,0.9814166,0.000023352135],"about_ca_topic_score_codex":0.00052685983,"about_ca_topic_score_gemma":0.0017804897,"teacher_disagreement_score":0.0028455956,"about_ca_system_score_codex":0.00045693465,"about_ca_system_score_gemma":0.00043276203,"threshold_uncertainty_score":0.009519458},"labels":[],"label_agreement":null},{"id":"W2053907476","doi":"10.1517/13543780902897623","title":"Spinal cord injury and neural repair: focus on neuroregenerative approaches for spinal cord injury","year":2009,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Spinal Cord Injury Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto Western Hospital; University Health Network","funders":"","keywords":"Medicine; Spinal cord injury; Clinical trial; Spinal cord; Intensive care medicine; Physical medicine and rehabilitation; Pathology","score_opus":0.2504881047520121,"score_gpt":0.46319645090178946,"score_spread":0.21270834614977735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053907476","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007179783,0.9974897,0.00012062132,0.0004939502,0.0003144344,0.000006347153,0.00000919554,0.000006543751,0.0014875113],"genre_scores_gemma":[0.00027042758,0.9985109,0.00018135678,0.0002431353,0.00024418635,0.0000057815523,0.000012196213,0.0000013956321,0.0005305653],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99971026,0.00006033541,0.000039685325,0.000042072246,0.00012438271,0.000023203389],"domain_scores_gemma":[0.9994369,0.00030099,0.00007474507,0.000017449353,0.00013025991,0.0000397495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008713416,0.0011064111,0.0018659391,0.0027492023,0.0003562056,0.0009538475,0.0008427588,0.0015498557,0.0076373224],"category_scores_gemma":[0.0007487212,0.00026959376,0.00065900636,0.0037420823,0.00069250376,0.0021812194,0.0006674932,0.0018837397,0.004047291],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006195232,0.00010010299,0.00012525648,0.027899519,0.00010590774,0.00028278612,0.00010144606,0.000325548,0.0023862517,0.0043660956,0.042941798,0.92130345],"study_design_scores_gemma":[0.00003551023,0.00016825268,0.0011114823,0.009796377,0.00011988615,0.001950155,0.00011868282,0.00007708762,0.00044021354,0.0027304483,0.9834313,0.000020603025],"about_ca_topic_score_codex":0.0012330548,"about_ca_topic_score_gemma":0.0030063004,"teacher_disagreement_score":0.0076373224,"about_ca_system_score_codex":0.00070137857,"about_ca_system_score_gemma":0.0017644673,"threshold_uncertainty_score":0.025549412},"labels":[],"label_agreement":null},{"id":"W2054297512","doi":"10.1517/13543780902980171","title":"Sunitinib in solid tumors","year":2009,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":119,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Sunitinib; GiST; Medicine; Sorafenib; Everolimus; Renal cell carcinoma; Imatinib; Tyrosine-kinase inhibitor; Bevacizumab; Oncology; Pharmacology; Internal medicine; Cancer; Stromal cell; Hepatocellular carcinoma; Chemotherapy","score_opus":0.11988726613130786,"score_gpt":0.4374837508832138,"score_spread":0.31759648475190594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054297512","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013680781,0.99740475,0.00006560874,0.00017579341,0.00023529545,0.00000378092,0.000013017822,0.000008397799,0.0019565609],"genre_scores_gemma":[0.0025934186,0.9943151,0.00022178095,0.00031181835,0.00043837793,0.000009220871,0.00006749245,0.0000032689159,0.0020395333],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998072,0.000036880738,0.000033573822,0.00003750077,0.000069660055,0.000015232671],"domain_scores_gemma":[0.9997843,0.00009088088,0.00004691429,0.000008995199,0.000049329996,0.000019552685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041294162,0.00059544423,0.0012505864,0.0019476132,0.00024503353,0.0007163205,0.000591518,0.000856648,0.007618927],"category_scores_gemma":[0.0004971443,0.00015910158,0.0004992599,0.0016601093,0.00028935363,0.00079894956,0.00044773688,0.0009803645,0.004217304],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000068438865,0.000035725512,0.00014717526,0.010872099,0.00007827675,0.0003366548,0.000031238684,0.0002325301,0.001015761,0.0013918023,0.030765703,0.95502466],"study_design_scores_gemma":[0.00004097702,0.00010640688,0.0009311178,0.0024849707,0.00012120104,0.0038994583,0.000028495178,0.00007998509,0.0007600298,0.0011040876,0.990431,0.000012253882],"about_ca_topic_score_codex":0.0010261989,"about_ca_topic_score_gemma":0.0017910873,"teacher_disagreement_score":0.007618927,"about_ca_system_score_codex":0.0006226137,"about_ca_system_score_gemma":0.0008753559,"threshold_uncertainty_score":0.0254879},"labels":[],"label_agreement":null},{"id":"W2056360850","doi":"10.1517/13543780802528609","title":"Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancer","year":2008,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Clusterin in disease pathology","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Clusterin; Prostate cancer; Cancer; Medicine; Clinical trial; Cancer research; Internal medicine; Oncology; Biology; Apoptosis; Biochemistry","score_opus":0.1531090493367765,"score_gpt":0.425771464691668,"score_spread":0.2726624153548915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056360850","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009018477,0.99536043,0.00037918708,0.00037356224,0.00030805444,0.000026167028,0.00003525446,0.000022799442,0.0025927294],"genre_scores_gemma":[0.0034244303,0.9925673,0.0005436148,0.0003369886,0.00019355208,0.00002869242,0.00013143536,0.0000033953802,0.0027706411],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999045,0.0000133536,0.000010008435,0.00001924355,0.000041093084,0.000011706058],"domain_scores_gemma":[0.9999052,0.000023723476,0.000023859955,0.000002533757,0.000028188073,0.000016547321],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035103763,0.0006785945,0.0007560973,0.0011971297,0.00018403551,0.0003852636,0.0006954929,0.00071280054,0.00275402],"category_scores_gemma":[0.0002096353,0.00014651746,0.00033598935,0.0009142116,0.0002243877,0.00050716696,0.00023386275,0.00087039894,0.00219032],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023401405,0.0001332505,0.00016833376,0.008259727,0.00009712401,0.00031594146,0.000037868977,0.00030631706,0.010715728,0.0011903418,0.028466946,0.9500743],"study_design_scores_gemma":[0.00020688375,0.00053646,0.0014145781,0.0011728825,0.00015592341,0.0031459993,0.000039796792,0.00019258067,0.0063406033,0.0006096416,0.98615706,0.000027447337],"about_ca_topic_score_codex":0.001183499,"about_ca_topic_score_gemma":0.0026296785,"teacher_disagreement_score":0.00275402,"about_ca_system_score_codex":0.0005967395,"about_ca_system_score_gemma":0.0007403225,"threshold_uncertainty_score":0.00921315},"labels":[],"label_agreement":null},{"id":"W2057495794","doi":"10.1517/13543784.2011.565329","title":"Brivanib alaninate for cancer","year":2011,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Cetuximab; Medicine; Pharmacodynamics; Pharmacology; Cancer; Regorafenib; Angiogenesis; Colorectal cancer; Pharmacokinetics; Oncology; Internal medicine","score_opus":0.11655984381337209,"score_gpt":0.41313203269809323,"score_spread":0.29657218888472114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057495794","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008614184,0.94990015,0.00066852645,0.0037499915,0.0023412283,0.00005129792,0.00024880082,0.00014443939,0.042034123],"genre_scores_gemma":[0.011829238,0.919319,0.0008882011,0.0039704666,0.002450527,0.00008187187,0.00081922754,0.000028404089,0.060613077],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99986255,0.00002409397,0.000010824187,0.000027997621,0.000053419644,0.000021138954],"domain_scores_gemma":[0.99991417,0.000017555993,0.000020832991,0.000004144548,0.000022430695,0.0000208873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026060877,0.0006111839,0.000581811,0.0010637059,0.00025520878,0.00068600336,0.00060439104,0.0010593402,0.023484195],"category_scores_gemma":[0.0003214451,0.00013537135,0.00035761663,0.0008302602,0.0002571996,0.00055333215,0.000549705,0.0013364664,0.020712292],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001585448,0.00005030187,0.00007171223,0.0031755068,0.00003353567,0.00034121345,0.000025108407,0.00012553798,0.0031839565,0.0030895332,0.111924715,0.8778202],"study_design_scores_gemma":[0.000055468456,0.00007876856,0.00021608175,0.00047268753,0.000017266399,0.0012398808,0.0000071786476,0.00003203543,0.0008598668,0.000659858,0.99635506,0.000005908374],"about_ca_topic_score_codex":0.000599663,"about_ca_topic_score_gemma":0.0013666013,"teacher_disagreement_score":0.023484195,"about_ca_system_score_codex":0.0005144167,"about_ca_system_score_gemma":0.0005591345,"threshold_uncertainty_score":0.0785625},"labels":[],"label_agreement":null},{"id":"W2057625697","doi":"10.1517/13543784.2013.831404","title":"Current Phase II clinical data for ridaforolimus in cancer","year":2013,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"PI3K/AKT/mTOR pathway; mTORC1; mTORC2; Everolimus; Cancer research; Medicine; Cancer; Protein kinase B; Clinical trial; Pharmacology; Signal transduction; Biology; Oncology; Internal medicine; Cell biology","score_opus":0.30661209334578565,"score_gpt":0.5347343585449083,"score_spread":0.2281222651991226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057625697","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001121187,0.98859113,0.00056753756,0.0015417425,0.0004933275,0.00008670321,0.00024648197,0.00003729265,0.0073145656],"genre_scores_gemma":[0.0073089353,0.98411036,0.00087245426,0.002371676,0.00056725735,0.00014126494,0.00058351376,0.000019296656,0.004025262],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99974674,0.00005992924,0.000031207626,0.00004466792,0.00009115548,0.00002627735],"domain_scores_gemma":[0.99948597,0.00019865968,0.000109082335,0.000016425412,0.00013209063,0.000057589514],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001142935,0.00066772796,0.0014577042,0.00073669135,0.00022338123,0.0010183889,0.0011473158,0.0010697081,0.009466793],"category_scores_gemma":[0.0010945143,0.00018591581,0.00077544973,0.0009721191,0.00036678166,0.00086668186,0.00043329556,0.0014905568,0.0043365164],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003365511,0.000102570855,0.00018012873,0.008781709,0.00009077253,0.00013938399,0.00003886618,0.00033960294,0.0024242927,0.0014641074,0.03326572,0.9528362],"study_design_scores_gemma":[0.00034265,0.0009602517,0.0011730458,0.003829787,0.0003040336,0.0016297424,0.000046674533,0.00021500325,0.0017541795,0.0016925603,0.9880266,0.000025527675],"about_ca_topic_score_codex":0.000543167,"about_ca_topic_score_gemma":0.0012911323,"teacher_disagreement_score":0.009466793,"about_ca_system_score_codex":0.0005990195,"about_ca_system_score_gemma":0.00095376023,"threshold_uncertainty_score":0.031669617},"labels":[],"label_agreement":null},{"id":"W2062518823","doi":"10.1517/13543784.14.8.1009","title":"Growth hormone therapy in heart failure: a novel therapy worthy of further consideration?","year":2005,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Heart Failure Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton General Hospital","funders":"","keywords":"Heart failure; Medicine; Cardiac function curve; Quality of life (healthcare); Hormone; Internal medicine; Growth hormone; Intensive care medicine; Cardiology","score_opus":0.08101180246770066,"score_gpt":0.3604330639189664,"score_spread":0.2794212614512657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062518823","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000104876475,0.99603784,0.000094050745,0.0024872473,0.00055914815,0.0000051371735,0.000009028454,0.000004813214,0.00069793005],"genre_scores_gemma":[0.0007262008,0.9962179,0.00024950315,0.0013482309,0.0007970498,0.000010636967,0.000014862645,0.0000017576532,0.0006337392],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99956995,0.00016094887,0.000060114337,0.00005560197,0.00011824922,0.00003517836],"domain_scores_gemma":[0.99953103,0.00022990687,0.000093089955,0.000020153975,0.0000911379,0.000034676406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013945472,0.00095837493,0.004451339,0.0012098558,0.00032342106,0.0015320232,0.0012257168,0.0023262957,0.0067196814],"category_scores_gemma":[0.00096496765,0.00028075246,0.0009290937,0.0018784256,0.0008987379,0.0031432288,0.0005805865,0.0029634866,0.0039026816],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030879854,0.00014736471,0.0001820204,0.02506239,0.00025314256,0.0006500191,0.00009398031,0.00022259876,0.0015342236,0.004164222,0.04745373,0.9199275],"study_design_scores_gemma":[0.00040962535,0.00046832956,0.0015200513,0.01540005,0.00038138774,0.0034623041,0.00029024328,0.00021349054,0.0003685238,0.005195517,0.97223985,0.000050587016],"about_ca_topic_score_codex":0.0010348305,"about_ca_topic_score_gemma":0.0036817067,"teacher_disagreement_score":0.0067196814,"about_ca_system_score_codex":0.00071878935,"about_ca_system_score_gemma":0.0012454867,"threshold_uncertainty_score":0.022479594},"labels":[],"label_agreement":null},{"id":"W2063706444","doi":"10.1517/13543784.17.6.827","title":"Acetyl-<scp>L</scp>-carnitine and α-lipoic acid: possible neurotherapeutic agents for mood disorders?","year":2008,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Biochemical Acid Research Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Neurocognitive; Carnitine; Neuroprotection; Lipoic acid; Mood; Mood disorders; Cognition; Medicine; Acetylcarnitine; Pharmacology; Antidepressant; Apathy; Psychology; Psychiatry; Neuroscience; Antioxidant; Internal medicine; Biochemistry; Chemistry","score_opus":0.058678572561528315,"score_gpt":0.3597756872211676,"score_spread":0.3010971146596393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063706444","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001563559,0.9990036,0.000039807095,0.00022272239,0.00009869024,0.0000034744064,0.0000067728065,0.0000025503948,0.0004660228],"genre_scores_gemma":[0.00081668055,0.99838233,0.00011291605,0.0001626137,0.00009878126,0.0000075940843,0.00001287085,4.8471253e-7,0.00040579343],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99986744,0.000032941512,0.000024117537,0.000020026353,0.00004100083,0.0000145443955],"domain_scores_gemma":[0.9997886,0.00009486492,0.000043679436,0.000004723411,0.00004925354,0.000018990779],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050927856,0.00062892964,0.0013668116,0.0018372858,0.00022065389,0.0006654054,0.0008331279,0.0011991806,0.0034638515],"category_scores_gemma":[0.00049190375,0.00017869096,0.0003636464,0.0019153538,0.00043378343,0.0010999417,0.00028819923,0.0008531437,0.0019200707],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002567764,0.000097244185,0.00027355013,0.030550124,0.00014163282,0.00089265266,0.000074501775,0.00018688884,0.0051291394,0.0017971939,0.019792404,0.9408079],"study_design_scores_gemma":[0.00016223908,0.00038237954,0.0028726836,0.010350107,0.00036532004,0.0060739224,0.00025364946,0.000115573566,0.002411647,0.0022316165,0.9747468,0.000034019256],"about_ca_topic_score_codex":0.001327373,"about_ca_topic_score_gemma":0.0032919184,"teacher_disagreement_score":0.0034638515,"about_ca_system_score_codex":0.0006063594,"about_ca_system_score_gemma":0.0008829861,"threshold_uncertainty_score":0.011587799},"labels":[],"label_agreement":null},{"id":"W2066759481","doi":"10.1517/13543784.16.1.1","title":"Discontinued drugs in 2005: anti-infectives","year":2006,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Drug-Induced Adverse Reactions","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pyrogenesis (Canada)","funders":"","keywords":"Econazole; Medicine; Anthrax vaccines; Antiseptic; Pharmacology; Azole; Antifungal; Virology; Dermatology; Immunology; Immune system; Miconazole","score_opus":0.05939597517357224,"score_gpt":0.378497513004909,"score_spread":0.31910153783133677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066759481","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022284954,0.9905172,0.00012452384,0.0012216652,0.0021583578,0.000011079006,0.000035438825,0.000016161976,0.005692733],"genre_scores_gemma":[0.0014037116,0.9858947,0.0003011476,0.002651521,0.0019233638,0.000011465357,0.00009577915,0.000005082823,0.00771325],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99958247,0.00005908327,0.0000638278,0.000053182073,0.00019902665,0.0000423964],"domain_scores_gemma":[0.99951375,0.00011814079,0.00013838137,0.000013310118,0.00015705566,0.000059486498],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060137466,0.0010792998,0.0014513785,0.002174489,0.00036284386,0.0012048819,0.0008188484,0.0019460642,0.00819059],"category_scores_gemma":[0.0010827958,0.0002919434,0.000629969,0.002030477,0.0003393568,0.0017363606,0.0005705269,0.0017521357,0.0063338],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008005523,0.000060187183,0.00019748756,0.0054598344,0.000044267315,0.0005792273,0.000054853343,0.000107432046,0.0010485392,0.0013257771,0.14111994,0.8499225],"study_design_scores_gemma":[0.00001964634,0.00009093954,0.0005782785,0.0013414064,0.00004143267,0.0020733976,0.00004089217,0.000027541711,0.00020854856,0.00029984146,0.99526995,0.000008066541],"about_ca_topic_score_codex":0.0011251013,"about_ca_topic_score_gemma":0.0042059408,"teacher_disagreement_score":0.00819059,"about_ca_system_score_codex":0.00077013834,"about_ca_system_score_gemma":0.0009384705,"threshold_uncertainty_score":0.027400315},"labels":[],"label_agreement":null},{"id":"W2069838467","doi":"10.1517/13543784.12.1.65","title":"Recent developments in the psychobiology and pharmacotherapy of depression: optimising existing treatments and novel approaches for the future","year":2003,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Treatment of Major Depression","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Addiction and Mental Health","funders":"","keywords":"Monoaminergic; Major depressive disorder; Tricyclic; Neuroscience; Psychology; Antidepressant; Monoamine neurotransmitter; Medicine; Psychiatry; Pharmacology; Psychotherapist; Serotonin; Mood; Receptor; Internal medicine","score_opus":0.27848004033976725,"score_gpt":0.43478211963056057,"score_spread":0.15630207929079332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069838467","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00027653002,0.99330235,0.00077951606,0.0034460332,0.0005387514,0.00001007614,0.0000096840495,0.000018172215,0.001618896],"genre_scores_gemma":[0.0019238847,0.99192953,0.002389442,0.0014968505,0.0011063423,0.00001580628,0.000024319033,0.0000034738414,0.0011103515],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99959594,0.00013743025,0.000064326756,0.000053195723,0.00011627727,0.000032759028],"domain_scores_gemma":[0.99929297,0.00032855416,0.00009083874,0.000027429993,0.00018845445,0.000071716124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001637132,0.0006880564,0.0011602743,0.0009535498,0.0002843422,0.0011873653,0.000952503,0.0020396188,0.00525231],"category_scores_gemma":[0.001033716,0.00022531427,0.0005060997,0.0011375785,0.00057962554,0.0024059115,0.00060339615,0.0019736334,0.0024967242],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016790001,0.00012662461,0.00018505444,0.0104374,0.00006529668,0.00034258948,0.000083645005,0.00066886435,0.0021574842,0.0046699243,0.023668366,0.9574268],"study_design_scores_gemma":[0.00012324245,0.00040370322,0.001854373,0.005920354,0.00021130386,0.0022810516,0.00028586385,0.0008461942,0.0008069549,0.009824782,0.9774,0.000042283187],"about_ca_topic_score_codex":0.0008887334,"about_ca_topic_score_gemma":0.00246751,"teacher_disagreement_score":0.00525231,"about_ca_system_score_codex":0.00080386986,"about_ca_system_score_gemma":0.0015046233,"threshold_uncertainty_score":0.017570674},"labels":[],"label_agreement":null},{"id":"W2070483380","doi":"10.1517/13543784.2014.966900","title":"Dovitinib: rationale, preclinical and early clinical data in urothelial carcinoma of the bladder","year":2014,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St Joseph's Health Centre; Western University","funders":"","keywords":"Receptor tyrosine kinase; Cancer research; Tyrosine kinase; Fibroblast growth factor receptor 3; Tyrosine-kinase inhibitor; Fibroblast growth factor receptor; In vivo; Fibroblast growth factor; Medicine; In vitro; Cancer; Receptor; Biology; Internal medicine; Biotechnology","score_opus":0.1606687305433176,"score_gpt":0.44059212969756373,"score_spread":0.27992339915424613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070483380","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00028780356,0.9964779,0.00016476541,0.0007789528,0.00038207,0.000013881341,0.000047369467,0.000010057869,0.0018372472],"genre_scores_gemma":[0.0021210024,0.99504197,0.00026330087,0.00073783385,0.00026397043,0.00002015465,0.000090409434,0.0000031845523,0.0014581009],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99976796,0.000040171373,0.00002936678,0.00004114476,0.00009354628,0.000027804572],"domain_scores_gemma":[0.99970526,0.00011813435,0.00004756723,0.000007931449,0.00009274479,0.000028425533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087582396,0.0007896643,0.0012802504,0.0012877868,0.00023926288,0.0010566581,0.0012200861,0.001380488,0.0027943156],"category_scores_gemma":[0.00086364243,0.00029455218,0.0006138702,0.0012957946,0.0004235315,0.0011864597,0.00051589054,0.0023905844,0.0020916716],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020094222,0.000090554226,0.0001493216,0.01557926,0.00010056625,0.00031165458,0.000046498455,0.00051809056,0.002943842,0.0043779556,0.0393013,0.93638],"study_design_scores_gemma":[0.0000744092,0.00024103295,0.00062445004,0.0036372023,0.00015148615,0.001446375,0.000028717797,0.0001926477,0.0010814609,0.0015435027,0.99095553,0.000023231818],"about_ca_topic_score_codex":0.00077820354,"about_ca_topic_score_gemma":0.0018655395,"teacher_disagreement_score":0.0027943156,"about_ca_system_score_codex":0.00086681073,"about_ca_system_score_gemma":0.000959388,"threshold_uncertainty_score":0.009347975},"labels":[],"label_agreement":null},{"id":"W2074643072","doi":"10.1517/13543784.10.2.213","title":"Clinical utility of the new fluoroquinolones for treating respiratory and urinary tract infections","year":2001,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Antibiotics Pharmacokinetics and Efficacy","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital; St. Paul's Hospital; University of Saskatchewan","funders":"","keywords":"Medicine; Dosing; Antimicrobial; Urinary system; Intensive care medicine; Respiratory tract infections; Pharmacokinetics; Pharmacodynamics; Bioavailability; Pharmacology; Internal medicine; Respiratory system; Biology; Microbiology","score_opus":0.1632236923694076,"score_gpt":0.4521198595069692,"score_spread":0.2888961671375616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074643072","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00028282014,0.9969927,0.000150171,0.00032112552,0.000119705175,0.000005968563,0.000010817108,0.000004733628,0.002111933],"genre_scores_gemma":[0.0020806077,0.99582064,0.000421633,0.00029615834,0.0002318651,0.000009629678,0.000019956811,0.000001102566,0.0011184672],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996669,0.00007427872,0.000041635365,0.00004131498,0.00015375036,0.000022150114],"domain_scores_gemma":[0.99974436,0.00009206404,0.00005117811,0.000007385721,0.00008774781,0.000017323382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065652956,0.00063800556,0.0011353997,0.0018455092,0.00021342572,0.000623736,0.00063034525,0.0011428234,0.0046090167],"category_scores_gemma":[0.00066971924,0.00015570952,0.00047279653,0.001193754,0.00029822247,0.00078995933,0.00026332441,0.00073874637,0.002259959],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010749175,0.00007730351,0.00023964817,0.0087737525,0.00006228548,0.00056591316,0.00005974173,0.00025728892,0.004269456,0.0013713769,0.0130539425,0.9711619],"study_design_scores_gemma":[0.00009562641,0.00048229034,0.0028627936,0.0042218454,0.0001663199,0.0065236064,0.00011062781,0.00017400745,0.0021187554,0.0016498995,0.98156655,0.000027736563],"about_ca_topic_score_codex":0.0010208874,"about_ca_topic_score_gemma":0.0023881304,"teacher_disagreement_score":0.0046090167,"about_ca_system_score_codex":0.0005133014,"about_ca_system_score_gemma":0.00080385676,"threshold_uncertainty_score":0.015418708},"labels":[],"label_agreement":null},{"id":"W2079084305","doi":"10.1517/13543784.11.6.801","title":"Anti-emetics in development","year":2002,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Nausea and vomiting management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Hospital and Health Sciences Centre","funders":"","keywords":"Nausea; Vomiting; Medicine; Opioid; Anesthesia; Motion sickness; Aprepitant; Internal medicine; Antiemetic; Psychiatry; Receptor","score_opus":0.15195587789629997,"score_gpt":0.39209928240458025,"score_spread":0.24014340450828028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079084305","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006095713,0.98484784,0.0005099924,0.00063238724,0.00084750855,0.00006854963,0.00012312146,0.00004313006,0.0123178065],"genre_scores_gemma":[0.0028674745,0.9825744,0.0012811732,0.0015096621,0.00053680944,0.00007008279,0.00029219242,0.000008108735,0.010860097],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99961215,0.000063877254,0.00005711696,0.000058541136,0.00016855242,0.000039864823],"domain_scores_gemma":[0.9996556,0.00008304365,0.00008032916,0.000017909848,0.00011918278,0.000043958436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007664969,0.0010471331,0.001289967,0.0017736601,0.0003050507,0.0010589891,0.0011104066,0.0015688055,0.018622002],"category_scores_gemma":[0.00083724316,0.00026798953,0.00053337426,0.0017204537,0.00031359072,0.0014073008,0.0006943481,0.0016351162,0.010844581],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012817957,0.00013701615,0.00012268175,0.00950912,0.00003998002,0.00034082102,0.00003767901,0.00013676901,0.0029217307,0.0016084858,0.025851449,0.9591661],"study_design_scores_gemma":[0.000066548615,0.00017450935,0.0005496202,0.0016708086,0.000057033336,0.0012059762,0.000022728478,0.000033533026,0.0008191747,0.0005095528,0.9948832,0.000007400019],"about_ca_topic_score_codex":0.00070100196,"about_ca_topic_score_gemma":0.001502234,"teacher_disagreement_score":0.018622002,"about_ca_system_score_codex":0.0004964252,"about_ca_system_score_gemma":0.001063789,"threshold_uncertainty_score":0.062296808},"labels":[],"label_agreement":null},{"id":"W2079671777","doi":"10.1517/13543784.12.9.1471","title":"C-peptide and diabetic neuropathy","year":2003,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Advanced Glycation End Products research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council; Diabetes Canada; National Institutes of Health; Canadian Diabetes Association; American Diabetes Association","keywords":"Medicine; Diabetes mellitus; Insulin; Diabetic neuropathy; Type 2 diabetes; Internal medicine; Type 1 diabetes; Endocrinology; Animal studies; Bioinformatics; Biology","score_opus":0.052835658344886655,"score_gpt":0.3660591950859705,"score_spread":0.31322353674108383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079671777","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010302417,0.96935755,0.00047474378,0.018823005,0.0042427275,0.00002033729,0.00011377498,0.000027683596,0.0059099244],"genre_scores_gemma":[0.013032023,0.96275073,0.00062627543,0.010286635,0.0076117073,0.00004824965,0.00024275902,0.00000825695,0.0053933715],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99956065,0.00012000011,0.000035681405,0.0000701442,0.00014985345,0.000063681764],"domain_scores_gemma":[0.99945194,0.0001615357,0.00011387329,0.000014293627,0.00017255216,0.00008586103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008375356,0.0006851625,0.00090625184,0.0004416024,0.00022076248,0.001218144,0.0008670073,0.0032199733,0.007603746],"category_scores_gemma":[0.0010900322,0.00012631537,0.00038483116,0.00042385748,0.00047607618,0.0008300316,0.0006269487,0.002552858,0.0035002672],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007497457,0.00015132134,0.0008758041,0.008114748,0.00022278185,0.0009471087,0.00007502188,0.00040776766,0.0046525626,0.009021134,0.23255906,0.7422229],"study_design_scores_gemma":[0.0002736248,0.000453049,0.002913499,0.0033449875,0.00016420738,0.0019825269,0.000108848835,0.0003456808,0.0012090441,0.008495613,0.98067033,0.00003860195],"about_ca_topic_score_codex":0.0007825136,"about_ca_topic_score_gemma":0.0010405886,"teacher_disagreement_score":0.007603746,"about_ca_system_score_codex":0.0006514253,"about_ca_system_score_gemma":0.0008822709,"threshold_uncertainty_score":0.025436997},"labels":[],"label_agreement":null},{"id":"W2085430830","doi":"10.1517/13543784.11.12.1795","title":"Novel therapies for sepsis: antiendotoxin therapies","year":2002,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Immune Response and Inflammation","field":"Immunology and Microbiology","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Health Sciences Centre; Manitoba Health","funders":"","keywords":"Sepsis; Lipopolysaccharide; Immune system; Lipid A; Monoclonal antibody; Immunology; Receptor; Septic shock; Biology; Antibody; Medicine; Internal medicine","score_opus":0.08159723834029357,"score_gpt":0.3380841695788234,"score_spread":0.25648693123852984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085430830","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00047440958,0.9926023,0.00062163186,0.0011490489,0.0009397154,0.000027445345,0.000019126092,0.000023134693,0.004143276],"genre_scores_gemma":[0.0020236527,0.98917353,0.0012177372,0.0013270989,0.0009173029,0.00004308691,0.000058582773,0.000004028745,0.0052350108],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997905,0.000044398228,0.000018763407,0.000027108093,0.0000986014,0.000020724543],"domain_scores_gemma":[0.9998466,0.000049409962,0.00002123293,0.0000070688097,0.000050768424,0.000024882069],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058055384,0.0010059831,0.0011094513,0.001319629,0.00028495202,0.000717094,0.0008666096,0.0015128311,0.0069070524],"category_scores_gemma":[0.00036984112,0.0001849843,0.00041664383,0.0008956071,0.00039602778,0.0011012165,0.0004437342,0.001810634,0.0047289436],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016577219,0.00026052084,0.00009400214,0.004917351,0.000048306225,0.0005507221,0.000046379148,0.00023487417,0.0072856727,0.0026959807,0.03258072,0.95111954],"study_design_scores_gemma":[0.00013027043,0.00037108432,0.00066529465,0.0013508087,0.000055418488,0.0025388931,0.0000394872,0.00012287486,0.0014189826,0.0017887185,0.9915029,0.000015265628],"about_ca_topic_score_codex":0.00041117336,"about_ca_topic_score_gemma":0.0012256223,"teacher_disagreement_score":0.0069070524,"about_ca_system_score_codex":0.0005149254,"about_ca_system_score_gemma":0.0005890275,"threshold_uncertainty_score":0.023106396},"labels":[],"label_agreement":null},{"id":"W2091033733","doi":"10.1517/13543784.10.9.1687","title":"Therapeutic potential of angiotensin II receptor antagonists","year":2001,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Renin-Angiotensin System Studies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Heart Institute","funders":"","keywords":"Angiotensin II; Renin–angiotensin system; Blockade; Angiotensin receptor; Angiotensin II receptor type 1; Homeostasis; Medicine; Receptor; Internal medicine; Pharmacology; Endocrinology; Blood pressure","score_opus":0.07544061395837655,"score_gpt":0.3672220431966472,"score_spread":0.29178142923827066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091033733","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005202118,0.9959335,0.00019878993,0.00046347917,0.00023510975,0.000008139784,0.000016848131,0.00000864445,0.0026152844],"genre_scores_gemma":[0.0042485404,0.99210304,0.0004823924,0.00064222905,0.00041329974,0.0000178414,0.000040437357,0.000002080575,0.002050113],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99980706,0.00005740641,0.000020389143,0.00003032309,0.00006799416,0.00001690495],"domain_scores_gemma":[0.9998691,0.000066440494,0.00002123928,0.0000046885953,0.00002557645,0.000012853412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044381883,0.0006900636,0.001332977,0.0010883409,0.00019310432,0.0006645204,0.00069863035,0.00096901174,0.0046200245],"category_scores_gemma":[0.00038018648,0.00013550062,0.0004501424,0.0006112407,0.00024170798,0.00062148785,0.0003048704,0.0012864341,0.00215177],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023600165,0.00019889222,0.00017614388,0.0065241186,0.00012566808,0.0009972367,0.000050703893,0.00032335744,0.0059165284,0.0026271958,0.015943676,0.9668805],"study_design_scores_gemma":[0.00021157214,0.00056274096,0.0017441118,0.0020399773,0.0001940181,0.0056586093,0.00007041132,0.00020148078,0.002078648,0.0020214145,0.985195,0.000022036002],"about_ca_topic_score_codex":0.0003569007,"about_ca_topic_score_gemma":0.0009859796,"teacher_disagreement_score":0.0046200245,"about_ca_system_score_codex":0.00034536165,"about_ca_system_score_gemma":0.00039896238,"threshold_uncertainty_score":0.015455484},"labels":[],"label_agreement":null},{"id":"W2091130375","doi":"10.1517/13543780903066772","title":"EGFR-directed therapies to treat non-small-cell lung cancer","year":2009,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Lung cancer; Medicine; Tyrosine kinase; Cancer research; Cancer; Angiogenesis; Epidermal growth factor receptor; Monoclonal antibody; Disease; Drug development; Targeted therapy; Drug; Oncology; Immunology; Pharmacology; Internal medicine; Receptor; Antibody","score_opus":0.04626132764116791,"score_gpt":0.3999452614262695,"score_spread":0.3536839337851016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091130375","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003420625,0.99358845,0.00042523906,0.00062562,0.0003568473,0.000032521122,0.0000346426,0.000019175042,0.0045753377],"genre_scores_gemma":[0.0013734258,0.99471915,0.00063241756,0.00048795695,0.00022791068,0.000026497406,0.000070852606,0.000003227786,0.002458641],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998227,0.000030681476,0.000015537113,0.000024137673,0.000089404115,0.000017698276],"domain_scores_gemma":[0.9998665,0.000045101344,0.000025242949,0.0000058391047,0.000040316347,0.000016952616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005712909,0.000852693,0.001391301,0.0016081203,0.0002475938,0.00057215843,0.0008773921,0.0010383823,0.0058401576],"category_scores_gemma":[0.0003455214,0.00021718217,0.00057379896,0.0012561776,0.0003452415,0.0008617407,0.0004725363,0.0017865127,0.0056982515],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007547272,0.00021564186,0.000109908455,0.0066472935,0.00008572006,0.00036868284,0.00004542479,0.00032003812,0.0053078486,0.0025357946,0.03304886,0.95123935],"study_design_scores_gemma":[0.00010704154,0.00026249237,0.0007508482,0.0016663031,0.000086365624,0.0023236559,0.000038818893,0.0001075018,0.0012301926,0.0014727825,0.9919355,0.000018476547],"about_ca_topic_score_codex":0.00080535497,"about_ca_topic_score_gemma":0.0026348913,"teacher_disagreement_score":0.0058401576,"about_ca_system_score_codex":0.00051440153,"about_ca_system_score_gemma":0.0005989227,"threshold_uncertainty_score":0.01953727},"labels":[],"label_agreement":null},{"id":"W2094045238","doi":"10.1517/13543784.14.3.251","title":"Parathyroid hormone and leptin – new peptides, expanding clinical prospects","year":2005,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Growth Hormone and Insulin-like Growth Factors","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; Institute for Biological Sciences","funders":"","keywords":"Teriparatide; Medicine; Leptin; Parathyroid hormone; Osteoporosis; Internal medicine; Osteoblast; Endocrinology; Anabolism; Hormone; Biology; Calcium","score_opus":0.12904821129417793,"score_gpt":0.42632336944373983,"score_spread":0.2972751581495619,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094045238","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000102844555,0.9976179,0.0001083754,0.00067126646,0.0003335709,0.0000043092577,0.0000059558283,0.0000063371294,0.0011493717],"genre_scores_gemma":[0.00067078136,0.99639845,0.00033110083,0.00080774364,0.0007069199,0.0000100135885,0.000018978455,0.0000018611353,0.0010542029],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999653,0.00007717347,0.000045341774,0.00005325764,0.00014374478,0.000027631782],"domain_scores_gemma":[0.9995389,0.00023920428,0.000051855186,0.000015961825,0.00009951397,0.00005466745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015217165,0.0010489883,0.0016387485,0.0019261148,0.00028355225,0.0011786855,0.0009909619,0.0021499568,0.0055085532],"category_scores_gemma":[0.00090501824,0.00040878015,0.000539147,0.0018655626,0.00081776717,0.003001305,0.0007669704,0.002678451,0.003428535],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001982914,0.00016011455,0.0001464328,0.006921634,0.00006097989,0.0005523723,0.000069771784,0.00034720864,0.002195542,0.0041902238,0.033093043,0.9520644],"study_design_scores_gemma":[0.00008789493,0.00018946615,0.0006268103,0.0018618379,0.000049949424,0.0015086333,0.000073354684,0.00012266592,0.0002795387,0.0028563025,0.99232626,0.000017332115],"about_ca_topic_score_codex":0.0007364107,"about_ca_topic_score_gemma":0.0020879614,"teacher_disagreement_score":0.0055085532,"about_ca_system_score_codex":0.0006545506,"about_ca_system_score_gemma":0.00096307514,"threshold_uncertainty_score":0.018427908},"labels":[],"label_agreement":null},{"id":"W2094081851","doi":"10.1517/13543784.2013.840289","title":"Investigational drugs for onychomycosis","year":2013,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Nail Diseases and Treatments","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mediprobe Research (Canada); University of Toronto","funders":"","keywords":"Terbinafine; Medicine; Adverse effect; Drug; Dermatology; Drug development; Pharmacology; Clinical trial; Intensive care medicine; Antifungal; Itraconazole; Internal medicine","score_opus":0.12005280775955049,"score_gpt":0.41042137815608937,"score_spread":0.29036857039653885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094081851","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014387346,0.9937382,0.00018993088,0.00045488463,0.00053592934,0.000019626883,0.00005837863,0.000018713461,0.0048403936],"genre_scores_gemma":[0.0012363028,0.9944463,0.0003633469,0.00057453295,0.00036169725,0.00001940688,0.00010819314,0.0000036152433,0.002886542],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997346,0.000043098375,0.000028600889,0.000041058454,0.00012689288,0.000025774463],"domain_scores_gemma":[0.9997737,0.00007207536,0.000054107964,0.00000908472,0.000067622124,0.000023469012],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037178554,0.0008087954,0.0011543087,0.0022077395,0.00025732323,0.0007986918,0.0008066783,0.0010951412,0.013418366],"category_scores_gemma":[0.00053990947,0.00018510286,0.0006228084,0.0018895763,0.00036935857,0.0008581047,0.0006190517,0.0017660973,0.0070879636],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000065905246,0.00006798816,0.000077184086,0.014578444,0.000072905525,0.00030913437,0.000036953807,0.000169065,0.002060832,0.0026456106,0.058114465,0.92180145],"study_design_scores_gemma":[0.000025401177,0.00006249491,0.00027129622,0.002879116,0.000065365304,0.0012312763,0.000020116417,0.00004735885,0.00036284514,0.0008448427,0.99418074,0.000009110319],"about_ca_topic_score_codex":0.00076390285,"about_ca_topic_score_gemma":0.001826175,"teacher_disagreement_score":0.013418366,"about_ca_system_score_codex":0.0005443616,"about_ca_system_score_gemma":0.00077608845,"threshold_uncertainty_score":0.044888914},"labels":[],"label_agreement":null},{"id":"W2095549754","doi":"10.1517/13543780903179294","title":"Emerging oligonucleotide therapies for asthma and chronic obstructive pulmonary disease","year":2009,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Neonatal Respiratory Health Research","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Business Development Bank of Canada","funders":"","keywords":"Medicine; Asthma; COPD; Disease; Inflammation; Intensive care medicine; Immunology; Internal medicine","score_opus":0.07718330351801966,"score_gpt":0.4155367821951554,"score_spread":0.3383534786771357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095549754","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024639757,0.9960473,0.00034913112,0.00042887384,0.00040204774,0.000015317093,0.000014969066,0.000011467499,0.0024844557],"genre_scores_gemma":[0.0010878266,0.99549085,0.0008237437,0.0004453927,0.00026401647,0.000023131188,0.00003687382,0.000002080743,0.0018260829],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997322,0.000052526455,0.000030636482,0.00004012847,0.000120243654,0.000024292329],"domain_scores_gemma":[0.999813,0.000075533775,0.000029538152,0.0000062223435,0.000055504912,0.00002020208],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069428794,0.00094546727,0.0014350757,0.0017637089,0.00032165265,0.00071160024,0.00084364176,0.0013997928,0.005115088],"category_scores_gemma":[0.0004568523,0.0002560357,0.00054349663,0.0013486139,0.00045887506,0.0012643063,0.00057926436,0.0020642586,0.0031532208],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008427296,0.00017837301,0.00009518128,0.009918879,0.00006395339,0.00039322217,0.00008132277,0.00029840964,0.007288979,0.0053044357,0.022791132,0.95350194],"study_design_scores_gemma":[0.00004676189,0.00020210088,0.00046456055,0.001902516,0.00006317797,0.0015164246,0.000056185432,0.000096104945,0.0011296555,0.002171422,0.9923361,0.000014960072],"about_ca_topic_score_codex":0.00067904446,"about_ca_topic_score_gemma":0.0018430786,"teacher_disagreement_score":0.005115088,"about_ca_system_score_codex":0.0006094626,"about_ca_system_score_gemma":0.0008233649,"threshold_uncertainty_score":0.017111659},"labels":[],"label_agreement":null},{"id":"W2095646768","doi":"10.1517/13543784.12.10.1655","title":"Targeting cellular energy production in neurological disorders","year":2003,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Coenzyme Q10 studies and effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre","funders":"","keywords":"Coenzyme Q10; Neuroprotection; Oxidative stress; Ataxia; Medicine; Amyotrophic lateral sclerosis; Creatine; Neuroscience; Disease; Excitotoxicity; Mitochondrial disease; Bioinformatics; Pharmacology; Biology; Pathology; Internal medicine; Biochemistry; Glutamate receptor","score_opus":0.024588816499651073,"score_gpt":0.29465874988490354,"score_spread":0.2700699333852525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095646768","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002816805,0.9954774,0.00042882471,0.00044550796,0.0003659927,0.000008519068,0.000011529267,0.000016307773,0.0029642608],"genre_scores_gemma":[0.0016187783,0.9954922,0.0003846063,0.00024497943,0.00016433955,0.000011472624,0.000019160916,0.0000021599758,0.0020621459],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998857,0.000020218275,0.000014037134,0.00002040098,0.000045282577,0.000014336904],"domain_scores_gemma":[0.99993956,0.000018680461,0.000008958575,0.000003218008,0.000021427715,0.000008177219],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003464375,0.00081513217,0.0012036934,0.001250649,0.0003300432,0.0007131824,0.0007680949,0.0012722652,0.003709633],"category_scores_gemma":[0.00020606063,0.00020140204,0.0002840052,0.0013366498,0.00047402573,0.0009637291,0.0006567095,0.0011722797,0.0034784225],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012444155,0.00009435548,0.00010458472,0.0102408435,0.000054248318,0.00062568334,0.00010628499,0.0005180624,0.0098418,0.008375132,0.028301274,0.9416133],"study_design_scores_gemma":[0.00002552587,0.00009397981,0.00043641138,0.0011205843,0.000037210935,0.0016725113,0.00006284722,0.00008163067,0.0013882509,0.0031744775,0.99189526,0.0000113097],"about_ca_topic_score_codex":0.0010880412,"about_ca_topic_score_gemma":0.0019107261,"teacher_disagreement_score":0.003709633,"about_ca_system_score_codex":0.0007899164,"about_ca_system_score_gemma":0.00073843414,"threshold_uncertainty_score":0.012409985},"labels":[],"label_agreement":null},{"id":"W2100771859","doi":"10.1517/13543784.2015.1009629","title":"Investigational drugs for the treatment of spinal cord injury: review of preclinical studies and evaluation of clinical trials from Phase I to II","year":2015,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Spinal Cord Injury Research","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto Western Hospital; University Health Network","funders":"AOSpine; Ontario Neurotrauma Foundation; European Commission; Acorda Therapeutics; Hadassah Medical Organization; Medtronic","keywords":"Medicine; Clinical trial; Riluzole; Spinal cord injury; Tolerability; Intensive care medicine; Neuroprotection; Pharmacology; Gabapentin; Adverse effect; Spinal cord; Disease; Internal medicine; Amyotrophic lateral sclerosis; Pathology; Alternative medicine","score_opus":0.7987099318314077,"score_gpt":0.7059770694690723,"score_spread":0.09273286236233536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100771859","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007038736,0.99899334,0.00008360093,0.00024088079,0.000110626876,0.000016376143,0.000026814198,0.00000462199,0.0004532631],"genre_scores_gemma":[0.00045717502,0.9989208,0.00015384775,0.000207886,0.00007371903,0.000015780037,0.000024746249,0.0000011854705,0.00014481798],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99942243,0.00013736094,0.00012318182,0.00007985554,0.00020293974,0.000034234716],"domain_scores_gemma":[0.9986045,0.0007480338,0.00025011564,0.00003167859,0.00032050043,0.000045301385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016677935,0.00095464673,0.0021332074,0.002645442,0.00022914834,0.00095582247,0.0012864947,0.0012060342,0.00459113],"category_scores_gemma":[0.002251751,0.00033926702,0.0012396041,0.0026092788,0.00052636646,0.0012242281,0.00054598105,0.0014452348,0.0015854011],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017447677,0.00007925095,0.000114887516,0.09543233,0.00028268617,0.00013560252,0.00006623434,0.000254253,0.0014159174,0.0020831465,0.023572456,0.8763887],"study_design_scores_gemma":[0.00015317148,0.0004531216,0.0012290229,0.061769426,0.0013699023,0.0012597508,0.000116495066,0.00017812315,0.0010557842,0.002164238,0.93020964,0.00004132301],"about_ca_topic_score_codex":0.0009147069,"about_ca_topic_score_gemma":0.0017821676,"teacher_disagreement_score":0.00459113,"about_ca_system_score_codex":0.0006076087,"about_ca_system_score_gemma":0.0019348569,"threshold_uncertainty_score":0.015358865},"labels":[],"label_agreement":null},{"id":"W2100830152","doi":"10.1517/13543784.17.11.1761","title":"Clazosentan: an endothelin receptor antagonist for treatment of vasospasm after subarachnoid hemorrhage","year":2008,"lang":"en","type":"article","venue":"Expert Opinion on Investigational Drugs","topic":"Intracranial Aneurysms: Treatment and Complications","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto","funders":"","keywords":"Subarachnoid hemorrhage; Endothelin receptor antagonist; Vasospasm; Medicine; Cerebral vasospasm; Endothelin receptor; Antagonist; Placebo; Clinical trial; Randomized controlled trial; Receptor antagonist; Anesthesia; Internal medicine; Receptor; Pathology","score_opus":0.04050734314660269,"score_gpt":0.30314685557252613,"score_spread":0.2626395124259234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100830152","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4095817,0.53574306,0.00555045,0.013026364,0.002232834,0.00082084915,0.000746848,0.00048188228,0.031816036],"genre_scores_gemma":[0.74757063,0.22464357,0.0066499338,0.005645184,0.0015762879,0.0003534804,0.0011181826,0.000035732086,0.012407006],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99989974,0.00003225544,0.000012480836,0.000012965002,0.000024970635,0.000017559438],"domain_scores_gemma":[0.99989927,0.000021870952,0.000033505807,0.0000043318505,0.000016532109,0.000024506337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003486779,0.00028592575,0.00076698756,0.00030545754,0.00016004646,0.00026171154,0.0005015439,0.00070851884,0.0026982913],"category_scores_gemma":[0.00033292532,0.00005902955,0.00024550286,0.0002652189,0.00016216746,0.00016984844,0.00010046451,0.00071259675,0.001136098],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009266087,0.0014576385,0.002783743,0.002376462,0.00028330897,0.0018349477,0.00007516239,0.00035864094,0.065593235,0.0008074902,0.019591423,0.8955719],"study_design_scores_gemma":[0.08507864,0.077379145,0.12542069,0.002136558,0.0017560516,0.03307487,0.00031470385,0.0041690655,0.12294807,0.0033941376,0.54414946,0.0001786654],"about_ca_topic_score_codex":0.00037102855,"about_ca_topic_score_gemma":0.0016484241,"teacher_disagreement_score":0.0026982913,"about_ca_system_score_codex":0.00029203473,"about_ca_system_score_gemma":0.00034365527,"threshold_uncertainty_score":0.009026706},"labels":[],"label_agreement":null},{"id":"W2101161401","doi":"10.1517/13543784.2010.515586","title":"Quetiapine: novel uses in the treatment of depressive and anxiety disorders","year":2010,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"AstraZeneca Canada","keywords":"Quetiapine; Tolerability; Anxiety; Psychiatry; Mania; Atypical antipsychotic; Bipolar disorder; Medicine; Psychology; Antipsychotic; Depression (economics); Schizophrenia (object-oriented programming); Clinical psychology; Adverse effect; Mood; Pharmacology","score_opus":0.05158241660745432,"score_gpt":0.3582140999012484,"score_spread":0.3066316832937941,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101161401","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016752955,0.9984205,0.000087153465,0.00023202236,0.000092579496,0.0000049701875,0.000015596604,0.0000075041226,0.00097222964],"genre_scores_gemma":[0.0015165047,0.9974196,0.00016065195,0.0002032697,0.00013581043,0.0000048371135,0.000022592416,0.0000011515907,0.0005356133],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99985516,0.000026241005,0.000019537034,0.000024798444,0.000060739596,0.000013473233],"domain_scores_gemma":[0.99984944,0.000061195664,0.000042913463,0.0000042474567,0.00002825055,0.000013930727],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033620308,0.00054657937,0.00111108,0.0017376256,0.00018868156,0.0006051764,0.00054016424,0.00075705844,0.0043395297],"category_scores_gemma":[0.0004691124,0.0001281407,0.00052008335,0.0018011642,0.00030005682,0.00068230875,0.00034919532,0.0009154921,0.0017788614],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011013788,0.000051549843,0.000166407,0.016358161,0.00013045089,0.00038525852,0.00005274947,0.00018873997,0.0022613262,0.0013445683,0.01699052,0.96196],"study_design_scores_gemma":[0.00013101827,0.000186459,0.002785696,0.0066948477,0.0004403823,0.0051597715,0.00008151278,0.00016104644,0.0012608336,0.0017964033,0.9812742,0.000027875241],"about_ca_topic_score_codex":0.0016621707,"about_ca_topic_score_gemma":0.0042743348,"teacher_disagreement_score":0.0043395297,"about_ca_system_score_codex":0.00049294106,"about_ca_system_score_gemma":0.0007338487,"threshold_uncertainty_score":0.0145171285},"labels":[],"label_agreement":null},{"id":"W2101906616","doi":"10.1517/13543784.16.10.1525","title":"Next-generation calcineurin inhibitors for ophthalmic indications","year":2007,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Ocular Diseases and Behçet’s Syndrome","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Institute for Nanotechnology","funders":"","keywords":"Calcineurin; Ciclosporin; Medicine; Tacrolimus; Pharmacology; Uveitis; Blepharitis; Transplantation; Ophthalmology; Immunology; Internal medicine","score_opus":0.23988800468594348,"score_gpt":0.4298117209830393,"score_spread":0.18992371629709584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101906616","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00026780766,0.99504685,0.00038079484,0.00037865213,0.00034674478,0.000016741747,0.000022612043,0.000021482629,0.0035184382],"genre_scores_gemma":[0.0014047285,0.9945247,0.00067509257,0.00044255814,0.00033584813,0.000025430378,0.00007705492,0.000003949919,0.0025106831],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997892,0.00003325716,0.000019178033,0.00002787988,0.00011001886,0.000020464598],"domain_scores_gemma":[0.9997867,0.00008728746,0.00003738666,0.000008344399,0.000051645333,0.000028666771],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058863795,0.001007403,0.0012551986,0.0023188274,0.00029246914,0.0006957441,0.0010331573,0.0013453985,0.009069605],"category_scores_gemma":[0.0004898746,0.00024553516,0.000557347,0.0017617104,0.0003584515,0.0011843634,0.00050045154,0.0015834363,0.0063402494],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009650042,0.00016001836,0.00012647876,0.0063826456,0.000067387045,0.00057524454,0.00004346468,0.0003339824,0.0039341506,0.0017562666,0.038332324,0.9481915],"study_design_scores_gemma":[0.00006802071,0.00012253902,0.00052861107,0.0010021321,0.000061245875,0.0024395743,0.000024743682,0.00010399285,0.0007784468,0.0007948673,0.994062,0.000013813366],"about_ca_topic_score_codex":0.0008162698,"about_ca_topic_score_gemma":0.0022373206,"teacher_disagreement_score":0.009069605,"about_ca_system_score_codex":0.00050878926,"about_ca_system_score_gemma":0.0007121714,"threshold_uncertainty_score":0.03034079},"labels":[],"label_agreement":null},{"id":"W2103370158","doi":"10.1517/13543784.13.3.199","title":"Recent advances in protein tyrosine phosphatase 1B inhibitors","year":2004,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Protein Tyrosine Phosphatases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Downregulation and upregulation; Leptin; Insulin resistance; Protein tyrosine phosphatase; Insulin; Type 2 diabetes; Diabetes mellitus; Obesity; Insulin receptor; Biology; Phosphatase; Tyrosine; Internal medicine; Endocrinology; Medicine; Cell biology; Biochemistry; Phosphorylation","score_opus":0.027311052924178392,"score_gpt":0.32922660250478314,"score_spread":0.30191554958060474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103370158","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022304528,0.9960508,0.00036894894,0.000538209,0.000599377,0.000008949489,0.000020293739,0.000018998866,0.002171402],"genre_scores_gemma":[0.0009542914,0.9949073,0.0005472684,0.0006994624,0.0005049066,0.000015033305,0.000048724676,0.0000035252674,0.0023194791],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997031,0.00004511363,0.000034400335,0.000061744235,0.00012547852,0.00003005531],"domain_scores_gemma":[0.99973017,0.000104164465,0.00003917038,0.000011077104,0.00007473121,0.00004067629],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007420396,0.0011800566,0.0014135372,0.0016611028,0.00030291508,0.0009155933,0.0008972748,0.0013213432,0.005188487],"category_scores_gemma":[0.00065019995,0.000394431,0.00049580645,0.0017552786,0.00044091107,0.001384773,0.00070130633,0.0021686307,0.004827419],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001767284,0.00015094485,0.00010387226,0.008802612,0.000079105695,0.0004957087,0.000058065696,0.000549343,0.0070114653,0.0045069265,0.05045918,0.927606],"study_design_scores_gemma":[0.000043690965,0.00013053109,0.000308507,0.0005767852,0.00005970224,0.0009994736,0.000018388891,0.00008990695,0.00093553774,0.000944265,0.9958801,0.000013106503],"about_ca_topic_score_codex":0.0007709313,"about_ca_topic_score_gemma":0.001981966,"teacher_disagreement_score":0.005188487,"about_ca_system_score_codex":0.00083950796,"about_ca_system_score_gemma":0.0007134176,"threshold_uncertainty_score":0.01735723},"labels":[],"label_agreement":null},{"id":"W2103567156","doi":"10.1517/13543784.15.8.933","title":"Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment","year":2006,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Antimicrobial Peptides and Activities","field":"Immunology and Microbiology","cited_by":432,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Cytotoxicity; Cancer cell; Lytic cycle; Cancer; Angiogenesis; Antimicrobial; Cancer research; Cytotoxic T cell; Apoptosis; Biology; Chemotherapy; Drug resistance; Drug; Pharmacology; Immunology; In vitro; Microbiology; Biochemistry","score_opus":0.08353260939165319,"score_gpt":0.36466099908877286,"score_spread":0.2811283896971197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103567156","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011613249,0.99395096,0.001061699,0.00037084083,0.00032939666,0.00002414881,0.000014800185,0.000023306133,0.0030635656],"genre_scores_gemma":[0.0061240434,0.98699784,0.0024796962,0.0004593116,0.0004294856,0.000052311527,0.000051538984,0.0000054646544,0.0034002776],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99983764,0.00003651926,0.000015379455,0.000024754085,0.00006754073,0.000018128343],"domain_scores_gemma":[0.99990296,0.000025967915,0.000019934265,0.0000046121545,0.000027379207,0.000019148303],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006341475,0.00095294364,0.001076633,0.001184913,0.00024700057,0.0006967653,0.0007727794,0.0012639096,0.0031521043],"category_scores_gemma":[0.00022963017,0.00024572393,0.00031578413,0.00087129173,0.00047181058,0.0012366322,0.0004931046,0.0013454196,0.0026278808],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001559057,0.00020519465,0.00014364142,0.0060584894,0.000046724846,0.00090061885,0.000102534286,0.0009557214,0.058554307,0.0067629116,0.013584227,0.9125297],"study_design_scores_gemma":[0.00010190518,0.0005333017,0.0005352879,0.00095831946,0.00004771956,0.0029611164,0.000061732266,0.00033457423,0.0108037535,0.0027688972,0.9808636,0.000029869943],"about_ca_topic_score_codex":0.00029776222,"about_ca_topic_score_gemma":0.0005450615,"teacher_disagreement_score":0.0031521043,"about_ca_system_score_codex":0.00056520617,"about_ca_system_score_gemma":0.0004411608,"threshold_uncertainty_score":0.0105448365},"labels":[],"label_agreement":null},{"id":"W2107217435","doi":"10.1517/13543784.14.9.1129","title":"The therapeutic potential of NS3 protease inhibitors in HCV infection","year":2005,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Hepatitis C virus research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"NS3; Protease; Hepatitis C virus; Virology; Viral replication; Hepatitis C; Medicine; Drug discovery; Biology; Virus; Enzyme; Immunology; Bioinformatics; Biochemistry","score_opus":0.08782441455950177,"score_gpt":0.4167827363426397,"score_spread":0.3289583217831379,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107217435","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00048459522,0.9955823,0.00019487698,0.000426949,0.00026171,0.000012211156,0.000019705843,0.000012955072,0.0030046806],"genre_scores_gemma":[0.0021356526,0.99523455,0.00035620204,0.0003678891,0.00025826186,0.000016115677,0.000037128735,0.000001965772,0.0015923225],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998275,0.000040431594,0.00001709288,0.000022508679,0.00007245422,0.00002002372],"domain_scores_gemma":[0.9998944,0.000039447346,0.000018713852,0.0000043625,0.000028153083,0.000014898344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006571643,0.00080955954,0.0015101165,0.0016916324,0.00028978154,0.0008950658,0.0009323001,0.0012151899,0.004634278],"category_scores_gemma":[0.00030827252,0.0002040198,0.00045819604,0.0013104073,0.0004278908,0.0009810798,0.00048878294,0.0013840187,0.003440644],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019032291,0.00017126637,0.00012029403,0.008831567,0.00008017468,0.0007576124,0.00007649753,0.00047227993,0.007677431,0.003945422,0.024766866,0.95291024],"study_design_scores_gemma":[0.00010645043,0.00038229674,0.00080713973,0.0016429315,0.000071706454,0.0022390387,0.000058113143,0.00015970517,0.001490236,0.0017483562,0.99127203,0.000021931075],"about_ca_topic_score_codex":0.0007013649,"about_ca_topic_score_gemma":0.0016252425,"teacher_disagreement_score":0.004634278,"about_ca_system_score_codex":0.0005539115,"about_ca_system_score_gemma":0.00054696394,"threshold_uncertainty_score":0.015503228},"labels":[],"label_agreement":null},{"id":"W2109977008","doi":"10.1517/13543784.9.2.383","title":"A review of clinical trials with fluoroquinolones with an emphasis on new agents","year":2000,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Pneumonia and Respiratory Infections","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital","funders":"","keywords":"Medicine; Intensive care medicine; Antimicrobial; Broad spectrum; Antibiotics; Respiratory tract infections; Clinical trial; Anti-Infective Agents; Pharmacology; Internal medicine; Respiratory system; Biology; Microbiology","score_opus":0.3822515389438884,"score_gpt":0.5327650230802695,"score_spread":0.1505134841363811,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109977008","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013720249,0.998938,0.0000764277,0.00018114045,0.00013571374,0.000018607228,0.00003388549,0.00000384467,0.00047529594],"genre_scores_gemma":[0.00085292396,0.9982102,0.00026632796,0.0002759955,0.00012558459,0.000028091916,0.00004845569,0.0000017215132,0.0001906734],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9990767,0.00028131314,0.00025401168,0.00010207401,0.0002522343,0.000033611585],"domain_scores_gemma":[0.9982268,0.0010530005,0.00031289077,0.00004063007,0.00030481626,0.00006186083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016992246,0.0010199167,0.0034892305,0.0028357815,0.00028933736,0.0010427276,0.001293827,0.00109119,0.0061356868],"category_scores_gemma":[0.0037317078,0.00031946084,0.0014071212,0.003947178,0.00035879682,0.0011025813,0.00044629365,0.00090744806,0.0014262287],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042934378,0.0000768328,0.00018994152,0.1170901,0.00051672023,0.00029081592,0.00006179143,0.00021338966,0.001227413,0.0006339468,0.01921292,0.8600568],"study_design_scores_gemma":[0.00054769637,0.0013000112,0.004060196,0.10230202,0.0045609735,0.004025174,0.00018437773,0.00016984345,0.0010935552,0.0013381254,0.88036275,0.00005529148],"about_ca_topic_score_codex":0.00078855327,"about_ca_topic_score_gemma":0.002246592,"teacher_disagreement_score":0.0061356868,"about_ca_system_score_codex":0.0008446452,"about_ca_system_score_gemma":0.0016594747,"threshold_uncertainty_score":0.020525873},"labels":[],"label_agreement":null},{"id":"W2112228502","doi":"10.1517/13543784.12.1.87","title":"Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes","year":2003,"lang":"en","type":"article","venue":"Expert Opinion on Investigational Drugs","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":208,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"","keywords":"Incretin; Dipeptidyl peptidase; Aminopeptidase; Peptide; Glucagon-like peptide-1; Dipeptidyl peptidase-4; Type 2 diabetes; Sitagliptin; Chemistry; Pharmacology; Biochemistry; Endocrinology; Internal medicine; Biology; Diabetes mellitus; Medicine; Enzyme; Amino acid","score_opus":0.02959327137273806,"score_gpt":0.2913622153120864,"score_spread":0.26176894393934835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112228502","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02295434,0.9315499,0.0058466434,0.011861327,0.0013610709,0.00011107757,0.00008908504,0.00008825432,0.026138252],"genre_scores_gemma":[0.20597117,0.761682,0.013723813,0.004914982,0.0018951654,0.00021037066,0.00016614003,0.00002057301,0.011415709],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99985385,0.000058387057,0.000011205901,0.000015327812,0.000040106614,0.000021119808],"domain_scores_gemma":[0.99991727,0.00003780796,0.000014317679,0.000003336208,0.00001400224,0.000013334986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006219809,0.0004537976,0.00080474856,0.0004444526,0.00021642847,0.0007435973,0.00038906958,0.00088133663,0.0036063485],"category_scores_gemma":[0.0002893412,0.00011632683,0.00037274713,0.00021053528,0.00028491995,0.0004830829,0.00024649757,0.001181256,0.0009054065],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012792978,0.00048159738,0.00059028855,0.0019698543,0.00011475209,0.0018918394,0.00009993823,0.00086177624,0.051657632,0.0129440315,0.012202082,0.9159068],"study_design_scores_gemma":[0.002747022,0.0063167745,0.0047516506,0.0015053566,0.0005182042,0.010065559,0.0003195797,0.002232854,0.032032248,0.017800713,0.9216303,0.00007970356],"about_ca_topic_score_codex":0.00018099375,"about_ca_topic_score_gemma":0.00057069556,"teacher_disagreement_score":0.0036063485,"about_ca_system_score_codex":0.00031994944,"about_ca_system_score_gemma":0.00033852487,"threshold_uncertainty_score":0.012064457},"labels":[],"label_agreement":null},{"id":"W2112309322","doi":"10.1517/13543784.10.7.1265","title":"Recent advances in the management of adult myositis","year":2001,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Inflammatory Myopathies and Dermatomyositis","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Polymyositis; Medicine; Myositis; Azathioprine; Methotrexate; Inclusion body myositis; Dermatomyositis; Infliximab; Combination therapy; Tacrolimus; Immunology; Cyclophosphamide; Cytotoxic T cell; Etanercept; Pharmacology; Rheumatoid arthritis; Dermatology; Internal medicine; Chemotherapy; Tumor necrosis factor alpha; Transplantation; Disease; Biology","score_opus":0.03867655144852411,"score_gpt":0.35170777275297277,"score_spread":0.31303122130444866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112309322","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016351549,0.9985091,0.00010684307,0.00025139953,0.00015334295,0.000004774749,0.0000073169986,0.000005626705,0.00079809176],"genre_scores_gemma":[0.00079710886,0.9977932,0.00033346534,0.00024341859,0.00031760306,0.000007233215,0.000024339293,0.0000012039044,0.0004823742],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99961215,0.00008381386,0.00007036557,0.000062151186,0.00014171153,0.000029920113],"domain_scores_gemma":[0.99947304,0.00023520687,0.00009604597,0.00001707133,0.00013300015,0.000045733897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009525143,0.001003762,0.0015589893,0.0022388455,0.0002917128,0.00092804217,0.0012197957,0.0011881868,0.0050479616],"category_scores_gemma":[0.0010439393,0.00024531147,0.0005351737,0.002356235,0.00040327353,0.0012773289,0.00061427016,0.0013163585,0.0027701475],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010578269,0.0000899016,0.00019149345,0.012412925,0.00006985378,0.0005174469,0.00006033101,0.0002923309,0.000952476,0.0007391625,0.014498463,0.9700698],"study_design_scores_gemma":[0.00007176943,0.00025553146,0.0017807425,0.0045273975,0.00019262775,0.004885572,0.00009185028,0.00015049752,0.00051487185,0.001130142,0.98637265,0.000026418644],"about_ca_topic_score_codex":0.0012728828,"about_ca_topic_score_gemma":0.002274643,"teacher_disagreement_score":0.0050479616,"about_ca_system_score_codex":0.0006700168,"about_ca_system_score_gemma":0.0008347354,"threshold_uncertainty_score":0.016887069},"labels":[],"label_agreement":null},{"id":"W2113703285","doi":"10.1517/13543784.14.1.37","title":"Nitric oxide and the angiogenic response: can we improve the results of therapeutic angiogenesis?","year":2005,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Nitric Oxide and Endothelin Effects","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Angiogenesis; Nitric oxide; Medicine; Endothelial dysfunction; Bench to bedside; Endothelium; Neovascularization; Therapeutic angiogenesis; Antiangiogenic therapy; Pharmacology; Cancer research; Bioinformatics; Biology; Internal medicine; Medical physics","score_opus":0.04957339502972656,"score_gpt":0.3434438970343578,"score_spread":0.2938705020046312,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113703285","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011518657,0.9962696,0.00018986184,0.0019980257,0.0005008981,0.000004439629,0.000007280994,0.0000063169755,0.0009083429],"genre_scores_gemma":[0.00082529173,0.9961725,0.00047988494,0.001007628,0.0006619214,0.000010029599,0.00001221059,0.000002873761,0.0008278153],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996207,0.00010057259,0.000045969187,0.000044976747,0.00015133744,0.000036434394],"domain_scores_gemma":[0.99944,0.0002917627,0.00007295842,0.000021904794,0.000119562086,0.000053786316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018535428,0.0009253435,0.0026752697,0.0013768498,0.00039629062,0.0014867533,0.001338226,0.003020062,0.005172136],"category_scores_gemma":[0.0012215892,0.0002517999,0.0005368901,0.0010815972,0.0011420894,0.003217137,0.0006876843,0.003057638,0.0036682212],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001702293,0.00014899665,0.00022167558,0.0108892275,0.00012251432,0.0006719351,0.000117721356,0.00027755758,0.0052180234,0.010020769,0.042175315,0.9299659],"study_design_scores_gemma":[0.00008732053,0.00030119132,0.00076092954,0.004332081,0.00009815333,0.0028160824,0.00018889495,0.0001464148,0.0010663536,0.0076552676,0.9825084,0.000038820483],"about_ca_topic_score_codex":0.0006784287,"about_ca_topic_score_gemma":0.0018978656,"teacher_disagreement_score":0.005172136,"about_ca_system_score_codex":0.00077324524,"about_ca_system_score_gemma":0.0009917454,"threshold_uncertainty_score":0.017302513},"labels":[],"label_agreement":null},{"id":"W2116152202","doi":"10.1517/13543784.11.7.991","title":"Bosentan: a dual endothelin receptor antagonist","year":2002,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Pulmonary Hypertension Research and Treatments","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Bosentan; Endothelin receptor antagonist; Medicine; Endothelin receptor; Pulmonary hypertension; Tolerability; Internal medicine; Cardiology; Pharmacology; Receptor; Adverse effect","score_opus":0.10954535217521799,"score_gpt":0.38386848033004844,"score_spread":0.27432312815483045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116152202","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00076635595,0.9947056,0.00031784497,0.00046684395,0.00040628106,0.00001866796,0.00003288302,0.000019466055,0.00326615],"genre_scores_gemma":[0.005233788,0.98641586,0.00079901196,0.0009416893,0.00045581502,0.000031193966,0.00011784028,0.0000033822503,0.006001463],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998646,0.000026924306,0.000014947339,0.000022252172,0.00005733847,0.000014003373],"domain_scores_gemma":[0.999933,0.000018519737,0.000016321961,0.0000022269542,0.000017506565,0.000012367492],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003456944,0.00067396497,0.0009787664,0.0009974607,0.00021351976,0.0005519828,0.0005940109,0.0009086044,0.0038383224],"category_scores_gemma":[0.00023269927,0.00014489015,0.0003353778,0.0008794089,0.00022088081,0.00069571525,0.00025850872,0.0011595434,0.0035062898],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024901214,0.00018990043,0.00018244406,0.006139902,0.00007885485,0.0006506139,0.000034720975,0.00018373545,0.0073148403,0.0011209047,0.02397225,0.95988286],"study_design_scores_gemma":[0.0002622417,0.0004949811,0.0018187999,0.00089729007,0.00012422024,0.0050202534,0.000030206453,0.00013250884,0.002831973,0.0006827538,0.98768497,0.00001982802],"about_ca_topic_score_codex":0.0004977071,"about_ca_topic_score_gemma":0.001224792,"teacher_disagreement_score":0.0038383224,"about_ca_system_score_codex":0.00035930015,"about_ca_system_score_gemma":0.0004935168,"threshold_uncertainty_score":0.012840509},"labels":[],"label_agreement":null},{"id":"W2122024610","doi":"10.1517/13543784.13.4.403","title":"Ximelagatran: the first oral direct thrombin inhibitor","year":2004,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University Medical Centre","funders":"","keywords":"Ximelagatran; Direct thrombin inhibitor; Medicine; Discovery and development of direct thrombin inhibitors; Coagulation; Anticoagulant; Thrombin; Intensive care medicine; Warfarin; Pharmacology; Atrial fibrillation; Dabigatran; Internal medicine","score_opus":0.13524794000117346,"score_gpt":0.3960961936146366,"score_spread":0.26084825361346314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122024610","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002481163,0.9951775,0.00013658163,0.00039982065,0.00029366722,0.000009755236,0.00003195292,0.000017508271,0.0036850935],"genre_scores_gemma":[0.0017183962,0.99362767,0.00024138414,0.00035556557,0.00028458145,0.000010173512,0.00005134554,0.000002445068,0.00370853],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99982363,0.000023719958,0.000020078083,0.00002876999,0.00008501462,0.000018846742],"domain_scores_gemma":[0.9998888,0.000032073985,0.000028662918,0.000004605531,0.000028108607,0.000017806446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024458164,0.0008032531,0.0011555821,0.0017159595,0.00023696465,0.00094641675,0.0006202683,0.0011837448,0.0070309783],"category_scores_gemma":[0.000375818,0.00018119837,0.0003380756,0.0017536184,0.00028230227,0.0009404626,0.00040735948,0.0009191827,0.006692264],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009422496,0.000064958236,0.00020771733,0.010163926,0.000049237588,0.00059084315,0.000041629442,0.00012127904,0.0028494098,0.001459188,0.035510585,0.94884694],"study_design_scores_gemma":[0.000039253202,0.00010616999,0.00079450605,0.0018612093,0.00006883412,0.004060621,0.000026511685,0.000032578067,0.0011316696,0.00063454796,0.99123514,0.000008966303],"about_ca_topic_score_codex":0.0009159523,"about_ca_topic_score_gemma":0.0012841681,"teacher_disagreement_score":0.0070309783,"about_ca_system_score_codex":0.0005031746,"about_ca_system_score_gemma":0.0010312761,"threshold_uncertainty_score":0.023520947},"labels":[],"label_agreement":null},{"id":"W2122461299","doi":"10.1517/13543784.17.5.811","title":"Roflumilast: an oral, once-daily selective PDE-4 inhibitor for the management of COPD and asthma","year":2008,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Phosphodiesterase function and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Foothills Medical Centre","funders":"","keywords":"Roflumilast; Medicine; COPD; Asthma; Intensive care medicine; Lung function; Internal medicine; Lung","score_opus":0.040720505888062065,"score_gpt":0.3306587140258579,"score_spread":0.2899382081377958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122461299","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021039092,0.99835724,0.000093734205,0.00023414017,0.0001549025,0.000010642663,0.000018119637,0.000007641085,0.00091318204],"genre_scores_gemma":[0.0011955247,0.9973802,0.0002354441,0.00023167409,0.00016583772,0.000014187224,0.000043062948,0.0000011575471,0.00073294784],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99981755,0.000029641114,0.000030313346,0.000027029188,0.00007537925,0.000020257467],"domain_scores_gemma":[0.99978286,0.000078944184,0.000053416,0.000004281779,0.000058903643,0.000021700398],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051876163,0.0007082398,0.0014609854,0.0025152962,0.00024473257,0.00060266675,0.000895759,0.0010772999,0.0039672772],"category_scores_gemma":[0.00054476154,0.00019484341,0.0006230438,0.0018830532,0.0002504722,0.0008729792,0.0003012938,0.0009359697,0.0020667973],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016607723,0.000080389706,0.00018471875,0.027255809,0.00014934875,0.00050599925,0.000039586917,0.0001271298,0.0033394364,0.000499555,0.018085271,0.9495667],"study_design_scores_gemma":[0.0002459709,0.00057174085,0.003268732,0.011207186,0.0007348624,0.009157599,0.00011341341,0.00017963364,0.0027757646,0.00088964845,0.97080946,0.000045957604],"about_ca_topic_score_codex":0.0009168521,"about_ca_topic_score_gemma":0.0020448773,"teacher_disagreement_score":0.0039672772,"about_ca_system_score_codex":0.0005241663,"about_ca_system_score_gemma":0.0009879721,"threshold_uncertainty_score":0.013271868},"labels":[],"label_agreement":null},{"id":"W2122631980","doi":"10.1517/13543784.11.11.1605","title":"Selective phosphodiesterase type 5 inhibition using tadalafil for the treatment of erectile dysfunction","year":2002,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Sexual function and dysfunction studies","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St Joseph's Health Centre","funders":"","keywords":"Tadalafil; Erectile dysfunction; Sildenafil; Medicine; cGMP-specific phosphodiesterase type 5; Broad spectrum; Placebo; Population; Pharmacotherapy; Pharmacology; Internal medicine; Alternative medicine; Chemistry; Pathology","score_opus":0.21173695906244597,"score_gpt":0.40449572255346905,"score_spread":0.19275876349102308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122631980","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008473019,0.9804212,0.0018460529,0.0016571609,0.0009691683,0.000078713405,0.00018095996,0.00006360239,0.0063101836],"genre_scores_gemma":[0.04782569,0.94135773,0.0029077253,0.002084247,0.0008664302,0.00005730471,0.00042522853,0.000015049544,0.0044606235],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998254,0.000046958656,0.000024518647,0.000025655016,0.000055612367,0.00002178281],"domain_scores_gemma":[0.9998598,0.000043886528,0.000042724798,0.0000062779377,0.000029046945,0.00001822996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006920825,0.00033118547,0.0005582639,0.0008785337,0.0001603324,0.000614219,0.00033983402,0.0004392421,0.0037752734],"category_scores_gemma":[0.00042128566,0.00009642231,0.00072724017,0.0006092059,0.00018350546,0.0003840381,0.000297146,0.0009892903,0.0013469177],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005156918,0.00029130158,0.00063035137,0.008869377,0.00027484645,0.00048763966,0.00008562707,0.000335541,0.03236935,0.0023623586,0.018162934,0.935615],"study_design_scores_gemma":[0.0008712683,0.009433702,0.013563572,0.005733194,0.0011684571,0.0063121393,0.00017355742,0.0009995325,0.024348551,0.0026816537,0.9346415,0.00007290693],"about_ca_topic_score_codex":0.00040495524,"about_ca_topic_score_gemma":0.0015042437,"teacher_disagreement_score":0.0037752734,"about_ca_system_score_codex":0.00023348264,"about_ca_system_score_gemma":0.0004021784,"threshold_uncertainty_score":0.012629509},"labels":[],"label_agreement":null},{"id":"W2126896835","doi":"10.1517/13543784.9.3.457","title":"Platelet substitutes and novel platelet products","year":2000,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Antiplatelet Therapy and Cardiovascular Diseases","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Queen's University","funders":"","keywords":"Platelet; Business; Chemistry; Medicine; Internal medicine","score_opus":0.06310912037077193,"score_gpt":0.3306338903687579,"score_spread":0.26752476999798597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126896835","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000433651,0.9956383,0.00026341496,0.00019553135,0.0002366972,0.0000113131255,0.000012409334,0.000008710199,0.0031999822],"genre_scores_gemma":[0.0016998496,0.9948126,0.0006220383,0.00027093588,0.00026651492,0.00001977303,0.000037741396,0.0000021604042,0.002268289],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996648,0.000053428896,0.000038884773,0.0000544347,0.00016770617,0.00002080052],"domain_scores_gemma":[0.9998888,0.000043943794,0.000021505095,0.000004622525,0.000029587192,0.0000116536785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045674978,0.0009563099,0.0012589896,0.002218199,0.00026808077,0.00092131423,0.00060115085,0.001082061,0.00359685],"category_scores_gemma":[0.0003801218,0.00021638225,0.00030843393,0.0017593865,0.00035532613,0.0010329015,0.0004751699,0.0011744715,0.0027964304],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000086685664,0.00013758538,0.00013873164,0.011387463,0.000053874784,0.0008161916,0.00008958334,0.00030363427,0.010814359,0.005119591,0.015616426,0.95543593],"study_design_scores_gemma":[0.000038238308,0.00021572782,0.00060990156,0.0019881695,0.00006439802,0.0033588267,0.000053617234,0.00009895436,0.002249851,0.0016784038,0.9896297,0.0000142926865],"about_ca_topic_score_codex":0.0004974064,"about_ca_topic_score_gemma":0.00090372964,"teacher_disagreement_score":0.00359685,"about_ca_system_score_codex":0.00035484257,"about_ca_system_score_gemma":0.0005099827,"threshold_uncertainty_score":0.012032628},"labels":[],"label_agreement":null},{"id":"W2127275456","doi":"10.1517/13543784.17.8.1247","title":"Promising antitumor activity with MGCD0103, a novel isotype-selective histone deacetylase inhibitor","year":2008,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Fondation de France","keywords":"Pharmacodynamics; Histone; Cancer research; Histone deacetylase; Pharmacokinetics; Pharmacology; Histone deacetylase inhibitor; Medicine; Cancer; Gene; Chemistry; Biology; Internal medicine; Biochemistry","score_opus":0.04875667779882451,"score_gpt":0.3654440281644459,"score_spread":0.31668735036562135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127275456","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006593903,0.9878177,0.00070147327,0.0003900894,0.00016701141,0.000022352062,0.00006125479,0.000036021163,0.004210152],"genre_scores_gemma":[0.030143952,0.96272486,0.0016068374,0.0006250632,0.00019480447,0.000030838033,0.00023493446,0.000006158591,0.0044325516],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999244,0.00001057196,0.0000074568266,0.0000155341,0.00003093334,0.000010969536],"domain_scores_gemma":[0.99996746,0.0000088738925,0.000007644289,0.0000012324041,0.000009268735,0.0000054755105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027828608,0.0004542949,0.0006266891,0.000450512,0.000108562956,0.0003725551,0.00044150773,0.0004461833,0.0022007423],"category_scores_gemma":[0.00014112928,0.00009059879,0.00031319514,0.00058515416,0.00012845302,0.00032746815,0.00013793712,0.0004611698,0.0010234782],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036193954,0.00012244999,0.00044666472,0.005171471,0.00007815513,0.00062874047,0.000034177487,0.0002665753,0.034690302,0.0008333264,0.007799237,0.9495669],"study_design_scores_gemma":[0.00052833685,0.0026877872,0.00743356,0.0013159203,0.0005735061,0.012806296,0.000103767845,0.00052791927,0.042870775,0.0011975789,0.92990667,0.000047822494],"about_ca_topic_score_codex":0.00063777086,"about_ca_topic_score_gemma":0.0014160365,"teacher_disagreement_score":0.0022007423,"about_ca_system_score_codex":0.00041553614,"about_ca_system_score_gemma":0.00044215354,"threshold_uncertainty_score":0.0073622465},"labels":[],"label_agreement":null},{"id":"W2129376177","doi":"10.1517/13543784.2014.998334","title":"Novel investigational drugs targeting IL-6 signaling for the treatment of depression","year":2015,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Tryptophan and brain disorders","field":"Neuroscience","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Major depressive disorder; Antidepressant; Signal transduction; Neuroscience; Drug development; Medicine; Function (biology); Bioinformatics; Pharmacology; Drug; Psychology; Biology; Psychiatry; Cognition; Anxiety; Cell biology","score_opus":0.15072664658707133,"score_gpt":0.37481996680945256,"score_spread":0.22409332022238124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129376177","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00036144812,0.99672395,0.0002779964,0.00051623245,0.00026620697,0.000012639297,0.00004506446,0.00001193989,0.001784563],"genre_scores_gemma":[0.0020452577,0.9957858,0.00038708205,0.00036173346,0.00016885014,0.000014299293,0.000057714646,0.0000021305102,0.0011771901],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999019,0.000020857286,0.000013096732,0.000018299042,0.000034680073,0.000011192533],"domain_scores_gemma":[0.99988186,0.00004506304,0.000024803956,0.0000037057362,0.000033668937,0.000010936719],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026029587,0.00044408458,0.000700642,0.0010366056,0.00016067951,0.00046968227,0.00057431357,0.00075759465,0.004827797],"category_scores_gemma":[0.0004007975,0.00013212561,0.00044516582,0.00075187464,0.0002380405,0.00053753145,0.0003963416,0.0013080873,0.0021680447],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010902597,0.000081504804,0.00011990295,0.014528419,0.0001030276,0.00024164651,0.00004357698,0.00031828333,0.0042946846,0.0035602723,0.028679479,0.94792014],"study_design_scores_gemma":[0.000050708182,0.00019127343,0.0007982559,0.0039200005,0.00015855899,0.0015176258,0.00004151826,0.00019452379,0.0012524342,0.0020030686,0.98985344,0.00001858117],"about_ca_topic_score_codex":0.0005940296,"about_ca_topic_score_gemma":0.0018245217,"teacher_disagreement_score":0.004827797,"about_ca_system_score_codex":0.0003784968,"about_ca_system_score_gemma":0.0005508035,"threshold_uncertainty_score":0.016150594},"labels":[],"label_agreement":null},{"id":"W2130229333","doi":"10.1517/13543784.2013.795945","title":"Investigational drugs for schizophrenia targeting the dopamine receptor: Phase II trials","year":2013,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Centre for Addiction and Mental Health","funders":"","keywords":"Schizophrenia (object-oriented programming); Pharmacology; Medicine; Dopamine; Dopamine receptor D2; Dopamine receptor; Investigational Drugs; Dopamine receptor D3; Psychiatry; Clinical trial; Neuroscience; Biology; Internal medicine","score_opus":0.1547790096082772,"score_gpt":0.43139162373715595,"score_spread":0.2766126141288787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130229333","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00032690258,0.9976616,0.00013544483,0.00039019738,0.00018618126,0.00012515028,0.00009385596,0.000006660371,0.0010739892],"genre_scores_gemma":[0.0033608712,0.9943169,0.00053580746,0.00084272237,0.00019993632,0.00016362334,0.00011025769,0.0000037125235,0.00046622267],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991679,0.00034411033,0.00017123937,0.00007924989,0.00019855288,0.00003885407],"domain_scores_gemma":[0.9979989,0.0010551985,0.0005237663,0.000044333843,0.00029348396,0.000084366904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025929406,0.0007504752,0.0021324675,0.001278758,0.00017868297,0.00089139846,0.0010711342,0.0014459388,0.0067684622],"category_scores_gemma":[0.0038960476,0.00021513045,0.0015544166,0.0018232526,0.00035209238,0.0007944847,0.00041103244,0.0011195436,0.0012274886],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013484088,0.00021884487,0.00024841688,0.19103451,0.0009914147,0.00017994975,0.00007365197,0.00022937455,0.0018025652,0.0019990737,0.025593072,0.7762807],"study_design_scores_gemma":[0.0046910485,0.0032807565,0.0035062048,0.22772856,0.0076697012,0.0016455818,0.00020587446,0.00041858395,0.00246103,0.0035054742,0.74481356,0.00007365167],"about_ca_topic_score_codex":0.0007382885,"about_ca_topic_score_gemma":0.002028692,"teacher_disagreement_score":0.0067684622,"about_ca_system_score_codex":0.0007886539,"about_ca_system_score_gemma":0.0023672485,"threshold_uncertainty_score":0.022642791},"labels":[],"label_agreement":null},{"id":"W2130413670","doi":"10.1517/13543784.9.5.1099","title":"Pharmacology and clinical assessment of cariporide for the treatment coronary artery diseases","year":2000,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Cardiac Ischemia and Reperfusion","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Myocardial infarction; Cardiology; Internal medicine; Clinical trial; Placebo; Coronary artery disease; Thrombolysis; Pharmacology","score_opus":0.07327883999910648,"score_gpt":0.44735957193004305,"score_spread":0.3740807319309366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130413670","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.40312365,0.5132673,0.008853459,0.01028217,0.0011577696,0.003947573,0.0018527696,0.0004404589,0.057074986],"genre_scores_gemma":[0.698076,0.26023802,0.0124424,0.008336561,0.0024543265,0.0024748999,0.002767013,0.00008265289,0.013128109],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994216,0.000280004,0.00005556383,0.00006187206,0.00011914715,0.00006188751],"domain_scores_gemma":[0.99926215,0.00014359076,0.00016812277,0.000044039934,0.0001767157,0.00020544411],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002338828,0.00079668366,0.0012219325,0.00070550444,0.00036856695,0.0010892163,0.00079888676,0.0015211703,0.0053812056],"category_scores_gemma":[0.0013124101,0.00023611535,0.00070411834,0.0005644748,0.0004267498,0.00057195505,0.0002762577,0.0019536112,0.001463754],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026871057,0.00937397,0.004282468,0.0029736797,0.00043721436,0.00091785175,0.00021337265,0.00084540545,0.14675434,0.0021487384,0.006932106,0.7982498],"study_design_scores_gemma":[0.052206654,0.47810465,0.08469094,0.00183563,0.0018766747,0.006956059,0.00037434223,0.0027672653,0.06451872,0.0029641236,0.3034628,0.00024220994],"about_ca_topic_score_codex":0.0006718337,"about_ca_topic_score_gemma":0.0017240463,"teacher_disagreement_score":0.0053812056,"about_ca_system_score_codex":0.0005418207,"about_ca_system_score_gemma":0.0012837925,"threshold_uncertainty_score":0.018001914},"labels":[],"label_agreement":null},{"id":"W2132420892","doi":"10.1517/13543784.17.5.619","title":"Osteoarthritic pain: a review of current, theoretical and emerging therapeutics","year":2008,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Osteoarthritis Treatment and Mechanisms","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Chronic pain; Tolerability; Intensive care medicine; Osteoarthritis; Clinical trial; Population; Etiology; Bioinformatics; Alternative medicine; Physical therapy; Psychiatry; Pathology; Biology","score_opus":0.06397579900833963,"score_gpt":0.3767876863065986,"score_spread":0.31281188729825893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132420892","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000078172394,0.9985196,0.00010529462,0.00044583762,0.00029436583,0.000004589147,0.000009659959,0.0000052936143,0.00053719233],"genre_scores_gemma":[0.00031643026,0.99866974,0.00021483372,0.00022455992,0.0002949654,0.000005962085,0.000011489853,8.5507696e-7,0.0002612431],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996222,0.00006659147,0.00006737026,0.00004937476,0.00016971353,0.000024785199],"domain_scores_gemma":[0.9992482,0.0004278347,0.00009443005,0.000017425542,0.00016060563,0.00005144242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011477163,0.00095636,0.0018754025,0.003406813,0.0003766815,0.0014212664,0.0011626612,0.001349271,0.0041416273],"category_scores_gemma":[0.0012342252,0.00036694465,0.00068022945,0.0035828194,0.0006925945,0.001903051,0.00057226367,0.0017789012,0.0021668854],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010832911,0.00010849279,0.00017471226,0.024135891,0.00010395104,0.000352227,0.00008554661,0.00043823285,0.0015053082,0.0029655995,0.04475439,0.9252673],"study_design_scores_gemma":[0.00005056904,0.00016658138,0.0009780154,0.0091583505,0.00015688202,0.0020921908,0.00016998779,0.00021360118,0.00036579967,0.0030812502,0.98353636,0.000030387104],"about_ca_topic_score_codex":0.001113665,"about_ca_topic_score_gemma":0.0024897773,"teacher_disagreement_score":0.0041416273,"about_ca_system_score_codex":0.00085991854,"about_ca_system_score_gemma":0.0015816928,"threshold_uncertainty_score":0.0138551},"labels":[],"label_agreement":null},{"id":"W2135873884","doi":"10.1517/13543784.14.11.1435","title":"MC-1 (pyridoxal 5′-phosphate): novel therapeutic applications to reduce ischaemic injury","year":2005,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Adenosine and Purinergic Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Medicure (Canada); University of Alberta","funders":"","keywords":"Medicine; Percutaneous coronary intervention; Cardiology; Ischemia; Internal medicine; Artery; Creatine kinase; Myocardial infarction","score_opus":0.06470835044174862,"score_gpt":0.3829273831335289,"score_spread":0.3182190326917803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135873884","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019588908,0.98145914,0.0013675548,0.0072426107,0.0016743252,0.000045511682,0.00015075043,0.000048514437,0.0060526743],"genre_scores_gemma":[0.021663057,0.9617473,0.0017944247,0.0057158056,0.003380828,0.0001174211,0.00040381544,0.0000120685045,0.005165305],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99975926,0.00006482944,0.000020422242,0.00003945383,0.00008096651,0.00003519915],"domain_scores_gemma":[0.9997496,0.00008884301,0.000055399752,0.000007987174,0.00006592783,0.000032281216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006372444,0.0005936445,0.0009027993,0.00054263085,0.00016613619,0.0010180629,0.00087027124,0.001764668,0.005419176],"category_scores_gemma":[0.0006446513,0.00013914787,0.0005304405,0.00034356504,0.00045477954,0.0006851269,0.0004223148,0.0021093024,0.0026885967],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009810862,0.00029067945,0.0005364463,0.011432291,0.00029968232,0.0009406085,0.00007164837,0.00065463997,0.020314073,0.008068652,0.09086896,0.8655411],"study_design_scores_gemma":[0.00065071206,0.0011021984,0.0016581515,0.0021781588,0.0003045967,0.0020300678,0.00006624997,0.00063140516,0.0060041468,0.0046612723,0.98066723,0.000045731467],"about_ca_topic_score_codex":0.0005731726,"about_ca_topic_score_gemma":0.0013446637,"teacher_disagreement_score":0.005419176,"about_ca_system_score_codex":0.0004931173,"about_ca_system_score_gemma":0.00048997224,"threshold_uncertainty_score":0.018128932},"labels":[],"label_agreement":null},{"id":"W2136699790","doi":"10.1517/13543784.9.6.1293","title":"The parathyroid hormone, its fragments and analogues - potent bone-builders for treating osteoporosis","year":2000,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Bone health and treatments","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada","funders":"","keywords":"Osteoporosis; Calcitonin; Medicine; Parathyroid hormone; Bone remodeling; Menopause; Endocrinology; Internal medicine; Osteoblast; Bone disease; Chemistry; Calcium","score_opus":0.06713230053955255,"score_gpt":0.3736084107162686,"score_spread":0.30647611017671605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136699790","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017932024,0.9972294,0.00015048524,0.00023197662,0.00021670142,0.000015677153,0.000017935967,0.000009554268,0.0019489259],"genre_scores_gemma":[0.0009551653,0.99663407,0.00032897998,0.00029423364,0.00019919289,0.00001575599,0.00004272405,0.0000018656399,0.0015280539],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998118,0.000031579624,0.00002276952,0.000026292824,0.00009183847,0.000015697662],"domain_scores_gemma":[0.9998411,0.00006226344,0.000030176157,0.000007005953,0.000039653063,0.000019765921],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005078016,0.0008874675,0.0013322548,0.0022528053,0.00031738772,0.00068448996,0.0008579289,0.0012165265,0.0054350616],"category_scores_gemma":[0.0004474043,0.00023664969,0.00044727192,0.0022107533,0.00047689304,0.001116413,0.00052739977,0.0015658344,0.0051001785],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014120268,0.00016574819,0.00014886181,0.00965812,0.000069163485,0.0003963484,0.00006547612,0.0002700062,0.0044263722,0.0022270104,0.028756017,0.9536756],"study_design_scores_gemma":[0.00009303871,0.000169033,0.00074061396,0.0011948863,0.000068589026,0.0017851485,0.00005002747,0.00006569098,0.0006639808,0.0013127946,0.9938437,0.000012501835],"about_ca_topic_score_codex":0.001124953,"about_ca_topic_score_gemma":0.0028756696,"teacher_disagreement_score":0.0054350616,"about_ca_system_score_codex":0.00039124393,"about_ca_system_score_gemma":0.0006628771,"threshold_uncertainty_score":0.01818204},"labels":[],"label_agreement":null},{"id":"W2137885383","doi":"10.1517/13543784.15.12.1479","title":"Can statins put the brakes on Alzheimer’s disease?","year":2006,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Biological Sciences","funders":"","keywords":"Disease; Medicine; Alzheimer's disease; Neuroscience; Intensive care medicine; Pharmacology; Psychology; Internal medicine","score_opus":0.0906705833483172,"score_gpt":0.37082078246105105,"score_spread":0.28015019911273387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137885383","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0023809029,0.507499,0.00030058823,0.4608684,0.020406105,0.000025644018,0.00051319326,0.00012882976,0.007877392],"genre_scores_gemma":[0.031519618,0.71588534,0.0008941443,0.18896887,0.046698537,0.00009519568,0.00037001458,0.00007789469,0.015490363],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99876046,0.00039556963,0.00014890444,0.00012703426,0.00033055176,0.00023745665],"domain_scores_gemma":[0.996042,0.0017209247,0.00040325578,0.00017387969,0.0010071348,0.00065277645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002367608,0.0006501863,0.0019943975,0.00092191354,0.000790859,0.0033279131,0.0009022928,0.007051792,0.02247552],"category_scores_gemma":[0.010416618,0.00029457212,0.0011534836,0.00076193217,0.0013662656,0.0051963446,0.0013564135,0.0060433503,0.007884345],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015483905,0.0002638518,0.0018634676,0.0033997786,0.00049078657,0.00077739474,0.0002546219,0.0001729606,0.000901353,0.017550379,0.4942662,0.47851095],"study_design_scores_gemma":[0.00067776995,0.0005287799,0.0039045396,0.00513024,0.00042170027,0.0004872738,0.0005978168,0.00018202742,0.00046346174,0.021985918,0.9655207,0.00009975107],"about_ca_topic_score_codex":0.004010983,"about_ca_topic_score_gemma":0.010471319,"teacher_disagreement_score":0.02247552,"about_ca_system_score_codex":0.0011409993,"about_ca_system_score_gemma":0.0025198776,"threshold_uncertainty_score":0.0751881},"labels":[],"label_agreement":null},{"id":"W2139097056","doi":"10.1517/13543784.9.4.807","title":"Influence of photodynamic therapy on immunological aspects of disease - an update","year":2000,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Photodynamic Therapy Research Studies","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"QLT (Canada)","funders":"","keywords":"Photodynamic therapy; Immune system; Immunity; Disease; Medicine; Immunology; Cancer research; Biology; Chemistry; Pathology","score_opus":0.05403188043651019,"score_gpt":0.38844002780130515,"score_spread":0.33440814736479496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139097056","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00029113865,0.99770075,0.00014207527,0.00020604164,0.00019086912,0.0000042139736,0.000011871801,0.0000058912547,0.0014472135],"genre_scores_gemma":[0.00077456766,0.9979195,0.00019933382,0.00013314254,0.0001871709,0.0000042424003,0.000017427496,9.0134967e-7,0.0007637181],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99981123,0.00003803986,0.000029133143,0.00002888262,0.00007780427,0.000014982563],"domain_scores_gemma":[0.99969685,0.00016638087,0.000035594054,0.000009355287,0.00007054974,0.000021208421],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055263453,0.0007625889,0.0014655399,0.0015030146,0.00021859004,0.00092510064,0.0006955353,0.001042673,0.004655501],"category_scores_gemma":[0.00044094198,0.00019702077,0.00038320592,0.0017003396,0.00035467293,0.0010208848,0.00035882264,0.0008194505,0.0025495926],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000076434575,0.000096473006,0.0002471471,0.008493391,0.00006137188,0.0004271405,0.000048490663,0.00021629372,0.0038422304,0.0012033295,0.013286665,0.972001],"study_design_scores_gemma":[0.000031897333,0.0002506784,0.0018926727,0.0032290632,0.00022080177,0.004206028,0.000113197006,0.00014677756,0.0022232013,0.0013276329,0.9863376,0.000020368785],"about_ca_topic_score_codex":0.0009155536,"about_ca_topic_score_gemma":0.002156524,"teacher_disagreement_score":0.004655501,"about_ca_system_score_codex":0.00052144466,"about_ca_system_score_gemma":0.0007029394,"threshold_uncertainty_score":0.015574217},"labels":[],"label_agreement":null},{"id":"W2140368374","doi":"10.1517/13543784.15.11.1337","title":"Cholesterol absorption inhibitors as a therapeutic option for hypercholesterolaemia","year":2006,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Cholesterol and Lipid Metabolism","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Robarts Clinical Trials; Western University","funders":"","keywords":"Ezetimibe; Sterol O-acyltransferase; Medicine; Cholesterol; Microsomal triglyceride transfer protein; Pharmacology; Bile acid; Drug; Internal medicine; Lipoprotein; Very low-density lipoprotein","score_opus":0.07968378855267716,"score_gpt":0.38652787534824584,"score_spread":0.3068440867955687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140368374","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002905108,0.9945539,0.0002496629,0.0006871369,0.00042828065,0.0000117444,0.000014915468,0.000015344765,0.003748531],"genre_scores_gemma":[0.0014019338,0.99352396,0.0005780201,0.00082557934,0.00041429725,0.000018772465,0.000038128852,0.0000029713458,0.003196287],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998275,0.000035338755,0.000019082367,0.000025465402,0.00007721662,0.000015410764],"domain_scores_gemma":[0.99989223,0.000042996573,0.000017665949,0.0000051333527,0.000027350075,0.000014706707],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046909208,0.00081413775,0.0013299292,0.0019466534,0.000303578,0.0006823221,0.0006582591,0.0013529138,0.006264756],"category_scores_gemma":[0.00032324073,0.00021006427,0.0004688011,0.0014327134,0.00039957385,0.0010677563,0.00039198963,0.0017270771,0.0046947794],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001617822,0.00016977897,0.00013005803,0.008010649,0.000074642325,0.001003596,0.000076318465,0.00019426718,0.0048651444,0.0037274265,0.04313133,0.938455],"study_design_scores_gemma":[0.00009010538,0.00017404564,0.0006684015,0.0013424915,0.000072658186,0.0036946991,0.000044323413,0.00007615247,0.0005963727,0.0012542339,0.9919727,0.000013787673],"about_ca_topic_score_codex":0.00061966735,"about_ca_topic_score_gemma":0.0018604322,"teacher_disagreement_score":0.006264756,"about_ca_system_score_codex":0.00042271233,"about_ca_system_score_gemma":0.0005959762,"threshold_uncertainty_score":0.020957649},"labels":[],"label_agreement":null},{"id":"W2143820646","doi":"10.1517/13543784.10.5.835","title":"Therapeutic potential of Na-H exchange inhibitors for the treatment of heart failure","year":2001,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Cardiac electrophysiology and arrhythmias","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Heart failure; Cardioprotection; Antiporter; Sodium–hydrogen antiporter; Intracellular pH; Intracellular; Pharmacology; In vivo; Gene isoform; Muscle hypertrophy; Medicine; Internal medicine; Ischemia; Chemistry; Biology; Cell biology; Sodium; Biochemistry; Membrane","score_opus":0.04920125121892773,"score_gpt":0.34811311058962807,"score_spread":0.29891185937070036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143820646","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007088245,0.99424464,0.00022477169,0.0007019451,0.00039804267,0.00001993663,0.000035070458,0.00001556196,0.003651191],"genre_scores_gemma":[0.003086514,0.9923833,0.0005173461,0.0007892901,0.00042275485,0.000032608772,0.000078556084,0.000003608452,0.0026860852],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99984777,0.00004019221,0.000018606956,0.000022367178,0.000052818767,0.000018208664],"domain_scores_gemma":[0.99984837,0.00006216196,0.000026087871,0.0000048971215,0.000038401875,0.000020066882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057633617,0.0008817565,0.0018010923,0.0013295187,0.00028438127,0.00070245354,0.0009604087,0.0014315076,0.0062956987],"category_scores_gemma":[0.0004044838,0.00016051398,0.00051846827,0.000978826,0.00032026682,0.0008743831,0.0003279793,0.0014648408,0.003488498],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034839468,0.0002997538,0.00015793339,0.006869677,0.00012885392,0.00081922347,0.00006334938,0.0004222126,0.0055316286,0.0021756995,0.029684378,0.95349884],"study_design_scores_gemma":[0.00035049903,0.0007281875,0.0017058859,0.0018284672,0.00018205165,0.002911134,0.000076714656,0.00018568957,0.0015050039,0.0015820189,0.9889176,0.000026814261],"about_ca_topic_score_codex":0.0006116926,"about_ca_topic_score_gemma":0.002183429,"teacher_disagreement_score":0.0062956987,"about_ca_system_score_codex":0.0003991098,"about_ca_system_score_gemma":0.00051518687,"threshold_uncertainty_score":0.021061242},"labels":[],"label_agreement":null},{"id":"W2145333806","doi":"10.1517/13543784.13.12.1593","title":"Amyotrophic lateral sclerosis: contemporary concepts in etiopathogenesis and pharmacotherapy","year":2004,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Amyotrophic Lateral Sclerosis Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Muscular Dystrophy Association","keywords":"Amyotrophic lateral sclerosis; Disease; Context (archaeology); Neuroscience; Clinical trial; Medicine; Degenerative Disorder; Neurochemical; Pharmacotherapy; Psychology; Pathology; Psychiatry; Biology","score_opus":0.16599653782673643,"score_gpt":0.4263400610695118,"score_spread":0.2603435232427753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145333806","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006507367,0.99726796,0.00020248178,0.00084797834,0.0002559097,0.0000061928463,0.000007250805,0.000008242358,0.0013390026],"genre_scores_gemma":[0.00038589476,0.9980768,0.00027774632,0.000447344,0.0002560337,0.000012489653,0.0000104120745,0.0000013429268,0.0005319185],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995221,0.00013417137,0.00006306094,0.00006463105,0.00018747077,0.000028679855],"domain_scores_gemma":[0.9995503,0.00021655507,0.00005779096,0.000026859687,0.000108279026,0.00004023443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011512268,0.0011060718,0.002166371,0.0028198184,0.0003961654,0.0017693057,0.0013970268,0.0021707604,0.004544198],"category_scores_gemma":[0.0010384906,0.00030943946,0.0005018275,0.003832205,0.0012917584,0.0026410576,0.00097096537,0.0027585314,0.0035644935],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007737305,0.00015439121,0.00011810477,0.010969129,0.000057061647,0.00031906815,0.00011523286,0.00039669458,0.0011293526,0.008941855,0.03091784,0.9468038],"study_design_scores_gemma":[0.000054560194,0.0001246543,0.0007011265,0.005113685,0.00005950818,0.0015964926,0.00012378156,0.00013518531,0.0002417874,0.008031528,0.98379636,0.000021545282],"about_ca_topic_score_codex":0.0012713748,"about_ca_topic_score_gemma":0.002579752,"teacher_disagreement_score":0.004544198,"about_ca_system_score_codex":0.0014076454,"about_ca_system_score_gemma":0.0015924802,"threshold_uncertainty_score":0.015201867},"labels":[],"label_agreement":null},{"id":"W2147648095","doi":"10.1517/13543784.9.12.2873","title":"Therapeutic potential of endothelin receptor antagonists in diabetes","year":2000,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Nitric Oxide and Endothelin Effects","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Diabetes mellitus; Medicine; Pathogenesis; Endothelins; Endothelin receptor; Bioinformatics; Receptor; Internal medicine; Endocrinology; Biology","score_opus":0.039939073131632696,"score_gpt":0.3417029854520782,"score_spread":0.3017639123204455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147648095","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00046120584,0.99727374,0.00016320002,0.00027749425,0.00019584301,0.0000091078355,0.000014836144,0.000006963316,0.0015975265],"genre_scores_gemma":[0.0024311976,0.9949823,0.0004273319,0.00049716333,0.00023457203,0.00001902375,0.000040416104,0.0000019572028,0.0013661521],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99984634,0.000038334547,0.000022016344,0.000026053061,0.000053816395,0.000013283373],"domain_scores_gemma":[0.99989295,0.000046443223,0.000022455155,0.000003754047,0.000023746272,0.000010710309],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039043353,0.0006577559,0.0013883369,0.0011681452,0.00023327526,0.0005965269,0.0006381649,0.0011498289,0.004048262],"category_scores_gemma":[0.0003145552,0.00014195919,0.0004964153,0.00089053944,0.00021902338,0.00074582105,0.00034352575,0.0012934647,0.0018454198],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023317971,0.00020802484,0.00013145612,0.009600143,0.000112421294,0.0007566105,0.00006406666,0.00032123242,0.0074695754,0.0017761308,0.013590109,0.9657371],"study_design_scores_gemma":[0.0002643324,0.0007907388,0.0020208482,0.0035924015,0.00025936612,0.005154996,0.00010816321,0.00022926426,0.0024250583,0.0020737078,0.98305076,0.000030432466],"about_ca_topic_score_codex":0.00043731922,"about_ca_topic_score_gemma":0.0012513227,"teacher_disagreement_score":0.004048262,"about_ca_system_score_codex":0.00034318154,"about_ca_system_score_gemma":0.00040642679,"threshold_uncertainty_score":0.013542771},"labels":[],"label_agreement":null},{"id":"W2148507562","doi":"10.1517/13543784.17.5.679","title":"Pharmacotherapy for erectile dysfunction","year":2008,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Sexual function and dysfunction studies","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Erectile dysfunction; Medicine; cGMP-specific phosphodiesterase type 5; Pharmacotherapy; Sildenafil; Pharmacology; Bioinformatics; Internal medicine; Biology","score_opus":0.17929959699025913,"score_gpt":0.4393145557107627,"score_spread":0.2600149587205036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148507562","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014518821,0.9983487,0.000077299876,0.00020577808,0.00016499369,0.00001221099,0.00002051715,0.0000044614153,0.0010207568],"genre_scores_gemma":[0.0011419352,0.9973369,0.00028208774,0.000350724,0.00021483653,0.00001957784,0.00003390443,0.0000015234059,0.00061839266],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99971074,0.000074808835,0.000055712095,0.00003484253,0.00010450721,0.000019380088],"domain_scores_gemma":[0.99966323,0.00017770601,0.00007721667,0.000008032314,0.00005910794,0.000014698839],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000512507,0.0008046692,0.0016814388,0.0024608758,0.00024231023,0.00060757913,0.0006730532,0.0009307496,0.008877592],"category_scores_gemma":[0.0010851165,0.0001524658,0.0006634517,0.0024352933,0.00023261919,0.00077297265,0.00035076647,0.0007133289,0.0021517845],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015086419,0.00011729542,0.00024572478,0.08391242,0.00040162253,0.0005965462,0.00006910136,0.00022763395,0.0017616512,0.0014851668,0.027650988,0.883381],"study_design_scores_gemma":[0.0002455422,0.00040273895,0.0040652603,0.0501794,0.0012539688,0.0075887623,0.00016635224,0.00018486059,0.0012789353,0.0015986554,0.93300223,0.00003324996],"about_ca_topic_score_codex":0.00081335305,"about_ca_topic_score_gemma":0.002039178,"teacher_disagreement_score":0.008877592,"about_ca_system_score_codex":0.00050262554,"about_ca_system_score_gemma":0.0012605457,"threshold_uncertainty_score":0.02969855},"labels":[],"label_agreement":null},{"id":"W2149879542","doi":"10.1517/13543784.15.5.507","title":"The potential of clusterin inhibiting antisense oligodeoxynucleotide therapy for prostate cancer","year":2006,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Clusterin in disease pathology","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Clusterin; Prostate cancer; Prostate; Gene silencing; Cancer research; Medicine; Cancer; Apoptosis; Oncology; Internal medicine; Biology; Gene","score_opus":0.05709997216926325,"score_gpt":0.3872571996764856,"score_spread":0.3301572275072223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149879542","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000680755,0.99655545,0.0004974923,0.00027701896,0.00027397706,0.000007867895,0.000010907687,0.000010769655,0.0016858532],"genre_scores_gemma":[0.002422433,0.99491924,0.0006311886,0.00028350824,0.00018979411,0.000013474348,0.000028715875,0.0000020910209,0.0015094491],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99990976,0.000015926122,0.000010165051,0.000015726338,0.000040404007,0.000008019582],"domain_scores_gemma":[0.9999087,0.000038967737,0.000015762687,0.0000021128267,0.000024166377,0.000010236767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035154502,0.0004945509,0.0006389594,0.0010162111,0.00017686906,0.00049704907,0.0004385547,0.0005913281,0.0016877387],"category_scores_gemma":[0.00023339738,0.00012074125,0.00025214226,0.0007159427,0.00020190078,0.0005809344,0.00020771845,0.00052898034,0.001158558],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009644646,0.000064613414,0.00019985677,0.008757645,0.00007043125,0.00048346483,0.00007508966,0.0005580033,0.01496004,0.0023239732,0.014806599,0.9576039],"study_design_scores_gemma":[0.00003390305,0.0002870231,0.0006944062,0.0008081565,0.00010091104,0.0021413076,0.000048807353,0.0001523117,0.004386213,0.0008188959,0.99050856,0.000019511204],"about_ca_topic_score_codex":0.0005394259,"about_ca_topic_score_gemma":0.0014574592,"teacher_disagreement_score":0.0016877387,"about_ca_system_score_codex":0.000395565,"about_ca_system_score_gemma":0.00048739908,"threshold_uncertainty_score":0.00564605},"labels":[],"label_agreement":null},{"id":"W2150692587","doi":"10.1517/13543784.2013.769957","title":"5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders","year":2013,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Obsessive-Compulsive Spectrum Disorders","field":"Psychology","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto Western Hospital","funders":"","keywords":"Schizophrenia (object-oriented programming); Psychiatry; Antipsychotic; Psychosis; Anxiety; Mood disorders; Dementia; Psychology; Management of schizophrenia; Depression (economics); 5-HT2A receptor; Medicine; Disease; Serotonin; 5-HT receptor; Internal medicine","score_opus":0.03747977311721774,"score_gpt":0.3762715629305328,"score_spread":0.3387917898133151,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150692587","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009007246,0.9962359,0.00011362264,0.0007307896,0.00022504752,0.000015074828,0.000043115233,0.00000955455,0.0017261361],"genre_scores_gemma":[0.0079705855,0.98884994,0.00032738975,0.0009724228,0.00042906753,0.000023953111,0.0000805434,0.0000027909282,0.0013432878],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998883,0.00003835345,0.000017780221,0.000016158398,0.000028820677,0.000010537477],"domain_scores_gemma":[0.99979824,0.000094041454,0.000057145302,0.0000030048293,0.000030707015,0.00001693278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030633184,0.00039779476,0.00084285793,0.0007915002,0.00013186243,0.000491292,0.00037763178,0.0007094902,0.0063922293],"category_scores_gemma":[0.0003718357,0.00008270574,0.000468385,0.00057604077,0.00017238704,0.0004165324,0.00023315896,0.0010352983,0.0012496945],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005520295,0.00016242085,0.0003026736,0.021695448,0.00020944365,0.00050966773,0.00007181427,0.00029172673,0.003810895,0.0024550457,0.022035511,0.94790334],"study_design_scores_gemma":[0.00075986487,0.0029219561,0.007715083,0.017915383,0.00128253,0.005807079,0.00025489327,0.0004578817,0.0022714448,0.0038750356,0.9566781,0.00006062063],"about_ca_topic_score_codex":0.00032647498,"about_ca_topic_score_gemma":0.0020798242,"teacher_disagreement_score":0.0063922293,"about_ca_system_score_codex":0.00026863648,"about_ca_system_score_gemma":0.0003283763,"threshold_uncertainty_score":0.02138418},"labels":[],"label_agreement":null},{"id":"W2152749001","doi":"10.1517/13543784.12.3.353","title":"Aromatase inhibitors for the treatment of infertility","year":2003,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Ovarian function and disorders","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"","keywords":"Ovarian hyperstimulation syndrome; Ovulation induction; Infertility; Ovulation; Medicine; Aromatase; Follicular phase; Internal medicine; Endocrinology; Polycystic ovary; Letrozole; Anovulation; Pregnancy; Hormone; Biology; In vitro fertilisation; Insulin; Insulin resistance","score_opus":0.10719836975608356,"score_gpt":0.3850609297580475,"score_spread":0.27786256000196397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152749001","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001811252,0.9952426,0.0001442044,0.00034028993,0.00032128565,0.000008782208,0.000015775671,0.000010053279,0.00373595],"genre_scores_gemma":[0.0016587332,0.993437,0.00029777264,0.00043078588,0.0003960011,0.000011118788,0.000048098005,0.0000027077597,0.00371777],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99982613,0.000031167598,0.000021160491,0.000023863506,0.00008032333,0.000017283312],"domain_scores_gemma":[0.9998306,0.00006720076,0.000033560333,0.000007072244,0.000041683346,0.00001975188],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032237073,0.000783898,0.0009982921,0.0017384033,0.0002469026,0.00046134193,0.00067389087,0.00084675895,0.007699428],"category_scores_gemma":[0.00042777372,0.0001586878,0.0004251056,0.0017477535,0.00031501285,0.00067554985,0.00036483188,0.0011735634,0.005307015],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010123185,0.00010245943,0.00021986356,0.007409485,0.00006917067,0.0009155182,0.00004757518,0.00018511471,0.0023915633,0.001412067,0.04777574,0.9393702],"study_design_scores_gemma":[0.00006702492,0.000114115595,0.0012729465,0.0015905603,0.000073263975,0.005143296,0.000038776772,0.000052539974,0.0005460944,0.0009737915,0.99011666,0.000010936488],"about_ca_topic_score_codex":0.001094054,"about_ca_topic_score_gemma":0.0027050418,"teacher_disagreement_score":0.007699428,"about_ca_system_score_codex":0.00042718655,"about_ca_system_score_gemma":0.00064557267,"threshold_uncertainty_score":0.025757134},"labels":[],"label_agreement":null},{"id":"W2152775636","doi":"10.1517/13543784.12.4.663","title":"Pregabalin: a new anxiolytic","year":2003,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Neuroscience and Neuropharmacology Research","field":"Neuroscience","cited_by":316,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Pregabalin; Gabapentin; Anticonvulsant; Pharmacology; Anxiolytic; Neuropathic pain; Medicine; Epilepsy; Anesthesia; Anxiety; Psychiatry","score_opus":0.2469151906030161,"score_gpt":0.4506774258193225,"score_spread":0.20376223521630643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152775636","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5967465,0.2923704,0.025720129,0.0038185488,0.0012213443,0.0006104322,0.0021527396,0.002049988,0.075309895],"genre_scores_gemma":[0.84094745,0.09876083,0.015396938,0.002762694,0.00039214062,0.00032955105,0.0018989746,0.00006722626,0.03944422],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99997115,0.0000039787155,0.0000019602412,0.0000067068927,0.000008345055,0.000007900367],"domain_scores_gemma":[0.9999858,0.0000015457018,0.0000036007807,7.700181e-7,0.0000024201531,0.000005869075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004451797,0.000371894,0.00021241208,0.00022308834,0.00013718382,0.00017783463,0.00031020123,0.00027357426,0.003156281],"category_scores_gemma":[0.00004048822,0.00006503685,0.00014389168,0.00013518908,0.00013888368,0.00018864215,0.00019080572,0.0006109131,0.0009432997],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012769446,0.0007608213,0.00066473644,0.0014936094,0.000055046057,0.0010555224,0.000067004934,0.0004552852,0.6173869,0.0021886248,0.005703206,0.3688924],"study_design_scores_gemma":[0.0015860981,0.010436857,0.01742557,0.00033285696,0.00023650884,0.016606146,0.00010307838,0.0023799231,0.5298983,0.0010353953,0.4198568,0.00010250286],"about_ca_topic_score_codex":0.0005097543,"about_ca_topic_score_gemma":0.0012101452,"teacher_disagreement_score":0.003156281,"about_ca_system_score_codex":0.00021625149,"about_ca_system_score_gemma":0.00012352219,"threshold_uncertainty_score":0.010558784},"labels":[],"label_agreement":null},{"id":"W2156708079","doi":"10.1517/13543784.15.6.649","title":"Pharmacological treatment of attention-deficit/hyperactivity disorder in adults","year":2006,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Peter's Hospital; Montreal Children's Hospital; Calgary Laboratory Services","funders":"","keywords":"Atomoxetine; Attention deficit hyperactivity disorder; Medicine; Guanfacine; Desipramine; Adverse effect; Psychiatry; Clinical trial; Psychosocial; Methylphenidate; Psychology; Antidepressant; Pharmacology; Anxiety; Clonidine; Internal medicine","score_opus":0.08516280517309431,"score_gpt":0.4026321275527526,"score_spread":0.31746932237965825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156708079","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022075349,0.99815613,0.00008228738,0.00015883255,0.00007951779,0.000011153201,0.00001432617,0.000008072031,0.0012688006],"genre_scores_gemma":[0.0011687535,0.99744534,0.000296235,0.00022125679,0.00010329658,0.0000134970205,0.000029094572,0.0000012410102,0.0007213028],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99974626,0.0000582277,0.000038842536,0.00003724828,0.00009844689,0.00002100069],"domain_scores_gemma":[0.999826,0.000061840336,0.00005263549,0.000005641384,0.000037835416,0.000016112212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005830989,0.0007014969,0.0015939008,0.0016678197,0.00019723822,0.0005574772,0.000855833,0.001166659,0.004474903],"category_scores_gemma":[0.00055169617,0.00020318196,0.0005893933,0.001449121,0.00024920353,0.0005877645,0.00037102608,0.00083875115,0.002785005],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006971572,0.00010886124,0.00018981501,0.017546918,0.000119200464,0.00030049586,0.00003167191,0.000095870186,0.001384961,0.00039633273,0.013411416,0.9663448],"study_design_scores_gemma":[0.00019974177,0.00047718335,0.0049338783,0.0147093665,0.0006032479,0.0062831673,0.00012524436,0.00018262542,0.0015917568,0.0010646384,0.9698037,0.000025503676],"about_ca_topic_score_codex":0.0018284459,"about_ca_topic_score_gemma":0.0044343164,"teacher_disagreement_score":0.004474903,"about_ca_system_score_codex":0.00046011378,"about_ca_system_score_gemma":0.0008345553,"threshold_uncertainty_score":0.014970064},"labels":[],"label_agreement":null},{"id":"W2160247377","doi":"10.1517/13543784.17.2.217","title":"The use of dexrazoxane for the prevention of anthracycline extravasation injury","year":2008,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Chemotherapy-related skin toxicity","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Canada Research Chairs","keywords":"Dexrazoxane; Anthracycline; Cardiotoxicity; Extravasation; Doxorubicin; Epirubicin; Medicine; Daunorubicin; Pharmacology; Idarubicin; Chemotherapy; Internal medicine; Pathology; Cancer; Cyclophosphamide; Breast cancer","score_opus":0.18770641767915827,"score_gpt":0.419788730279666,"score_spread":0.23208231260050774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160247377","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00039306967,0.9985362,0.000081361766,0.00009922319,0.000057451776,0.000007035511,0.000011226601,0.000002897776,0.00081148784],"genre_scores_gemma":[0.002700031,0.99647117,0.0002534331,0.00012603628,0.000059174967,0.000007976181,0.000019503432,7.639034e-7,0.00036196105],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997521,0.00006493335,0.00005668722,0.00003509988,0.00007691682,0.000014276855],"domain_scores_gemma":[0.9995708,0.00019988218,0.00012612509,0.000008934865,0.00008005141,0.000014238304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050035707,0.00047116468,0.0010213869,0.0017585669,0.00015776462,0.00044524498,0.0005773588,0.00071539334,0.003454464],"category_scores_gemma":[0.00076711323,0.00015332479,0.0005107182,0.0013795925,0.00022264976,0.0005734204,0.00019605942,0.00041411296,0.00094837864],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021022993,0.00008838018,0.0005714493,0.061769944,0.00025171047,0.0009944069,0.00008011163,0.00017908945,0.00872326,0.0008221327,0.00868096,0.91762835],"study_design_scores_gemma":[0.00022723747,0.0010575273,0.009471173,0.02988445,0.0015427544,0.021526378,0.00027891732,0.00028989208,0.012523231,0.001278726,0.92186636,0.000053409574],"about_ca_topic_score_codex":0.0007018543,"about_ca_topic_score_gemma":0.0015376601,"teacher_disagreement_score":0.003454464,"about_ca_system_score_codex":0.00034314883,"about_ca_system_score_gemma":0.00082080264,"threshold_uncertainty_score":0.011556387},"labels":[],"label_agreement":null},{"id":"W2165059215","doi":"10.1517/13543780902762827","title":"Caprospinol: moving from a neuroactive steroid to a neurotropic drug","year":2009,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Alzheimer's disease research and treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Neuroactive steroid; Neuroprotection; Pharmacology; Neurotoxicity; Drug; Respiratory chain; Hippocampus; Neurodegeneration; Neuroscience; Amyloid beta; Medicine; Disease; Chemistry; Mitochondrion; Psychology; Internal medicine; Biochemistry; Receptor; Toxicity; GABAA receptor","score_opus":0.08218918296770682,"score_gpt":0.38739984561135765,"score_spread":0.3052106626436508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165059215","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022653166,0.9367584,0.005385718,0.0160037,0.0024124212,0.00012304813,0.00022088569,0.0001564239,0.016286166],"genre_scores_gemma":[0.10232947,0.8444385,0.00914326,0.02286136,0.002867332,0.00010216759,0.0005336582,0.00003718054,0.01768711],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99977225,0.0000416709,0.00002017384,0.000047597558,0.00008430694,0.00003407157],"domain_scores_gemma":[0.99981266,0.000033374105,0.0000366965,0.0000071866934,0.00006548719,0.000044656805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059147325,0.00056161336,0.0006955151,0.00066174037,0.0002717289,0.0010412342,0.0005762717,0.0016587772,0.0036519298],"category_scores_gemma":[0.00034506203,0.00014412621,0.00037813035,0.0005274457,0.0009407095,0.0014121797,0.00049762,0.0019623684,0.002246511],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00081498665,0.00031117233,0.0007828006,0.0035414372,0.00007069253,0.0018058589,0.00025262113,0.00047151733,0.10981687,0.011819136,0.028314993,0.8419979],"study_design_scores_gemma":[0.00043865017,0.0036697707,0.0029450676,0.00078930904,0.00012334995,0.004006795,0.000284177,0.00065490516,0.029640771,0.0071957354,0.95018333,0.0000682475],"about_ca_topic_score_codex":0.0012317431,"about_ca_topic_score_gemma":0.0041076466,"teacher_disagreement_score":0.0036519298,"about_ca_system_score_codex":0.0010409019,"about_ca_system_score_gemma":0.00072727306,"threshold_uncertainty_score":0.012216866},"labels":[],"label_agreement":null},{"id":"W2165328648","doi":"10.1517/13543784.15.1.47","title":"Exogenous surfactant therapy for ARDS","year":2005,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Neonatal Respiratory Health Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St Joseph's Health Centre","funders":"","keywords":"ARDS; Medicine; Surfactant therapy; Intensive care medicine; Acute respiratory distress; Respiratory distress; Pulmonary surfactant; Pathophysiology; Neonatal respiratory distress syndrome; Clinical trial; Lung; Internal medicine; Anesthesia","score_opus":0.255999150866969,"score_gpt":0.4965203684000783,"score_spread":0.2405212175331093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165328648","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011015683,0.9983516,0.00006536648,0.00026720532,0.00020176468,0.0000073916626,0.000011306078,0.000004216678,0.0009810276],"genre_scores_gemma":[0.00077315496,0.997698,0.0001659806,0.00037580257,0.00020654747,0.000011681874,0.000025026291,0.0000014455259,0.00074232713],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9996947,0.00008362811,0.000043377873,0.000040084666,0.00011825247,0.00001995305],"domain_scores_gemma":[0.99974436,0.00011576968,0.00005450428,0.000010580546,0.000054593547,0.000020215648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060762954,0.0007598642,0.001552994,0.0019262028,0.00024448,0.00061611744,0.00076930725,0.0012103636,0.0057765073],"category_scores_gemma":[0.00078981096,0.00016305219,0.00065445865,0.0015645237,0.00035454956,0.0008302456,0.00044865246,0.0013590811,0.0036644677],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015435778,0.00010651301,0.00012842937,0.018978735,0.0002059754,0.00045025695,0.000051228864,0.00012876846,0.0022557732,0.0012883474,0.03923997,0.9370118],"study_design_scores_gemma":[0.00018642056,0.00027785377,0.0013296754,0.009711554,0.00032120734,0.0035058183,0.00005931842,0.000091641654,0.001070899,0.001511314,0.9819151,0.000019061812],"about_ca_topic_score_codex":0.000924397,"about_ca_topic_score_gemma":0.0020636644,"teacher_disagreement_score":0.0057765073,"about_ca_system_score_codex":0.00046314628,"about_ca_system_score_gemma":0.00073177775,"threshold_uncertainty_score":0.019324303},"labels":[],"label_agreement":null},{"id":"W2166753714","doi":"10.1517/13543780902832661","title":"Cathepsin K inhibitors for osteoporosis and potential off-target effects","year":2009,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Bone Metabolism and Diseases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":209,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institutes of Health; Canada Research Chairs","keywords":"Cathepsin K; Cathepsin; Osteoporosis; Medicine; Cathepsin A; Cancer research; Pharmacology; Chemistry; Biochemistry; Internal medicine; Osteoclast; Enzyme; In vitro","score_opus":0.01784050697919237,"score_gpt":0.3063636798781626,"score_spread":0.2885231728989702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166753714","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005046618,0.9947694,0.0003709965,0.0007585468,0.0003980056,0.000017496404,0.00003486145,0.000019924852,0.003125989],"genre_scores_gemma":[0.002096572,0.9933587,0.0005723731,0.00061128434,0.00027308022,0.000022506483,0.000060702867,0.00000385783,0.0030009162],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998192,0.000031276068,0.000017912778,0.00002672093,0.00008255924,0.000022288561],"domain_scores_gemma":[0.99986005,0.00004774249,0.000026307787,0.0000059623303,0.00004239483,0.00001746247],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005478556,0.0008443129,0.001398896,0.0012824069,0.00027196706,0.00068493537,0.00093665224,0.0014615066,0.0052049193],"category_scores_gemma":[0.000392784,0.0002952835,0.0005231365,0.0011377864,0.0004324812,0.001036257,0.0005188682,0.001985301,0.0041893097],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002094284,0.00020797507,0.00011300454,0.0077624163,0.00008283966,0.0007002404,0.00006757437,0.0004921323,0.009831156,0.0051014456,0.05128651,0.92414516],"study_design_scores_gemma":[0.00009891176,0.00020917985,0.00040333509,0.00094566605,0.00005643772,0.0019095967,0.000027296468,0.00012678944,0.0015700441,0.0015848833,0.99304974,0.000018042363],"about_ca_topic_score_codex":0.0006292954,"about_ca_topic_score_gemma":0.0020844669,"teacher_disagreement_score":0.0052049193,"about_ca_system_score_codex":0.0006440777,"about_ca_system_score_gemma":0.0006546904,"threshold_uncertainty_score":0.017412186},"labels":[],"label_agreement":null},{"id":"W2168406738","doi":"10.1517/13543784.10.12.2157","title":"Therapeutic potential of mycobacterial cell wall-DNA complexes","year":2001,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Mycobacterium research and diagnosis","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BioPhage Pharma (Canada)","funders":"","keywords":"Cell wall; Cell; Effector; Apoptosis; Biology; DNA; Cell division; Immune system; Mechanism of action; Cell growth; Mycobacterium; Cancer cell; Mycobacterium phlei; Cancer research; Microbiology; Cancer; Chemistry; Cell biology; Bacteria; Immunology; In vitro; Biochemistry; Genetics","score_opus":0.07827342594698494,"score_gpt":0.3700735214891212,"score_spread":0.29180009554213626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168406738","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0028752529,0.9927072,0.00031741,0.00021240066,0.00013569447,0.000011468995,0.000016044825,0.000009472146,0.0037150388],"genre_scores_gemma":[0.017503148,0.9775339,0.0008908014,0.00035380246,0.00016830982,0.000024941124,0.000064028056,0.000002224138,0.0034589714],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999075,0.000021117981,0.000008077746,0.000015089203,0.000036813173,0.0000114061895],"domain_scores_gemma":[0.9999558,0.00001554855,0.00000911326,0.0000020653665,0.000011965749,0.0000056003664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022836664,0.00044081043,0.00070994574,0.0007101826,0.00017535171,0.0004578337,0.0003940638,0.0007510952,0.0019796859],"category_scores_gemma":[0.00014287817,0.00011634502,0.00022078166,0.00050086767,0.0001799748,0.0003953245,0.00018312213,0.00048912107,0.0010934907],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022319733,0.00015483033,0.00021655796,0.008776317,0.00005735758,0.00096823054,0.00010421478,0.00040169165,0.07993441,0.0032135115,0.0061833663,0.89976645],"study_design_scores_gemma":[0.00011162275,0.0009821679,0.0017068952,0.0012428872,0.000111024405,0.0043884944,0.00008515963,0.00024954893,0.03601266,0.0013165779,0.9537719,0.000021092823],"about_ca_topic_score_codex":0.00037489535,"about_ca_topic_score_gemma":0.0007513164,"teacher_disagreement_score":0.0019796859,"about_ca_system_score_codex":0.00033930066,"about_ca_system_score_gemma":0.00030745217,"threshold_uncertainty_score":0.006622672},"labels":[],"label_agreement":null},{"id":"W2287387906","doi":"10.1517/13543784.2015.1083010","title":"An evaluation of RVX-208 for the treatment of atherosclerosis","year":2015,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Bromodomain; Apolipoprotein B; Mechanism (biology); Epigenetics; Pharmacology; Reverse cholesterol transport; Lipoprotein; Mechanism of action; Drug; Medicine; Cholesterol; Bioinformatics; Biology; Internal medicine; In vitro; Biochemistry; Gene","score_opus":0.19381988199036995,"score_gpt":0.4284758641484715,"score_spread":0.23465598215810154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2287387906","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003133722,0.9973183,0.000113481714,0.00031984472,0.00023769226,0.000011573986,0.000027146978,0.000006374948,0.0016522575],"genre_scores_gemma":[0.0020866003,0.99581295,0.00026217388,0.00048610044,0.00015908081,0.000017596645,0.00005052832,0.000002424515,0.0011225234],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998392,0.000032325977,0.000024881481,0.000027690881,0.000060769737,0.000015100321],"domain_scores_gemma":[0.99981755,0.00008111592,0.00003216669,0.000004043233,0.00005057216,0.000014651001],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051149575,0.00055766077,0.00088387635,0.0014781639,0.0001863485,0.0006063398,0.00053712405,0.00086595875,0.0037138332],"category_scores_gemma":[0.0005193737,0.00015775513,0.0005292993,0.001069,0.00025782763,0.0006478393,0.00036004404,0.0013426291,0.0016654523],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021555477,0.000097051096,0.00010660655,0.020086821,0.000097311895,0.00031225482,0.000051510917,0.00019283216,0.0034310464,0.002534442,0.02223238,0.95064217],"study_design_scores_gemma":[0.0001022652,0.00047133578,0.0010273313,0.0068108207,0.00024832875,0.0025983974,0.00005347427,0.00015206303,0.0021466976,0.0011792079,0.9851854,0.00002477614],"about_ca_topic_score_codex":0.0005612243,"about_ca_topic_score_gemma":0.0012254711,"teacher_disagreement_score":0.0037138332,"about_ca_system_score_codex":0.00044914306,"about_ca_system_score_gemma":0.00073040905,"threshold_uncertainty_score":0.012424052},"labels":[],"label_agreement":null},{"id":"W2299867389","doi":"10.1517/13543784.2016.1142529","title":"Novel investigational therapies for onychomycosis: an update","year":2016,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Nail Diseases and Treatments","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mediprobe Research (Canada); University of Toronto","funders":"","keywords":"Medicine; Terbinafine; Dermatology; Adverse effect; Azole; Pharmacology; Drug; Clinical trial; Investigational Drugs; Antifungal; Internal medicine; Itraconazole","score_opus":0.11589128427420814,"score_gpt":0.4118034750595802,"score_spread":0.29591219078537206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2299867389","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012166155,0.99817586,0.00008309402,0.00034525254,0.00023711655,0.000007485161,0.000028491228,0.0000063292855,0.0009946636],"genre_scores_gemma":[0.0005271031,0.9982424,0.00020375854,0.00030403366,0.0001691789,0.000007685382,0.0000450756,0.0000014263869,0.00049930706],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99976736,0.00004168556,0.000043069915,0.00003200425,0.00009491539,0.000021055059],"domain_scores_gemma":[0.99955755,0.00019469263,0.0000763561,0.000009859858,0.0001288999,0.00003254242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005064843,0.0006608725,0.001138872,0.0021634786,0.00023537695,0.0009267676,0.000781467,0.001085451,0.006667804],"category_scores_gemma":[0.0007846368,0.00022061246,0.0006696829,0.0018972217,0.00031389736,0.0011649195,0.00053842244,0.0017006617,0.002430981],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007478047,0.000083086205,0.0001235087,0.022228386,0.00008822729,0.00028946856,0.000051216397,0.00016643274,0.0012332085,0.0014863387,0.034823265,0.93935215],"study_design_scores_gemma":[0.000030635507,0.00011440477,0.00049038365,0.0063770926,0.00018601099,0.0017139397,0.00005163807,0.00007714925,0.00029221975,0.00070535456,0.9899475,0.000013683183],"about_ca_topic_score_codex":0.00074616336,"about_ca_topic_score_gemma":0.0020120437,"teacher_disagreement_score":0.006667804,"about_ca_system_score_codex":0.00043065625,"about_ca_system_score_gemma":0.0008983934,"threshold_uncertainty_score":0.022305965},"labels":[],"label_agreement":null},{"id":"W2342567337","doi":"10.1080/13543784.2016.1182498","title":"Novel approaches for preventing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation","year":2016,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Fonds De La Recherche Scientifique - FNRS; Terry Fox Foundation","keywords":"Immunology; Graft-versus-host disease; Hematopoietic stem cell transplantation; Transplantation; Medicine; Disease; Stem cell; Calcineurin; Pathogenesis; Immune system; Biology; Internal medicine","score_opus":0.09843819540201718,"score_gpt":0.33775760871798355,"score_spread":0.23931941331596637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2342567337","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020883739,0.997681,0.000183405,0.0004111156,0.00027500786,0.0000080691425,0.000026092714,0.000006883301,0.0011995101],"genre_scores_gemma":[0.0014468743,0.9972573,0.00024210397,0.00030417074,0.00019212847,0.000009940765,0.000039930455,0.00000139304,0.00050622487],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99984634,0.000030503474,0.0000219321,0.000026389695,0.000060967886,0.000013751274],"domain_scores_gemma":[0.99984205,0.00006485132,0.000032654352,0.0000043032715,0.000045337507,0.000010842023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000348166,0.0004633927,0.0007671531,0.0011158878,0.0001541467,0.00059046363,0.0005813016,0.0007339624,0.004188512],"category_scores_gemma":[0.00050257717,0.000110558976,0.0004911953,0.00071197364,0.0002316016,0.0006440912,0.00039198087,0.0012124897,0.0014113173],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000082832004,0.00007169414,0.00014070714,0.020222262,0.00012625869,0.00019122762,0.000042616553,0.00030879956,0.0029223526,0.0032022553,0.02171547,0.95097345],"study_design_scores_gemma":[0.00004172582,0.00016977318,0.00095879874,0.007117906,0.00019780525,0.0016247075,0.0000566808,0.00014407048,0.0012502654,0.0020819365,0.9863377,0.000018745648],"about_ca_topic_score_codex":0.00047212793,"about_ca_topic_score_gemma":0.0010324194,"teacher_disagreement_score":0.004188512,"about_ca_system_score_codex":0.00031590607,"about_ca_system_score_gemma":0.00052835577,"threshold_uncertainty_score":0.014011979},"labels":[],"label_agreement":null},{"id":"W2416001425","doi":"10.1080/13543784.2016.1195808","title":"Investigational targeted therapies for the treatment of testicular germ cell tumors","year":2016,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Brentuximab vedotin; Clinical trial; Oncology; Internal medicine; Targeted therapy; Germ cell tumors; Sunitinib; Disease; Ifosfamide; Chemotherapy; Cancer; Lymphoma; Etoposide; Hodgkin lymphoma","score_opus":0.06552153533269944,"score_gpt":0.36070765393514304,"score_spread":0.2951861186024436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2416001425","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000059730544,0.9990859,0.00004546713,0.00016218307,0.00010105098,0.0000051746756,0.000014660469,0.0000027852711,0.0005231194],"genre_scores_gemma":[0.0006076433,0.9987876,0.000106307176,0.00015611456,0.00008993043,0.0000058609357,0.000021161486,7.6852353e-7,0.0002246511],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99971753,0.000063574145,0.000046467234,0.000037479535,0.00011200927,0.000022863984],"domain_scores_gemma":[0.99952877,0.00023398519,0.00010910127,0.000010692979,0.000092510956,0.000024918416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000680212,0.0005903178,0.0010888869,0.0020970958,0.00018277047,0.00077117677,0.0006883981,0.00088770094,0.005137483],"category_scores_gemma":[0.0010015144,0.00016119405,0.0007411717,0.0018381445,0.00031958055,0.0007701992,0.00053451094,0.0014081185,0.0014651289],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000081977094,0.00005606401,0.00014181146,0.041282855,0.00019258639,0.00017896874,0.0000514281,0.00025551612,0.0010414281,0.0019287901,0.024468929,0.9303196],"study_design_scores_gemma":[0.00005939517,0.00014050197,0.0009195318,0.022129176,0.0005047006,0.0015325361,0.00007284283,0.00010875587,0.00052572327,0.0015765496,0.97241163,0.000018845014],"about_ca_topic_score_codex":0.0007152437,"about_ca_topic_score_gemma":0.0017084415,"teacher_disagreement_score":0.005137483,"about_ca_system_score_codex":0.0004857268,"about_ca_system_score_gemma":0.0009838336,"threshold_uncertainty_score":0.017186582},"labels":[],"label_agreement":null},{"id":"W2539921642","doi":"10.1080/13543784.2016.1254187","title":"Lomitapide for the treatment of hypertriglyceridemia","year":2016,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Lipid metabolism and disorders","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Hypertriglyceridemia; Medicine; Microsomal triglyceride transfer protein; Acute pancreatitis; Triglyceride; Clinical trial; Intensive care medicine; Familial hypercholesterolemia; Internal medicine; Cholesterol; Lipoprotein","score_opus":0.10633249717807947,"score_gpt":0.40067559040270684,"score_spread":0.2943430932246274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2539921642","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017817838,0.99718434,0.0000839156,0.00063351035,0.00027917663,0.000010117458,0.000030261837,0.000006970339,0.0015935049],"genre_scores_gemma":[0.0017393199,0.9961384,0.00017045824,0.000749815,0.0002690584,0.000010435213,0.00005480691,0.0000019075912,0.00086578395],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998276,0.000036344274,0.00003046441,0.000029264442,0.00006307372,0.000013171373],"domain_scores_gemma":[0.99977094,0.00009374062,0.00006482723,0.0000051505294,0.00005047416,0.000014761828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038070153,0.0004150245,0.00083327916,0.0014801486,0.00016982383,0.00062334194,0.00056834455,0.00082574645,0.005837129],"category_scores_gemma":[0.0006427474,0.00013376701,0.0005515618,0.000967839,0.00028249103,0.0006916605,0.00038399635,0.0012541906,0.0022095626],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001348554,0.00004654477,0.00017773586,0.030197041,0.00016987517,0.0003662074,0.000057267098,0.00013183932,0.0015008546,0.0017577603,0.043355517,0.92210454],"study_design_scores_gemma":[0.00008863199,0.00013546263,0.0010898133,0.014905056,0.0003613851,0.0043839216,0.00006714238,0.00009869243,0.0008207406,0.0014130636,0.9766142,0.000021850554],"about_ca_topic_score_codex":0.0005618717,"about_ca_topic_score_gemma":0.0013268921,"teacher_disagreement_score":0.005837129,"about_ca_system_score_codex":0.0003057282,"about_ca_system_score_gemma":0.00058068254,"threshold_uncertainty_score":0.019527197},"labels":[],"label_agreement":null},{"id":"W2611809642","doi":"10.1080/13543784.2017.1324847","title":"The neurogenic compound, NSI-189 phosphate: a novel multi-domain treatment capable of pro-cognitive and antidepressant effects","year":2017,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Neurogenesis and neuroplasticity mechanisms","field":"Neuroscience","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Brain and Cognition Discovery Foundation","funders":"","keywords":"Neurogenesis; Antidepressant; Neuroscience; Cognition; Subventricular zone; Psychology; Neural stem cell; Major depressive disorder; Hippocampus; Stem cell; Biology","score_opus":0.1842359574083909,"score_gpt":0.3839717961617744,"score_spread":0.1997358387533835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2611809642","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.046381515,0.8766081,0.010687579,0.011912899,0.0036424333,0.00058573345,0.0026470309,0.00036868578,0.047166124],"genre_scores_gemma":[0.18986413,0.7578403,0.006239711,0.007939426,0.0018260395,0.0004193143,0.0028880571,0.00004138223,0.032941796],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99992716,0.0000132726955,0.0000070209103,0.000016215663,0.000025953686,0.000010332074],"domain_scores_gemma":[0.99995375,0.000008467598,0.000016070011,0.0000016529975,0.000013749553,0.0000062831577],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018632576,0.00035258668,0.00040211188,0.00024425052,0.00012535091,0.0004623937,0.00039172143,0.0006667967,0.0053569227],"category_scores_gemma":[0.00016864648,0.00008841186,0.00028914819,0.00017688643,0.00021753593,0.00032492122,0.00025530296,0.00095408154,0.0016700983],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018905048,0.0003121626,0.0006484956,0.014321095,0.00019296982,0.0012367488,0.000118252705,0.0008709796,0.1432117,0.009529474,0.0678446,0.759823],"study_design_scores_gemma":[0.0009851197,0.0033543424,0.0029101968,0.0017681656,0.0003733705,0.0036957492,0.000116846044,0.0012095976,0.052004598,0.0032227614,0.930304,0.000055258097],"about_ca_topic_score_codex":0.00041209237,"about_ca_topic_score_gemma":0.0014501335,"teacher_disagreement_score":0.0053569227,"about_ca_system_score_codex":0.0002911632,"about_ca_system_score_gemma":0.00031875595,"threshold_uncertainty_score":0.017920732},"labels":[],"label_agreement":null},{"id":"W2732154709","doi":"10.1080/13543784.2017.1349753","title":"Alicaforsen for the treatment of inflammatory bowel disease","year":2017,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Cell Adhesion Molecules Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Robarts Clinical Trials; Western University","funders":"","keywords":"Medicine; Pouchitis; Inflammatory bowel disease; Vedolizumab; Ulcerative colitis; Placebo; Clinical trial; Gastroenterology; Internal medicine; Crohn's disease; Disease; Immunology; Pathology","score_opus":0.17651780968923894,"score_gpt":0.4477101717914101,"score_spread":0.2711923621021711,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2732154709","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013218864,0.99666166,0.00012709427,0.0004403929,0.00043072965,0.00001352676,0.00004292716,0.000012898244,0.002138606],"genre_scores_gemma":[0.0011393476,0.9960962,0.00022316545,0.0004864242,0.00031159617,0.0000152333505,0.000088525696,0.000002976097,0.0016366364],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99978906,0.000038890237,0.00002808761,0.00003818174,0.00008690144,0.000018896302],"domain_scores_gemma":[0.9998154,0.000063139094,0.000044448094,0.0000060675957,0.00005023955,0.00002067825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039714077,0.00065175164,0.00094382913,0.001666188,0.00019693511,0.0007253782,0.0005660747,0.00091916736,0.009494068],"category_scores_gemma":[0.0005574795,0.00014852374,0.00053984736,0.0012392688,0.0002913334,0.00076719146,0.0005296547,0.001679004,0.005176856],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000099288794,0.00005662422,0.000084647,0.018567452,0.000111817506,0.00014230779,0.000043108255,0.00018778737,0.002441378,0.0025385844,0.044383347,0.9313437],"study_design_scores_gemma":[0.000041071136,0.00009157652,0.00034544503,0.00337885,0.0001111165,0.0008132105,0.000021867287,0.000045125547,0.00039075277,0.0010472101,0.9937033,0.000010487886],"about_ca_topic_score_codex":0.0005937311,"about_ca_topic_score_gemma":0.0011330686,"teacher_disagreement_score":0.009494068,"about_ca_system_score_codex":0.00039146515,"about_ca_system_score_gemma":0.0006413336,"threshold_uncertainty_score":0.03176081},"labels":[],"label_agreement":null},{"id":"W2734923678","doi":"10.1080/13543784.2017.1353598","title":"Experimental and early investigational drugs for androgenetic alopecia","year":2017,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Hair Growth and Disorders","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health Research Institute; University of British Columbia","funders":"Canadian Institutes of Health Research; Canadian Dermatology Foundation","keywords":"Medicine; Investigational Drugs; Hair loss; Drug development; Ruxolitinib; Clinical trial; Dermatology; Pharmacology; Bioinformatics; Drug; Internal medicine; Biology","score_opus":0.12233725084206386,"score_gpt":0.4059214545339066,"score_spread":0.28358420369184273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2734923678","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011796199,0.9974226,0.0001229948,0.00033639255,0.00026043187,0.000014223837,0.00004746464,0.0000074678087,0.001670498],"genre_scores_gemma":[0.0013111989,0.9969133,0.00022687139,0.00043918993,0.00022093367,0.000017098018,0.00006163055,0.0000020779175,0.0008076225],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99971,0.000062180865,0.000044692053,0.000049519913,0.000112251924,0.000021332786],"domain_scores_gemma":[0.9994191,0.0003218214,0.000103309765,0.000017514129,0.000110650275,0.000027654629],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006260808,0.00055586605,0.00093658885,0.0017360135,0.00020444451,0.0007651454,0.00066836306,0.0010475024,0.008271688],"category_scores_gemma":[0.0010040044,0.00017697617,0.00070165703,0.0012031541,0.0004275226,0.0009403918,0.0004986514,0.0014269432,0.0027010285],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010136435,0.00006713302,0.00011781998,0.036946893,0.000112615504,0.00021139406,0.00004646688,0.000121421064,0.0020770298,0.0033488637,0.026380789,0.9304681],"study_design_scores_gemma":[0.000046224413,0.00012350196,0.0007090252,0.008901476,0.00020548211,0.0014106728,0.0000396414,0.000047481026,0.0007847438,0.0013441422,0.9863712,0.000016277349],"about_ca_topic_score_codex":0.0006031394,"about_ca_topic_score_gemma":0.001268188,"teacher_disagreement_score":0.008271688,"about_ca_system_score_codex":0.0004205662,"about_ca_system_score_gemma":0.00086184376,"threshold_uncertainty_score":0.027671576},"labels":[],"label_agreement":null},{"id":"W2902357040","doi":"10.1080/13543784.2019.1554054","title":"Therapeutic targets and early stage clinical trials for pulmonary fibrosis","year":2018,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Institute of Circulatory and Respiratory Health","keywords":"Clinical trial; Medicine; Identifier; Trial registration; Intensive care medicine; Internal medicine; Computer science","score_opus":0.264726498184007,"score_gpt":0.47917078060269047,"score_spread":0.21444428241868346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902357040","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011618868,0.6862663,0.011194381,0.1740945,0.032235827,0.011733377,0.0058484557,0.0006865454,0.06632179],"genre_scores_gemma":[0.18577066,0.47159144,0.050391063,0.19457673,0.02890767,0.029204942,0.008633948,0.00050348236,0.03042005],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9841061,0.011848009,0.0010281617,0.0007695421,0.0016447732,0.0006034413],"domain_scores_gemma":[0.97118384,0.014636856,0.0039171246,0.0015935036,0.005821778,0.0028468515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.023967454,0.0009020873,0.002582536,0.0007920045,0.0007476642,0.0041722567,0.00183338,0.004996549,0.03732108],"category_scores_gemma":[0.02886338,0.00029285,0.0032102908,0.0007991266,0.0013274621,0.0038354173,0.0017335024,0.007975482,0.0064606243],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021103041,0.0017242755,0.0015157862,0.05898516,0.0015838016,0.00042498525,0.0004591745,0.0010315742,0.003776852,0.031634636,0.22071104,0.6570498],"study_design_scores_gemma":[0.031467356,0.020979742,0.0044560046,0.056425393,0.0018860786,0.00072029105,0.0004351696,0.0015311821,0.0021464357,0.03812009,0.84171194,0.000120389035],"about_ca_topic_score_codex":0.0006338708,"about_ca_topic_score_gemma":0.0017582538,"teacher_disagreement_score":0.03732108,"about_ca_system_score_codex":0.0019681558,"about_ca_system_score_gemma":0.00462211,"threshold_uncertainty_score":0.12675357},"labels":[],"label_agreement":null},{"id":"W2905977615","doi":"10.1080/13543784.2019.1559295","title":"Rapastinel - an investigational NMDA-R modulator for major depressive disorder: evidence to date","year":2018,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Treatment of Major Depression","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Major depressive disorder; Antidepressant; Treatment-resistant depression; Adverse effect; Investigational Drugs; Clinical trial; Medicine; Depression (economics); Psychiatry; Meta-analysis; Cognition; Psychology; Pharmacology; Internal medicine; Anxiety","score_opus":0.1509173299690087,"score_gpt":0.42581684556225025,"score_spread":0.27489951559324155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905977615","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010144394,0.9991829,0.000031991673,0.00019057219,0.00006451719,0.0000065387753,0.000027394137,0.000003314594,0.00039134192],"genre_scores_gemma":[0.0012976597,0.99808794,0.000105347324,0.00023273745,0.00006576736,0.000010763927,0.000033579665,0.0000011824765,0.00016504076],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99964213,0.000082380575,0.00009312535,0.000057002115,0.00010220535,0.000023159519],"domain_scores_gemma":[0.99869895,0.0007459253,0.0003163665,0.000019416944,0.00018361314,0.000035787074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094605837,0.0006419996,0.0017518965,0.0013204305,0.00018690637,0.0010447019,0.0009409448,0.0011690776,0.006483184],"category_scores_gemma":[0.002513452,0.00023164134,0.0011283901,0.0015991498,0.00032601654,0.0008479645,0.0004195837,0.0010701658,0.001430412],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035928682,0.000050573835,0.00021211918,0.1800345,0.0006505577,0.00014528313,0.0000591866,0.00017719824,0.00086961547,0.0012207652,0.019249048,0.7969718],"study_design_scores_gemma":[0.00036062053,0.0006427144,0.0029480944,0.171085,0.006356408,0.0022923716,0.00018502162,0.00023597827,0.0013185216,0.0022646645,0.8122608,0.000049824015],"about_ca_topic_score_codex":0.00092400465,"about_ca_topic_score_gemma":0.0022164267,"teacher_disagreement_score":0.006483184,"about_ca_system_score_codex":0.00049382716,"about_ca_system_score_gemma":0.0012878635,"threshold_uncertainty_score":0.021688461},"labels":[],"label_agreement":null},{"id":"W2997288603","doi":"10.1080/13543784.2020.1709822","title":"Phase I/II parallel double-blind randomized controlled clinical trial of perispinal etanercept for chronic stroke: improved mobility and pain alleviation","year":2020,"lang":"en","type":"article","venue":"Expert Opinion on Investigational Drugs","topic":"Botulinum Toxin and Related Neurological Disorders","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Etanercept; Medicine; Physical therapy; Placebo; Stroke (engine); Visual analogue scale; Randomized controlled trial; Chronic pain; Clinical trial; Chronic stroke; Physical medicine and rehabilitation; Rehabilitation; Internal medicine; Tumor necrosis factor alpha","score_opus":0.1003967417263509,"score_gpt":0.3981617017785402,"score_spread":0.29776496005218933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2997288603","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.70579374,0.013944334,0.007699357,0.0030780192,0.0040958812,0.2393761,0.012360183,0.001567957,0.012084388],"genre_scores_gemma":[0.6625207,0.00820019,0.011457126,0.005417111,0.0020633836,0.28333563,0.005047166,0.0001810228,0.021777617],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9986387,0.0005293148,0.00011576656,0.0003070586,0.00014336767,0.0002659196],"domain_scores_gemma":[0.9987651,0.00022265883,0.0003170583,0.00013313378,0.00016990601,0.00039217412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031068898,0.0034785348,0.006232331,0.0009320363,0.0009896047,0.0017249337,0.0018836823,0.0035339096,0.02250708],"category_scores_gemma":[0.0029218476,0.0013423907,0.0019691011,0.0008630941,0.0021224804,0.001985114,0.00055684417,0.0035229966,0.0041671307],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9750753,0.010644418,0.00013506938,0.0013372711,0.00051232317,0.000026401487,0.00003578941,0.00017552757,0.0019935581,0.00015147781,0.0014358731,0.008476812],"study_design_scores_gemma":[0.97957015,0.019411169,0.00020816,0.000025536068,0.000084174135,0.000008688027,0.000005524522,0.00010372837,0.000098424825,0.000088171844,0.0003903268,0.000005942874],"about_ca_topic_score_codex":0.0012010982,"about_ca_topic_score_gemma":0.003211817,"teacher_disagreement_score":0.02250708,"about_ca_system_score_codex":0.0012028734,"about_ca_system_score_gemma":0.0027948166,"threshold_uncertainty_score":0.07529366},"labels":[],"label_agreement":null},{"id":"W3014880052","doi":"10.1080/13543784.2020.1751121","title":"Investigational non-JAK inhibitors for chronic phase myelofibrosis","year":2020,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Princess Margaret Cancer Foundation","keywords":"Myelofibrosis; Ruxolitinib; Medicine; Clinical trial; Phases of clinical research; Tofacitinib; Pharmacology; Internal medicine; Oncology; Bone marrow","score_opus":0.08566006386425828,"score_gpt":0.41308605949262,"score_spread":0.3274259956283617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3014880052","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.019143466,0.84401375,0.0022689386,0.03848732,0.0058590234,0.00023474755,0.0017833024,0.00032475975,0.08788475],"genre_scores_gemma":[0.1776419,0.6848627,0.005096383,0.040782697,0.011604131,0.0004050815,0.004176376,0.00008942749,0.07534141],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99976176,0.000057971345,0.000026706914,0.000026912887,0.000093125214,0.00003363662],"domain_scores_gemma":[0.99958295,0.00011173059,0.00014864693,0.000014533243,0.00007440158,0.00006783669],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004662839,0.00020546383,0.00034134285,0.00022894415,0.00014363533,0.0004624951,0.00029935708,0.00053440395,0.00867918],"category_scores_gemma":[0.0006550027,0.00006076487,0.00036353932,0.00023420369,0.00023425106,0.00043595978,0.00024304344,0.0010755821,0.00288231],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007808157,0.00012823597,0.0011308187,0.0024837367,0.000087213724,0.0006909254,0.000038140843,0.00022304089,0.005432549,0.0035419231,0.13913195,0.8463306],"study_design_scores_gemma":[0.000523039,0.00085693883,0.0033710022,0.0012534243,0.000094678464,0.0031131706,0.000028078171,0.00018620242,0.0018635804,0.00165708,0.9870388,0.00001402123],"about_ca_topic_score_codex":0.0002220085,"about_ca_topic_score_gemma":0.0012065868,"teacher_disagreement_score":0.00867918,"about_ca_system_score_codex":0.00033881515,"about_ca_system_score_gemma":0.0004836042,"threshold_uncertainty_score":0.029034734},"labels":[],"label_agreement":null},{"id":"W4211020510","doi":"10.1080/13543784.2022.2040479","title":"Emerging neuroprotective interventions in periventricular leukomalacia - A systematic review of preclinical studies","year":2022,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Neonatal and fetal brain pathology","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Neuroprotection; Psychological intervention; Clinical trial; Context (archaeology); Periventricular leukomalacia; Cerebral palsy; Intensive care medicine; Pathology; Pharmacology; Physical therapy; Pregnancy; Psychiatry","score_opus":0.1825023867716277,"score_gpt":0.4551623112909132,"score_spread":0.27265992451928556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4211020510","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015836231,0.99923706,0.000044917353,0.0001278136,0.00006528871,0.000044828816,0.00009576704,0.000002934286,0.00022298252],"genre_scores_gemma":[0.0017621979,0.9976599,0.00012949693,0.00020582229,0.00004407655,0.00005805412,0.000069056325,0.0000013384416,0.00007003678],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99826777,0.0005263474,0.00055223104,0.00016808062,0.00039689997,0.0000886824],"domain_scores_gemma":[0.9913607,0.0063699437,0.0011806051,0.00009909805,0.0008744302,0.000115236086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003608172,0.0011841869,0.00454521,0.0053642425,0.00032817887,0.0017211845,0.0016334692,0.0015537322,0.0074693062],"category_scores_gemma":[0.012887134,0.0004694083,0.003941262,0.0050291917,0.0004987909,0.001505785,0.00090112904,0.0010120181,0.0006632506],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021594024,0.000024411067,0.00018860596,0.86423445,0.00226329,0.00009319281,0.000086933534,0.00012355759,0.0002543408,0.00041525438,0.0041395966,0.12796049],"study_design_scores_gemma":[0.0002307214,0.00028711115,0.0021309375,0.8777324,0.023977004,0.00046743525,0.0001687379,0.00009290011,0.00029184893,0.0005662149,0.09402194,0.000032600496],"about_ca_topic_score_codex":0.003963906,"about_ca_topic_score_gemma":0.012464541,"teacher_disagreement_score":0.0074693062,"about_ca_system_score_codex":0.001674353,"about_ca_system_score_gemma":0.0059807547,"threshold_uncertainty_score":0.02498728},"labels":[],"label_agreement":null},{"id":"W4211244827","doi":"10.1517/13543784.11.2.189","title":"The macrolides","year":2002,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Pneumonia and Respiratory Infections","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; St. Paul's Hospital; Royal University Hospital","funders":"","keywords":"Clarithromycin; Azithromycin; Erythromycin; Medicine; Macrolide Antibiotics; Antimicrobial; Antibiotics; Intensive care medicine; Dosing; Adverse effect; Antibiotic resistance; Clinical trial; Pharmacology; Biology; Internal medicine; Microbiology","score_opus":0.10257103055064343,"score_gpt":0.3915771278110502,"score_spread":0.28900609726040677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4211244827","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004129146,0.99086386,0.0006121443,0.00049227534,0.00037784796,0.000018532852,0.000052269254,0.000030718544,0.007139405],"genre_scores_gemma":[0.0045662355,0.98349345,0.0013670928,0.0012458828,0.0004596974,0.000043241755,0.0001387682,0.0000066396083,0.0086789625],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99958163,0.0000771239,0.000047343492,0.00008122758,0.00017846422,0.000034167493],"domain_scores_gemma":[0.99978334,0.000054852917,0.000056532637,0.0000152914,0.00005745259,0.00003254931],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032728902,0.0010860034,0.0011413981,0.0016504115,0.00032083035,0.00090639904,0.00072043116,0.0014452987,0.0048551913],"category_scores_gemma":[0.000617934,0.00020097446,0.00038090683,0.0011878269,0.00059600524,0.0009913519,0.00070920284,0.0014519072,0.0058055534],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010114066,0.000086083055,0.00025721404,0.005409347,0.000056480603,0.00042523813,0.00006858167,0.00019449873,0.00609646,0.004695086,0.042588186,0.9400217],"study_design_scores_gemma":[0.000022494394,0.000081216596,0.00056951435,0.0008519902,0.000023522227,0.0018388742,0.000018682347,0.000032447548,0.001394685,0.00087386137,0.99428433,0.000008305175],"about_ca_topic_score_codex":0.00095002865,"about_ca_topic_score_gemma":0.0014954638,"teacher_disagreement_score":0.0048551913,"about_ca_system_score_codex":0.0006635708,"about_ca_system_score_gemma":0.0007549141,"threshold_uncertainty_score":0.016242206},"labels":[],"label_agreement":null},{"id":"W4230784343","doi":"10.1517/13543784.14.7.905","title":"Stiripentol","year":2005,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Epilepsy research and treatment","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dravet syndrome; Medicine; Carbamazepine; Epilepsy; Felbamate; CYP2C19; Tolerability; Clobazam; Pharmacology; Myoclonic epilepsy; Orphan drug; Adjunctive treatment; Clinical trial; Pediatrics; Adverse effect; Internal medicine; Bioinformatics; Psychiatry","score_opus":0.13481690479529249,"score_gpt":0.4447422447116589,"score_spread":0.3099253399163664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4230784343","genre_codex":"other","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3390535,0.2172493,0.029876733,0.0060813334,0.005082603,0.0015976808,0.01307189,0.0048464993,0.38314044],"genre_scores_gemma":[0.71696794,0.07957528,0.012621083,0.004291688,0.0007901391,0.0005236514,0.011632899,0.0004908046,0.1731065],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99979144,0.000024283529,0.000012300451,0.000054297092,0.00007148226,0.000046218043],"domain_scores_gemma":[0.99992,0.000010793173,0.000014339283,0.0000071003146,0.000018798133,0.00002899265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001163377,0.00072766305,0.0004273692,0.000945565,0.00040283182,0.0005670168,0.00044052082,0.00067603646,0.02853349],"category_scores_gemma":[0.000222968,0.00017897249,0.00059648824,0.0003905657,0.00030454883,0.00048016862,0.0005528087,0.0013616204,0.011548451],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005251302,0.0011034849,0.0011808377,0.00335302,0.00015021375,0.002569711,0.00015912269,0.0007955585,0.33310702,0.008142786,0.031950902,0.612236],"study_design_scores_gemma":[0.00075240544,0.0036894428,0.0038486032,0.00034064296,0.0001841313,0.0064480007,0.00011282213,0.0005250583,0.24224962,0.0015865582,0.7401817,0.00008098568],"about_ca_topic_score_codex":0.00072769524,"about_ca_topic_score_gemma":0.0009828677,"teacher_disagreement_score":0.02853349,"about_ca_system_score_codex":0.0004514212,"about_ca_system_score_gemma":0.0004931716,"threshold_uncertainty_score":0.09545404},"labels":[],"label_agreement":null},{"id":"W4232214719","doi":"10.1517/13543784.9.7.1511","title":"Psoriatic arthritis","year":2000,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto","funders":"","keywords":"Psoriatic arthritis; Medicine; Rheumatoid arthritis; Arthritis; Psoriasis; Dactylitis; Inflammatory arthritis; Immunology; Osteolysis; Cytokine; Pathogenesis; Dermatology; Enthesitis; Surgery","score_opus":0.05957936896122606,"score_gpt":0.36995000607833156,"score_spread":0.3103706371171055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232214719","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011419953,0.6192453,0.0062631224,0.017857594,0.011805925,0.00084415264,0.008990305,0.0021569477,0.32141677],"genre_scores_gemma":[0.19981414,0.48770574,0.010608457,0.035138156,0.010845953,0.0008594108,0.0166384,0.0003936561,0.23799613],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983735,0.00030807953,0.00013042518,0.00020762335,0.00073098403,0.00024928158],"domain_scores_gemma":[0.9987685,0.00021218645,0.00024956412,0.0000963089,0.0004241817,0.00024914346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007565918,0.00089097605,0.0017019412,0.0013201791,0.00090992637,0.002623419,0.00076612405,0.0019136091,0.09341421],"category_scores_gemma":[0.0029962754,0.00029668852,0.00075154984,0.0015170779,0.00045401935,0.0008241373,0.0010780868,0.0018260187,0.049264997],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004195424,0.00016839884,0.0025970554,0.0042617726,0.00022020101,0.0014953739,0.00012471841,0.000097161734,0.0061341235,0.006107392,0.46167445,0.5166998],"study_design_scores_gemma":[0.00010512658,0.00014235743,0.0035498552,0.00094998954,0.00009405116,0.0074820546,0.00008490852,0.000065815526,0.00084585766,0.002445451,0.98420703,0.000027527196],"about_ca_topic_score_codex":0.0010230177,"about_ca_topic_score_gemma":0.0015117913,"teacher_disagreement_score":0.09341421,"about_ca_system_score_codex":0.00057028444,"about_ca_system_score_gemma":0.0010571475,"threshold_uncertainty_score":0.31250167},"labels":[],"label_agreement":null},{"id":"W4233825669","doi":"10.1517/eoid.12.10.1655.21840","title":"Targeting cellular energy production in neurological disorders","year":2003,"lang":"en","type":"article","venue":"Expert Opinion on Investigational Drugs","topic":"Diet and metabolism studies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Production (economics); Medicine; Neuroscience; Biology","score_opus":0.022253948457351243,"score_gpt":0.26888812325229017,"score_spread":0.24663417479493893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233825669","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.037865903,0.91419536,0.009049501,0.008483055,0.0014427004,0.0000776544,0.00015643549,0.0001209452,0.02860842],"genre_scores_gemma":[0.18699522,0.7920165,0.0066084913,0.0016700447,0.0005375161,0.00010541256,0.00017759022,0.000018823415,0.0118703535],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999317,0.000019690608,0.000007692971,0.000010797777,0.000018878967,0.000011273275],"domain_scores_gemma":[0.99996984,0.000008000157,0.00000519286,0.0000026213934,0.000009325751,0.0000050441445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020505166,0.00034231352,0.0005228661,0.00053047185,0.0002011942,0.0005172658,0.00036500877,0.00070357276,0.0029193538],"category_scores_gemma":[0.00013772724,0.000090985624,0.00015982975,0.00040055515,0.00041503774,0.00051513925,0.0005008882,0.00078138773,0.0008271284],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001587576,0.00043371768,0.000709441,0.0054784664,0.00009007759,0.0018973744,0.000251399,0.0010217796,0.23942415,0.040812172,0.02069041,0.6876035],"study_design_scores_gemma":[0.00031531582,0.0019482243,0.008220166,0.0013487467,0.00020050418,0.008805709,0.00044092815,0.00094234047,0.13803881,0.051647134,0.7880417,0.00005030371],"about_ca_topic_score_codex":0.00053802226,"about_ca_topic_score_gemma":0.0009887688,"teacher_disagreement_score":0.0029193538,"about_ca_system_score_codex":0.0005780672,"about_ca_system_score_gemma":0.00038188195,"threshold_uncertainty_score":0.009766161},"labels":[],"label_agreement":null},{"id":"W4238239896","doi":"10.1517/eoid.13.2.139.26339","title":"Current and investigational treatment of psoriatic arthritis","year":2004,"lang":"en","type":"article","venue":"Expert Opinion on Investigational Drugs","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital","funders":"","keywords":"Investigational Drugs; Psoriatic arthritis; Medicine; Psoriasis; Dermatology; Intensive care medicine; Internal medicine; Clinical trial","score_opus":0.0353861475486092,"score_gpt":0.31567753421729017,"score_spread":0.280291386668681,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4238239896","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003090227,0.9771936,0.0005031149,0.0031472794,0.000833494,0.000029318931,0.00009451198,0.000030422765,0.015077967],"genre_scores_gemma":[0.041257583,0.9365757,0.0017276094,0.0034273607,0.0021868113,0.000092821094,0.00028177645,0.000008794801,0.014441526],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995259,0.00013720444,0.000054695058,0.000054312288,0.00019056944,0.000037337653],"domain_scores_gemma":[0.99964714,0.000089434965,0.000094278825,0.00002312922,0.00008637077,0.000059677073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076545205,0.00030082336,0.00051555235,0.00049010885,0.0002589673,0.0006221745,0.0005364758,0.0007916224,0.011360558],"category_scores_gemma":[0.00081568497,0.00008422118,0.00038682582,0.0005607821,0.00026435225,0.00049597636,0.00028366907,0.0009167468,0.0032841286],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048232308,0.0002383191,0.0004480824,0.0035161655,0.00006895923,0.00035639375,0.000049620223,0.000051264862,0.004379502,0.0015875677,0.02500301,0.9638187],"study_design_scores_gemma":[0.000507973,0.0017046197,0.0048224605,0.0019824738,0.00020655346,0.0041341255,0.000099121695,0.00009431128,0.003407494,0.0016296672,0.98139346,0.000017628097],"about_ca_topic_score_codex":0.00034011857,"about_ca_topic_score_gemma":0.001049541,"teacher_disagreement_score":0.011360558,"about_ca_system_score_codex":0.0003374038,"about_ca_system_score_gemma":0.00047543313,"threshold_uncertainty_score":0.038004875},"labels":[],"label_agreement":null},{"id":"W4241182179","doi":"10.1517/13543784.10.10.1869","title":"Eletriptan","year":2001,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Migraine and Headache Studies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Sumatriptan; Triptans; Migraine; Zolmitriptan; Medicine; Pharmacology; Onset of action; Rizatriptan; Anesthesia; Agonist; Adverse effect; Internal medicine; Receptor","score_opus":0.1467284620387652,"score_gpt":0.4242388683436477,"score_spread":0.27751040630488255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241182179","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005626414,0.99217755,0.00015770199,0.0002635094,0.0002010266,0.00003290243,0.00008300268,0.000021991633,0.0064997133],"genre_scores_gemma":[0.004337109,0.98785806,0.00041886137,0.0005608933,0.00015762726,0.000037257636,0.00021545833,0.000003832379,0.0064110486],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997358,0.00005068061,0.000037196594,0.000049433802,0.00010643409,0.000020455758],"domain_scores_gemma":[0.9998605,0.000046799985,0.00003385845,0.00000615883,0.000035378365,0.000017282044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033933658,0.0007390298,0.0010741169,0.0021775684,0.0002774172,0.00061942235,0.00079211174,0.00091072614,0.018930972],"category_scores_gemma":[0.0005917952,0.000175282,0.0004838325,0.0019375181,0.00018223745,0.000727332,0.00044274886,0.00081593485,0.0068484102],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020093255,0.00009616608,0.00012051994,0.015643831,0.0001065725,0.00038462615,0.000037311733,0.00007693043,0.00238008,0.0005553646,0.020179143,0.9602185],"study_design_scores_gemma":[0.0002143353,0.00027830663,0.0020467346,0.0040434897,0.00024062977,0.0039526275,0.000051361698,0.000040137063,0.0021407772,0.0004940582,0.986482,0.000015461],"about_ca_topic_score_codex":0.000967267,"about_ca_topic_score_gemma":0.0021863761,"teacher_disagreement_score":0.018930972,"about_ca_system_score_codex":0.0003848167,"about_ca_system_score_gemma":0.0006302501,"threshold_uncertainty_score":0},"labels":[],"label_agreement":null},{"id":"W4244867483","doi":"10.1517/eoid.12.11.1855.21883","title":"Experimental and clinical studies show that the probucol derivative AGI-1067 prevents vascular growth","year":2003,"lang":"en","type":"article","venue":"Expert Opinion on Investigational Drugs","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Probucol; Restenosis; Medicine; Internal medicine; Endocrinology; Lipoprotein; Cholesterol; Stent","score_opus":0.052125097192935115,"score_gpt":0.3499731531585472,"score_spread":0.2978480559656121,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4244867483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6320173,0.3195835,0.011633783,0.0038632264,0.00066301477,0.0003794462,0.0014167697,0.0007906045,0.029652253],"genre_scores_gemma":[0.91449594,0.07317341,0.0032719416,0.001498272,0.0004482147,0.00017119314,0.0015559354,0.000049912156,0.00533527],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9997614,0.000054334618,0.000019016104,0.000040272913,0.00009413974,0.000030778792],"domain_scores_gemma":[0.9993125,0.0002500983,0.00019218816,0.000056197223,0.00010810038,0.000081030565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005912047,0.00056951965,0.000590798,0.00046610544,0.00019469911,0.000355613,0.00021592327,0.0004626843,0.003427543],"category_scores_gemma":[0.00077076897,0.00009078958,0.00034068874,0.00038396544,0.0004927783,0.0003040484,0.00023255196,0.0011850733,0.00087992765],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074530523,0.004211448,0.018313032,0.003566389,0.00050229457,0.0015763124,0.00012944758,0.00085810776,0.19851676,0.0028141155,0.008555946,0.7535031],"study_design_scores_gemma":[0.0049938434,0.09294004,0.23757051,0.0014706738,0.0019828477,0.02296063,0.0004649226,0.0037939725,0.27119687,0.0061248546,0.35627672,0.00022407676],"about_ca_topic_score_codex":0.00040015116,"about_ca_topic_score_gemma":0.0006255571,"teacher_disagreement_score":0.003427543,"about_ca_system_score_codex":0.0002287229,"about_ca_system_score_gemma":0.00034704924,"threshold_uncertainty_score":0.011466265},"labels":[],"label_agreement":null},{"id":"W4246532558","doi":"10.1517/eoid.13.3.199.27347","title":"Recent advances in protein tyrosine phosphatase 1B inhibitors","year":2004,"lang":"en","type":"article","venue":"Expert Opinion on Investigational Drugs","topic":"Protein Tyrosine Phosphatases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"","keywords":"Insulin resistance; Downregulation and upregulation; Protein tyrosine phosphatase; Leptin; Type 2 diabetes; Insulin; Diabetes mellitus; Obesity; Insulin receptor; Biology; Phosphatase; Internal medicine; Endocrinology; Tyrosine; Medicine; Cell biology; Biochemistry; Phosphorylation","score_opus":0.01315410682153738,"score_gpt":0.2786591131533658,"score_spread":0.2655050063318284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246532558","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015286964,0.9872149,0.0014485752,0.0029200038,0.0012180649,0.000016675684,0.000060340084,0.000049177463,0.005543443],"genre_scores_gemma":[0.007903435,0.9799745,0.0018387184,0.002766795,0.0017466443,0.00003632048,0.00016291438,0.000013526179,0.005557127],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996369,0.00007025452,0.000041466577,0.00007015971,0.00012818328,0.000053046373],"domain_scores_gemma":[0.99955136,0.00017737882,0.00006767011,0.000019105499,0.00011469149,0.00006969386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010790727,0.0008287177,0.0010581884,0.0009845786,0.00025576685,0.0009910672,0.0006294976,0.0013423152,0.004934769],"category_scores_gemma":[0.000842204,0.00033911018,0.00046610413,0.00094626396,0.0004402148,0.0014441485,0.00061851117,0.002327468,0.0031349342],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005776399,0.00028422888,0.00023081394,0.005454705,0.0001061709,0.0007005586,0.00010039796,0.0007050271,0.021732606,0.010413053,0.04493472,0.9147602],"study_design_scores_gemma":[0.00011954437,0.000559141,0.00055686204,0.00037387767,0.00011397793,0.0014226114,0.00003278087,0.00026943284,0.0051456694,0.002339232,0.9890448,0.000022051358],"about_ca_topic_score_codex":0.00043109036,"about_ca_topic_score_gemma":0.0011803968,"teacher_disagreement_score":0.004934769,"about_ca_system_score_codex":0.00074479193,"about_ca_system_score_gemma":0.00059243914,"threshold_uncertainty_score":0.0165084},"labels":[],"label_agreement":null},{"id":"W4322763591","doi":"10.1080/13543784.2023.2187286","title":"The potential role of opioid vaccines and monoclonal antibodies in the opioid overdose crisis","year":2023,"lang":"en","type":"editorial","venue":"Expert Opinion on Investigational Drugs","topic":"Opioid Use Disorder Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute on Drug Abuse; National Institutes of Health; World Health Organization","keywords":"Opioid; Monoclonal antibody; Opioid overdose; Medicine; Virology; Antibody; Immunology; (+)-Naloxone; Internal medicine; Receptor","score_opus":0.011568094082562333,"score_gpt":0.29870801845156664,"score_spread":0.2871399243690043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322763591","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008169265,0.07175731,0.00018290251,0.08000134,0.8444872,0.000029726836,0.00009275654,0.00004233893,0.003324755],"genre_scores_gemma":[0.00064467936,0.037414726,0.00016786605,0.050406795,0.9065157,0.00002763999,0.0000459888,0.000019526964,0.0047570434],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972197,0.0007475905,0.00038632413,0.00027468178,0.0011524394,0.0002192378],"domain_scores_gemma":[0.98661625,0.0077594747,0.0009515211,0.00021388869,0.0032942968,0.0011646779],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005003884,0.001793167,0.0030164288,0.0018813665,0.0013661536,0.0042735613,0.0033973178,0.018114349,0.010376458],"category_scores_gemma":[0.017643075,0.0007404086,0.002537641,0.00085617066,0.0017933206,0.0030951882,0.001158425,0.015107376,0.006162607],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005800667,0.000014779369,0.000037971673,0.0008413666,0.000056507582,0.00022368885,0.000012804024,0.00002983067,0.000061580125,0.0004617983,0.98375964,0.014442026],"study_design_scores_gemma":[0.00016513348,0.000050370163,0.0002579293,0.001522116,0.00017662252,0.0005214503,0.00004139991,0.00014822783,0.00009195183,0.0016726144,0.9953294,0.000022880675],"about_ca_topic_score_codex":0.0018019086,"about_ca_topic_score_gemma":0.003994571,"teacher_disagreement_score":0.018114349,"about_ca_system_score_codex":0.0023423221,"about_ca_system_score_gemma":0.002480131,"threshold_uncertainty_score":0.034712672},"labels":[],"label_agreement":null},{"id":"W4366990971","doi":"10.1080/13543784.2023.2206559","title":"Efficacy, safety, and tolerability of ulotaront (SEP-363856, a trace amine-associated receptor 1 agonist) for the treatment of schizophrenia and other mental disorders: a systematic review of preclinical and clinical trials","year":2023,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Brain and Cognition Discovery Foundation; University Health Network","funders":"","keywords":"Tolerability; Adverse effect; Schizophrenia (object-oriented programming); Clinical trial; Medicine; Psychiatry; Systematic review; Antipsychotic; Pharmacology; Psychology; MEDLINE; Internal medicine","score_opus":0.22589218821859425,"score_gpt":0.493442865454273,"score_spread":0.26755067723567877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366990971","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015239868,0.9972687,0.000118174255,0.00014980628,0.00005780434,0.00031343702,0.00033355205,0.0000067801507,0.00022771387],"genre_scores_gemma":[0.01945755,0.978643,0.0005471051,0.00042683198,0.00005623615,0.0004968409,0.00023830729,0.0000052205005,0.0001289497],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99506074,0.0014493581,0.0021257475,0.0003655059,0.0008601579,0.0001384347],"domain_scores_gemma":[0.98280936,0.011386905,0.0036844015,0.0001987174,0.0017035255,0.0002170917],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0073837466,0.001254233,0.008485933,0.0069101113,0.00056434167,0.0019936638,0.0017239511,0.0017129758,0.0039548795],"category_scores_gemma":[0.02277074,0.00073986343,0.007763184,0.007165801,0.00085651706,0.0016101763,0.0011602908,0.0008856867,0.0002853756],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035185282,0.000011875666,0.00036094605,0.9665883,0.009430022,0.00006839692,0.00009466387,0.00006039543,0.00022112955,0.00009406488,0.0005440795,0.022174256],"study_design_scores_gemma":[0.00063005637,0.0006299714,0.0041624987,0.80224216,0.17694686,0.00041486046,0.00026014514,0.00012953168,0.00039686824,0.0003019239,0.013836583,0.000048651014],"about_ca_topic_score_codex":0.0055141356,"about_ca_topic_score_gemma":0.017694296,"teacher_disagreement_score":0.008485933,"about_ca_system_score_codex":0.0026883753,"about_ca_system_score_gemma":0.008144842,"threshold_uncertainty_score":0.039049447},"labels":[],"label_agreement":null},{"id":"W4378347895","doi":"10.1080/13543784.2023.2212155","title":"Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study","year":2023,"lang":"en","type":"article","venue":"Expert Opinion on Investigational Drugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Celltrion","keywords":"Tocilizumab; Medicine; Bioequivalence; Clinical endpoint; Cmax; Pharmacokinetics; Adverse effect; Internal medicine; Confidence interval; Pharmacology; Randomized controlled trial; European union; Area under the curve; Rheumatoid arthritis; Gastroenterology","score_opus":0.11854610921628209,"score_gpt":0.39229762798865775,"score_spread":0.2737515187723757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378347895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946464,0.00080106163,0.0010101828,0.0000915255,0.00008503409,0.0025452273,0.00031852876,0.000050963677,0.00045107913],"genre_scores_gemma":[0.99406755,0.00059419614,0.0014468437,0.0002642819,0.00022591955,0.0025415355,0.0003230308,0.00001961602,0.00051716703],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99878186,0.0006589341,0.000092325,0.00019349299,0.00015295917,0.00012043953],"domain_scores_gemma":[0.99816555,0.00045880897,0.0005909218,0.0001973448,0.00014854137,0.00043887537],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024222294,0.0011298954,0.0025499566,0.00038128826,0.00038380825,0.00070565066,0.00076732674,0.0013022443,0.0033594703],"category_scores_gemma":[0.0029861417,0.0006138974,0.0012530837,0.00047152842,0.0013649995,0.0009160702,0.00024742578,0.0022191806,0.00063342537],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9278772,0.025983563,0.0012204439,0.00037722144,0.00054913247,0.000051020852,0.00010143099,0.00067141734,0.02370369,0.00009626942,0.00046340964,0.01890513],"study_design_scores_gemma":[0.4913146,0.49486142,0.003956743,0.000023292301,0.00090492744,0.000114873634,0.000029332316,0.001406025,0.0065272255,0.00011598932,0.00071549544,0.000030055646],"about_ca_topic_score_codex":0.00046916367,"about_ca_topic_score_gemma":0.00046287244,"teacher_disagreement_score":0.0033594703,"about_ca_system_score_codex":0.0009496422,"about_ca_system_score_gemma":0.0016134399,"threshold_uncertainty_score":0.012810111},"labels":[],"label_agreement":null},{"id":"W4383186645","doi":"10.1080/13543784.2023.2233892","title":"Clinical development of passive tau-based immunotherapeutics for treating primary and secondary tauopathies","year":2023,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Alzheimer's disease research and treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ministry of Health, British Columbia","keywords":"Primary (astronomy); Medicine; Neuroscience; Internal medicine; Oncology; Psychology; Physics","score_opus":0.1588989828028061,"score_gpt":0.443967261644877,"score_spread":0.28506827884207087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383186645","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011390219,0.9531101,0.0065557347,0.008678852,0.0022600102,0.00036423613,0.0005360277,0.00018108905,0.016923739],"genre_scores_gemma":[0.085524,0.8816399,0.008870179,0.010879377,0.002330221,0.0006349644,0.001603807,0.000057338482,0.008460195],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996692,0.00010352057,0.000031849242,0.000054086937,0.00009593244,0.000045495584],"domain_scores_gemma":[0.99962246,0.000102741804,0.00007665224,0.000012578511,0.0001464195,0.000039174527],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011657858,0.00048598988,0.0007371447,0.00047476985,0.00017053488,0.00084000087,0.0006626068,0.0011743624,0.006806542],"category_scores_gemma":[0.0009959224,0.000115762385,0.0007374282,0.00028110578,0.00030667023,0.0010015792,0.0004986915,0.0017376009,0.0024354602],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009813767,0.00044170604,0.0007027332,0.014714728,0.00025093323,0.00050619565,0.00016598363,0.0007115075,0.027767766,0.0048970664,0.04657034,0.90228957],"study_design_scores_gemma":[0.0012137211,0.0038397755,0.0030083235,0.0077022407,0.0006347135,0.0027552324,0.00019544223,0.0011055958,0.013062037,0.0057134787,0.96071106,0.000058326154],"about_ca_topic_score_codex":0.00026028344,"about_ca_topic_score_gemma":0.0007574034,"teacher_disagreement_score":0.006806542,"about_ca_system_score_codex":0.00040115602,"about_ca_system_score_gemma":0.0006950075,"threshold_uncertainty_score":0.022770166},"labels":[],"label_agreement":null},{"id":"W4386347132","doi":"10.1080/13543784.2023.2254684","title":"Investigational monoclonal antibodies in early development for psoriatic arthritis: beyond the biosimilars","year":2023,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Memorial University of Newfoundland","funders":"","keywords":"Psoriatic arthritis; Biosimilar; Medicine; Psoriasis; Investigational Drugs; Clinical trial; Ixekizumab; Monoclonal antibody; Arthritis; Intensive care medicine; Immunology; Secukinumab; Internal medicine; Antibody","score_opus":0.11954500560529793,"score_gpt":0.3821567219202426,"score_spread":0.2626117163149446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386347132","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017411789,0.99559325,0.00026146116,0.0012703664,0.0006775681,0.000012391118,0.000026746748,0.0000097411785,0.0019743484],"genre_scores_gemma":[0.001427294,0.9948946,0.0003197949,0.0012593543,0.0006304781,0.000013758779,0.000051571344,0.0000029662797,0.0014002423],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99951494,0.00011492161,0.00004682148,0.00005354994,0.00023113893,0.000038646238],"domain_scores_gemma":[0.9992843,0.0003045705,0.00013734301,0.000013268983,0.00020543067,0.00005502994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012019555,0.0005501856,0.00079189026,0.001251421,0.0001463354,0.001053503,0.0007106301,0.001576886,0.0051498106],"category_scores_gemma":[0.0014054594,0.00015584216,0.0005190666,0.0010811822,0.00041010915,0.0013633189,0.00048497706,0.0023515676,0.00293425],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001068743,0.00005553123,0.000105756284,0.009949476,0.00005924441,0.00021196075,0.0000486339,0.00019261608,0.001964432,0.0054641212,0.04505674,0.93678457],"study_design_scores_gemma":[0.000045390352,0.00012623736,0.00027113085,0.0033834635,0.00005692221,0.00091459864,0.000030282463,0.000072634844,0.00054467155,0.0018660098,0.99267876,0.000009895759],"about_ca_topic_score_codex":0.00054918753,"about_ca_topic_score_gemma":0.0010253678,"teacher_disagreement_score":0.0051498106,"about_ca_system_score_codex":0.0005359818,"about_ca_system_score_gemma":0.0009772773,"threshold_uncertainty_score":0.017227829},"labels":[],"label_agreement":null},{"id":"W4390744560","doi":"10.1080/13543784.2024.2305136","title":"Approaches to combating methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) biofilm infections","year":2024,"lang":"en","type":"editorial","venue":"Expert Opinion on Investigational Drugs","topic":"Bacterial biofilms and quorum sensing","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; School of Medicine; National Institutes of Health; NYU Grossman School of Medicine; York University; New York University","keywords":"Methicillin-resistant Staphylococcus aureus; Microbiology; Staphylococcus aureus; Biofilm; Medicine; Biology; Bacteria","score_opus":0.04675818851187052,"score_gpt":0.2883816623992882,"score_spread":0.24162347388741767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390744560","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012448044,0.12277166,0.00032246805,0.04103653,0.83105373,0.000052511754,0.00012897511,0.000059750637,0.0044499515],"genre_scores_gemma":[0.0013653507,0.14010245,0.0005087284,0.05662242,0.78269833,0.00007869555,0.00014978062,0.00004879891,0.018425414],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980368,0.00041018776,0.00022364993,0.00018621894,0.0009585854,0.00018459435],"domain_scores_gemma":[0.9951989,0.0017127048,0.00044323507,0.00009179048,0.0018864411,0.00066693494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033022591,0.0015417798,0.0020562694,0.0013871553,0.0009300223,0.0035432728,0.0022088701,0.00893822,0.0094144745],"category_scores_gemma":[0.007848103,0.00055626326,0.0016029687,0.00079968496,0.001254705,0.0022710608,0.001226431,0.010194951,0.0052956897],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008575276,0.000023708199,0.000018345765,0.0012861394,0.00004514089,0.000111057656,0.000013065046,0.000037591195,0.0003378792,0.0007084856,0.9711921,0.02614071],"study_design_scores_gemma":[0.00011206249,0.00006704217,0.00014259729,0.0008184407,0.000082049795,0.00017251885,0.000020063742,0.00007285462,0.00020235196,0.0009097172,0.9973864,0.000013985273],"about_ca_topic_score_codex":0.0013856884,"about_ca_topic_score_gemma":0.00422433,"teacher_disagreement_score":0.0094144745,"about_ca_system_score_codex":0.0017587334,"about_ca_system_score_gemma":0.0020885246,"threshold_uncertainty_score":0.0314945},"labels":[],"label_agreement":null},{"id":"W4391399172","doi":"10.1080/13543784.2024.2313105","title":"Duchenne muscular dystrophy: promising early-stage clinical trials to watch","year":2024,"lang":"en","type":"article","venue":"Expert Opinion on Investigational Drugs","topic":"Muscle Physiology and Disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Duchenne muscular dystrophy; Muscular dystrophy; Medicine; Clinical trial; Disease; Physical therapy; Physical medicine and rehabilitation; Pediatrics; Intensive care medicine; Internal medicine","score_opus":0.10370736443026966,"score_gpt":0.43758176156918466,"score_spread":0.333874397138915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391399172","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009840691,0.91329455,0.004317246,0.044536497,0.007357601,0.0010711185,0.001462532,0.0002569564,0.01786282],"genre_scores_gemma":[0.1011175,0.7381253,0.014484582,0.11117792,0.011112854,0.0025965695,0.003862153,0.00020235329,0.017320793],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983949,0.000930742,0.000117527285,0.00017238839,0.0002605021,0.00012399653],"domain_scores_gemma":[0.9957852,0.002078957,0.0006648954,0.00011704458,0.00075030257,0.00060356274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0058265766,0.0008130245,0.0019839667,0.00036675105,0.00028114195,0.0023281444,0.00089650403,0.0031377277,0.017193928],"category_scores_gemma":[0.0056952047,0.00014814538,0.0021729346,0.0003487066,0.0005974906,0.0021337394,0.00061563466,0.003113007,0.0036323194],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010460179,0.0011144709,0.0017260078,0.029739711,0.0016699537,0.00046171094,0.00018075343,0.0008146971,0.008719278,0.010560811,0.1605642,0.7739881],"study_design_scores_gemma":[0.020940654,0.018911583,0.0070217103,0.050800912,0.0035025575,0.0013882132,0.00038790618,0.0012833835,0.0036624912,0.021541351,0.870443,0.00011642526],"about_ca_topic_score_codex":0.00035065282,"about_ca_topic_score_gemma":0.0014486485,"teacher_disagreement_score":0.017193928,"about_ca_system_score_codex":0.0007686796,"about_ca_system_score_gemma":0.0016300248,"threshold_uncertainty_score":0.057519495},"labels":[],"label_agreement":null},{"id":"W4392096159","doi":"10.1080/13543784.2024.2323528","title":"A modest proposal: targeting αv integrin-mediated activation of latent TGFbeta as a novel therapeutic approach to treat scleroderma fibrosis","year":2024,"lang":"en","type":"article","venue":"Expert Opinion on Investigational Drugs","topic":"Connective Tissue Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Scleroderma (fungus); Fibrosis; Integrin; Cancer research; Medicine; Immunology; Internal medicine; Receptor","score_opus":0.044870518804165045,"score_gpt":0.31950002056080734,"score_spread":0.2746295017566423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392096159","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0058285166,0.58058214,0.0121275075,0.30476516,0.05954481,0.00038552936,0.00064118847,0.00039316734,0.035732042],"genre_scores_gemma":[0.051717337,0.6480541,0.01255422,0.18283066,0.03954049,0.0009212168,0.0008262648,0.00012729575,0.0634284],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99924856,0.00026102064,0.000046024834,0.000125624,0.0002164707,0.00010235791],"domain_scores_gemma":[0.99894804,0.00040472168,0.00008760236,0.00003898722,0.0003718003,0.00014886806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025867834,0.00059898524,0.0009320101,0.0005419558,0.00049574807,0.0023503364,0.0011264698,0.004749663,0.009572541],"category_scores_gemma":[0.0027332534,0.00023092667,0.0007969547,0.0003427488,0.0017397371,0.0032533945,0.0008299909,0.007470014,0.005851253],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013564597,0.00040454426,0.00051726034,0.0061981278,0.00031796694,0.0013882963,0.00034666882,0.0008895846,0.024783138,0.12303481,0.38282517,0.457938],"study_design_scores_gemma":[0.00038380106,0.0007224153,0.0003916158,0.0010756763,0.00014287034,0.0007855662,0.00017153451,0.00038492144,0.0023035323,0.030569546,0.96303046,0.000038066377],"about_ca_topic_score_codex":0.00045644728,"about_ca_topic_score_gemma":0.0011091501,"teacher_disagreement_score":0.009572541,"about_ca_system_score_codex":0.0008700001,"about_ca_system_score_gemma":0.0021691364,"threshold_uncertainty_score":0.03202331},"labels":[],"label_agreement":null},{"id":"W4407232469","doi":"10.1080/13543784.2025.2462592","title":"Investigational gene expression inhibitors for the treatment of idiopathic pulmonary fibrosis","year":2025,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Pirfenidone; Nintedanib; Idiopathic pulmonary fibrosis; Medicine; Genetic enhancement; Tolerability; Clinical trial; Disease; Pulmonary fibrosis; Bioinformatics; Intensive care medicine; Fibrosis; Lung; Immunology; Adverse effect; Internal medicine; Gene; Biology; Genetics","score_opus":0.04677634943419064,"score_gpt":0.34750848443140736,"score_spread":0.30073213499721674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407232469","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017158044,0.99737287,0.00016893225,0.00043620693,0.00037175964,0.000010121166,0.000041273193,0.000009496836,0.0014177235],"genre_scores_gemma":[0.0013849684,0.996829,0.00020586335,0.00042239312,0.00018102299,0.000014827138,0.000064916,0.0000020882105,0.0008948887],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99982685,0.000037090133,0.00002047093,0.000027612034,0.0000699699,0.000018028633],"domain_scores_gemma":[0.9997696,0.00011858682,0.000040304254,0.0000049099876,0.00005219266,0.000014381687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003918972,0.00044986315,0.00071787345,0.0010571727,0.000121326855,0.0005632508,0.0005579035,0.00077207346,0.0041421857],"category_scores_gemma":[0.00065580476,0.00012377191,0.00050866534,0.00072881783,0.00023028531,0.0005528598,0.00032420366,0.0014075307,0.0017751211],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010910527,0.000055177657,0.0000815872,0.020096602,0.00011434908,0.00013795974,0.00004739599,0.0002781038,0.003002108,0.0036279568,0.041102316,0.9313474],"study_design_scores_gemma":[0.00004106998,0.0001261428,0.00038083142,0.0039709667,0.00014227266,0.00060226873,0.000023459288,0.00008612961,0.00073555316,0.0010426401,0.992837,0.0000115974635],"about_ca_topic_score_codex":0.0004287284,"about_ca_topic_score_gemma":0.001043381,"teacher_disagreement_score":0.0041421857,"about_ca_system_score_codex":0.0003299784,"about_ca_system_score_gemma":0.0005124247,"threshold_uncertainty_score":0.013857007},"labels":[],"label_agreement":null},{"id":"W4410591077","doi":"10.1080/13543784.2025.2510664","title":"A randomized, Phase I study of the safety, tolerability, and pharmacokinetics of BI 764198, a transient receptor potential channel 6 (TRPC6) inhibitor, in healthy Japanese men","year":2025,"lang":"en","type":"article","venue":"Expert Opinion on Investigational Drugs","topic":"Ion Channels and Receptors","field":"Neuroscience","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"Boehringer Ingelheim","keywords":"Tolerability; Pharmacokinetics; TRPC6; Pharmacology; Transient receptor potential channel; Medicine; Receptor; Internal medicine; Adverse effect","score_opus":0.030759186528401816,"score_gpt":0.3303914103887965,"score_spread":0.2996322238603947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410591077","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98589754,0.0017791745,0.0009402099,0.00034686498,0.00027738334,0.008056711,0.0011226053,0.00012584122,0.0014535345],"genre_scores_gemma":[0.98053724,0.0015751604,0.0025223868,0.001211159,0.00034086907,0.009166264,0.0011435294,0.000040070438,0.0034633589],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99932516,0.0003107829,0.000043400563,0.00016328358,0.000055776763,0.00010166576],"domain_scores_gemma":[0.99869066,0.00020758237,0.0003322932,0.00012930254,0.00009472416,0.0005454077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001896421,0.0017423326,0.0029423526,0.00035193918,0.0007423462,0.0009156909,0.0009920114,0.0016292273,0.0075851553],"category_scores_gemma":[0.0017935383,0.0010375713,0.0012222048,0.00046936178,0.0013955488,0.001285881,0.00047312968,0.0028778485,0.0013141292],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9603027,0.018655865,0.0008282902,0.00046657756,0.00069665426,0.00005937267,0.00009356091,0.00025421238,0.006423192,0.00007042386,0.00079931505,0.011349815],"study_design_scores_gemma":[0.84079313,0.15459795,0.0026590256,0.000018267408,0.00039942635,0.00005321174,0.000029454379,0.00028380658,0.0004808873,0.000088771136,0.0005785788,0.000017469127],"about_ca_topic_score_codex":0.0010006484,"about_ca_topic_score_gemma":0.0023470202,"teacher_disagreement_score":0.0075851553,"about_ca_system_score_codex":0.0008340922,"about_ca_system_score_gemma":0.002221751,"threshold_uncertainty_score":0.02537489},"labels":[],"label_agreement":null},{"id":"W4410639051","doi":"10.1080/13543784.2025.2511177","title":"Prospects for multi-focal motor neuropathy treatment by complement inhibition","year":2025,"lang":"en","type":"editorial","venue":"Expert Opinion on Investigational Drugs","topic":"Peripheral Neuropathies and Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"","keywords":"Neuroscience; Multifocal motor neuropathy; Complement (music); Medicine; Physical medicine and rehabilitation; Psychology; Biology; Genetics; Mismatch negativity","score_opus":0.03560388577186867,"score_gpt":0.3361237313942681,"score_spread":0.3005198456223994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410639051","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013567272,0.09344408,0.0003878435,0.08067061,0.82017654,0.000054273663,0.00014727976,0.00010790211,0.0048758476],"genre_scores_gemma":[0.0010180005,0.076831065,0.00044442498,0.08813887,0.8194447,0.000067265675,0.00015390426,0.000042803706,0.013858883],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99874854,0.00032531982,0.00019187556,0.00014230915,0.0004767207,0.000115112874],"domain_scores_gemma":[0.9947425,0.002225207,0.00030211077,0.00012776605,0.0019714776,0.00063089986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035986241,0.0015979679,0.0021351045,0.0010299304,0.0009172042,0.0023167953,0.0018624832,0.008483915,0.012980085],"category_scores_gemma":[0.0077034147,0.0003971703,0.0018861037,0.0005026073,0.0010540803,0.0030726094,0.00091799366,0.01246821,0.011766571],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011593934,0.000025461864,0.000018776102,0.000694438,0.000033942884,0.00013428027,0.000008045337,0.000042666346,0.00013270837,0.0007942156,0.964622,0.033377506],"study_design_scores_gemma":[0.00019092148,0.00009086989,0.00016184362,0.0006399965,0.00009231303,0.00029212673,0.000017363078,0.000109211,0.000107386986,0.0017297729,0.99654984,0.00001839624],"about_ca_topic_score_codex":0.00081157126,"about_ca_topic_score_gemma":0.00233259,"teacher_disagreement_score":0.012980085,"about_ca_system_score_codex":0.0014528338,"about_ca_system_score_gemma":0.0013623772,"threshold_uncertainty_score":0.0434227},"labels":[],"label_agreement":null},{"id":"W4411413756","doi":"10.1080/13543784.2025.2522885","title":"Acetylcholine and muscarinic receptor targeting in bipolar disorder: does xanomeline-trospium chloride and other investigational muscarinic agonists hold promise as mechanistically informed treatments for manic episodes, mixed features and cognitive deficits in bipolar disorder?","year":2025,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Receptor Mechanisms and Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Muscarinic acetylcholine receptor; Mania; Bipolar disorder; Pharmacology; Medicine; Muscarinic acetylcholine receptor M4; Muscarinic acetylcholine receptor M1; Muscarinic acetylcholine receptor M3; Investigational Drugs; Acetylcholine; Cognition; Internal medicine; Psychiatry; Receptor; Clinical trial","score_opus":0.018240322109553266,"score_gpt":0.31328305457724753,"score_spread":0.29504273246769425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411413756","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0030024387,0.9583929,0.00040671177,0.02910493,0.002959519,0.000053083826,0.00027847296,0.000038985465,0.0057629286],"genre_scores_gemma":[0.018411536,0.94269127,0.0007724698,0.023264283,0.0077534113,0.00006944335,0.00047275098,0.000015887355,0.006548986],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997857,0.000058472066,0.000025108862,0.00003574288,0.00006620069,0.000028725965],"domain_scores_gemma":[0.99934524,0.00020578496,0.00018230826,0.00000854664,0.00020131186,0.000056790308],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095560576,0.0003174997,0.0008720452,0.00033137054,0.00015145064,0.00071532343,0.0006416772,0.0015529897,0.0064695585],"category_scores_gemma":[0.0012394328,0.00010719061,0.00062131084,0.00027616104,0.000363575,0.0008335547,0.00028174784,0.0016978445,0.002259126],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017016303,0.000108513734,0.0007048624,0.01895553,0.00024126265,0.00058531377,0.000116114774,0.00029809866,0.0074298154,0.0034052348,0.18427521,0.78217846],"study_design_scores_gemma":[0.0009381912,0.0022803103,0.0048661605,0.016697472,0.00062399305,0.001876412,0.00030245018,0.0005130569,0.00217457,0.006797434,0.9628661,0.00006382985],"about_ca_topic_score_codex":0.00077035336,"about_ca_topic_score_gemma":0.0037631197,"teacher_disagreement_score":0.0064695585,"about_ca_system_score_codex":0.0005496358,"about_ca_system_score_gemma":0.0007821911,"threshold_uncertainty_score":0.021642804},"labels":[],"label_agreement":null},{"id":"W4412394230","doi":"10.1080/13543784.2025.2532446","title":"Isatuximab for the treatment of multiple myeloma: current clinical advances and future directions","year":2025,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Kite Pharma; Chugai Pharmaceutical; Genentech; Juno Therapeutics; Incyte; BeiGene; Adaptive Biotechnologies; Regeneron Pharmaceuticals; Array BioPharma; Karyopharm Therapeutics; Exelixis; Sanofi; GlaxoSmithKline; Johns Hopkins University; Amgen; Pfizer; Legend Biotech; MorphoSys; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Multiple myeloma; Current (fluid); Medicine; Intensive care medicine; Immunology; Engineering","score_opus":0.11858936609891704,"score_gpt":0.4678993425352598,"score_spread":0.34930997643634276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412394230","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003305641,0.99912494,0.000032937147,0.00032411798,0.00011221811,0.0000035222122,0.000010428995,0.0000035960272,0.00035515713],"genre_scores_gemma":[0.00033808983,0.99896836,0.00009848866,0.0002667609,0.00010829198,0.000004946361,0.000018844848,9.686182e-7,0.00019522823],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995789,0.00010748416,0.000059169728,0.000057182642,0.00015928636,0.00003793112],"domain_scores_gemma":[0.9991524,0.0004195504,0.00016772209,0.000016237842,0.00020082877,0.00004323337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013372283,0.0007046803,0.0014354672,0.0019616531,0.00021503244,0.0011793184,0.0009189905,0.0012037124,0.006232921],"category_scores_gemma":[0.0016602958,0.00022035283,0.0010764598,0.0022442355,0.00039289502,0.0011072335,0.0006388896,0.0020761003,0.002142407],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011122376,0.000036324524,0.00009878399,0.03662687,0.00020173508,0.000076411045,0.000043564738,0.00026904332,0.00053117913,0.0019967023,0.03412653,0.92588156],"study_design_scores_gemma":[0.00007235815,0.000122555,0.0007201507,0.02435687,0.0005134742,0.00063854194,0.00006448901,0.00012273125,0.00020240308,0.0022383893,0.9709297,0.000018427472],"about_ca_topic_score_codex":0.0014966633,"about_ca_topic_score_gemma":0.0029586342,"teacher_disagreement_score":0.006232921,"about_ca_system_score_codex":0.000721015,"about_ca_system_score_gemma":0.001663275,"threshold_uncertainty_score":0.020851195},"labels":[],"label_agreement":null},{"id":"W4416026301","doi":"10.1080/13543784.2025.2587276","title":"Diffuse large B-cell lymphoma: what clinical progress have we seen in the last 5 years?","year":2025,"lang":"en","type":"article","venue":"Expert Opinion on Investigational Drugs","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Refractory (planetary science); Primary tumor; Clinical trial; Targeted therapy; First line treatment; Brentuximab vedotin","score_opus":0.03428570444146658,"score_gpt":0.3572830119342453,"score_spread":0.3229973074927787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416026301","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016432372,0.9570565,0.00030095203,0.03661975,0.0027252638,0.000006161087,0.0002889762,0.00003937878,0.0013196631],"genre_scores_gemma":[0.018818231,0.9591998,0.00063963386,0.013483582,0.006534963,0.000017353983,0.0004088543,0.00001583885,0.0008816885],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992741,0.00018554904,0.00010024676,0.00016078603,0.0001849011,0.00009436605],"domain_scores_gemma":[0.99575174,0.0016569734,0.00067320006,0.00006974521,0.0014443423,0.00040396876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024529297,0.0004052727,0.0014340661,0.00081776956,0.00030975795,0.0024977517,0.00054089556,0.0018343724,0.0045852503],"category_scores_gemma":[0.006470036,0.0001596281,0.00069141964,0.0012001884,0.0007417773,0.0033755149,0.00057349337,0.002504827,0.0016866231],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052483036,0.000040685387,0.007135341,0.009760094,0.0003095637,0.0003425324,0.00025131542,0.00040522346,0.0009911329,0.0025642558,0.12453779,0.8531372],"study_design_scores_gemma":[0.00014224614,0.0004669029,0.029033436,0.023563728,0.00092205475,0.003844193,0.0022186125,0.00067178375,0.0007505441,0.008825928,0.9293957,0.0001648533],"about_ca_topic_score_codex":0.0023202489,"about_ca_topic_score_gemma":0.0055702,"teacher_disagreement_score":0.0045852503,"about_ca_system_score_codex":0.0011972956,"about_ca_system_score_gemma":0.0016618534,"threshold_uncertainty_score":0.015339136},"labels":[],"label_agreement":null}]}